ResMed
Annual Report 2006

Plain-text annual report

A N N U A L R E P O R T 2 0 0 6 The tides are rising in the sleep industry as the market for sleep therapy products continues to grow. During the past year, ResMed significantly outperformed industry growth rates with our revolutionary combi- nation of the new S8™ flow generator line and the Mirage Swift™ Nasal Pillows System. In addition, the impacts of our education and awareness initiatives are rippling through new markets, such as cardiology and diabetes. The horizon is bright as we continue to invest in future growth. ResMed 2006 Annual Report Contents Chairman’s Report 1 Financial 4 Products 6 Growth 8 Awareness 10 Leadership 12 Form 10-K follows page 12 Statements contained in this Annual Report that are not historical facts are ‘forward-looking’ statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expens- es, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the US Securities & Exchange Commission. Those reports are available on the Company's website. Chairman’s report Peter C. Farrell, CEO and Chairman of the Board, on ResMed’s record performance and the path ahead. For fiscal year ending June 30, 2006, ResMed once again delivered record financial performance, achieving $607M in revenues, an increase of 43% over 2005 revenues while pro forma net income (pro forma measures exclude the impact of stock- based compensation costs, restructuring expenses, American Jobs Creation Act of 2004 (AJCA) repatriation tax and acquisition-related expenses) rose 47% to $109M, 18% of revenues. Pro forma diluted earnings per share were $1.42 and pro forma operating income was $154M, an increase of 38% and 42%, respectively, over the prior year. I recently received a letter that validated both the above comment and the commitment of the whole ResMed team to advancing the treatment of sleep- disordered breathing. Among other things, the letter Total operating cash flow for fiscal 2006 was $99M, from Dr. Rafael Pelayo of Stanford University stated: resulting in cash and cash equivalents of $220M. “Several patients have contacted me to tell me how The balance sheet demonstrated our financial well they were doing after I switched them over to strength, with a 30% increase in assets to $1.0B. ResMed products. The (Mirage) Swift mask has been Shareholders’ equity was up 56% to $738M, from very useful in our population. It has greatly simplified $474M in fiscal 2005, proving our continued commit- the way we deal with mask adjustments.” ment to maximizing shareholder value. During this fiscal year, we received FDA clearance Quality products and innovation for the VPAP™ Adapt SV, the only product cleared for Our patients and customers depend on us to deliver homecare use in the US to treat central sleep apnea, the most technically sophisticated and reliable periodic breathing (Cheyne-Stokes respiration) and products on the market. We continue to exceed mixed apnea. Our leadership in innovation and customer expectations in this regard and last year quality continues as we make further inroads into was no exception with the full launch of the popular the treatment of more complex sleeping disorders. S8 platform of flow generators. The combination of The VPAP Adapt SV is essentially equivalent to the the S8 series, coupled with the Mirage Swift Nasal AutoSet CS™ 2, which we have been successfully Pillows System, has substantially raised the bar for marketing in Europe and the rest of the world for a the entire industry. number of years. 1 Peter Farrell “I have never been more optimistic about the future of ResMed than I am today.” These devices are the only proven and approved products for the treatment of periodic breathing, which occurs, to a large extent, in severe congestive heart failure. The good news is that our clinical experience has shown that, by treating the periodic breathing and normalizing breathing abnormalities, we are able to see significant cardiovascular improvement. This is an excellent outcome, which we continue to see reinforced as we gather more C H A I R M A N ’ S Education and awareness focus Our battle against ignorance—which I have stated is still our biggest competitor—continues on a daily basis. Our jointly-funded public awareness campaign has generated over 1,000 stories in the general media. In addition, almost 4,000 peer-reviewed clinical studies have been published, many of which document the multiple health benefits of compliant positive airway pressure therapy. Nearly every med- ical silo is impacted by sleep-disordered breathing, from cardiology to endocrinology and from gastroen- terology to urology. Sadly, sleep-disordered breathing is not being recognized in these and many other medical specialties to the extent needed. This is gradually changing but, in our view, not fast enough. clinical data in these severely ill patients. We have much more education to do. Award-winning growth This past year, we have also received numerous accolades and awards that acknowledge our continu- ing growth as well as the quality of our products. For the ninth consecutive year, we were selected by Forbes magazine as one of the 200 Best Small Companies in America based on growth in net revenues and net profit after tax over five years. This is a significant achievement. Despite significant progress in raising public aware- ness and improving physician education of the dangers of untreated sleep-disordered breathing, the vast majority of sleep-disordered breathing sufferers remain untreated. The figures are staggering: as many as one in two heart failure patients and almost three-quarters of patients with type 2 diabetes suffer from sleep-disordered breathing at some level.1,2 As the research on diabetes continues, physicians As global demand for our products reached new are recognizing that positive airway pressure therapy heights, we completed work on our technologically not only reduces the classic symptoms of sleep- sophisticated manufacturing and product develop- disordered breathing (nocturia, excessive daytime ment facilities in Australia, set on 30 acres in sleepiness, high blood pressure, heart arrhythmias Sydney’s Norwest Business Park. At this site, we and so on), but also improves blood sugar levels in now produce several hundreds of thousands of diabetes sufferers.3 Our efforts to reach the type 2 masks and tens of thousands of flow generators diabetes patient population reflect our commitment per month, which are used in 67 countries. to promoting physician and public awareness and improving people’s lives. 2 R E P O R T 2 0 0 6 organizations during the year, including the Pissarro Exhibition at the Art Gallery of New South Wales, the Sydney Biennale, the Preuss School at the University of California San Diego, the Old Globe Theatre, the La Jolla Playhouse, the San Diego Museum of Photographic Arts, the Museum of Contemporary Arts – San Diego and many others. The future I have never been more optimistic about the future of ResMed than I am today. As people have heard me say before, we are just lacing our shoes before the marathon. We have barely scratched the surface of Clinical acceptance growing this very under-penetrated market; there are millions Encouragingly, the growing body of research on of patients across the globe whose lives are yet to sleep-disordered breathing has impacted clinical be improved as a result of our products, services guidelines, which increasingly include recommenda- and, most importantly, support from ResMed people. tions for the screening and treatment of sleep-disor- dered breathing, including the American College of Cardiology/American Heart Associations, the Heart Failure Society of America,4 the American Society of Anesthesiologists5 and the National Institutes of Health’s JNC-7 Guidelines for Hypertension.6 On a personal note, I am pleased to report that I was selected as National Entrepreneur of the Year for Health Sciences for the United States for 2005; I was also selected for the 2006 Alumni Achieve- ment Award by the Alumni Association of the University of New South Wales. For both of these Global reach expanding accolades I am indebted to the ResMed team. With almost 2,500 employees and consultants in 67 countries and counting, our global reach is expanding. With new offices in India and China and the acquisition of Saime to form ResMed Paris, we are driving market share in Europe and Asia Pacific, which constitute nearly half of global revenue. Charitable funding Finally, I want to thank our Board of Directors and the Medical Advisory Board for their continued guidance and encouragement. Most importantly, I want to thank all ResMed employees for their unfailing com- mitment and express gratitude for the support of our customers. Without satisfied employees and cus- tomers, this company would not exist. Thanks to both Through our US and Australia Foundations, we have employees and customers for your continued support. funded over 33 projects in 2006, totaling $1.1M. These include the next generation of clinical studies with such leading academic organizations as the Mayo Clinic, Stanford, the University of Pittsburgh and Harvard. In addition, the ResMed Foundations have partially funded numerous arts and education Peter C. Farrell, PhD AM Chairman and Chief Executive Officer, ResMed Inc. 3 F I N A N C I A L 154.1 156.2 Pro forma income* Income from operations Income before taxes $M 108.6 107.9 85.4 84.7 67.2 67.1 54.6 51.2 02 03 04 05 2006 R i s i n g t i d e s record of ResMed is the leading global technology company in the sleep-disordered breathing space, and we have the track record to prove it. Our consis- tent financial growth—averaging 32% every year for over 10 years—reflects the success of our teams around the globe. This track record continues with the fiscal year ending on June 30, 2006. ResMed announced record revenue and income results for the end of the 2006 fiscal year with its 45th consecutive quarter of growth. Revenue for the year was $607M, a 43% increase over the year ended June 30, 2005. Our revenues in the fourth quarter of fiscal year 2006 exceed the entire year’s revenues for 2001, demonstrating significant growth over the past five years. Assets and shareholder equity Shareholder equity Assets $M 549.2 474.1 459.6 376.2 286.4 361.5 192.9 1007.2 774.1 738.1 02 03 04 05 2006 4 *excluding the impact of stock-based compensation costs, restructuring expenses and acquisition-related expenses. Financial highlights for 2006: • Revenue of $607M, a 43% increase from last year. • Net income of $109M, a 47% increase from last year. • Earnings per share of $1.42, a 38% increase from last year. • Income from operations of $154M, a 42% increase from last year. 607.0 425.5 Net revenue $M 339.3 273.6 204.1 2 0 0 6 Pro forma diluted earnings 1.42 per share** (split adjusted) 0.66 0.55 1.03 0.82 02 03 04 05 Pro forma net income** $M 73.8 57.3 45.7 37.5 2006 108.6 02 03 04 05 2006 02 03 99.0 04 05 2006 Operating cashflow $M 76.5 59.3 71.1 35.6 02 03 04 05 2006 ** excluding the impact of stock- based compensation costs, restructuring expenses, AJCA repatriation tax and acquisition- related expenses. 5 P R O D U C T S Pediatric system ResMed recently received clearance for the treat- ment of sleep apnea in pediatric patients with the VPAP™ III ST-A bilevel flow generator and the Mirage Kidsta™ nasal mask. This is the first positive airway pressure system cleared by the FDA for treatment of sleep-disordered breathing in pediatric patients and enables ResMed to reach a group of patients who previously had few treatment options. The big splash ResMed is the global market leader in the sleep-disordered breathing industry. In the past year, we have focused on developing innovative products that will enable us to open new markets and treat a greater number of patients. Technological advances Better together: the S8 and Mirage Swift ResMed’s S8 series coupled with the Mirage Swift Nasal Pillows System defines a new generation of consumer-oriented products that maximize patient comfort and integrate easily into patients’ lifestyles. The S8 series of flow generators offers expiratory pressure relief (EPR), a new comfort mode designed to increase compliance. VPAP Adapt SV The VPAP Adapt SV and Ultra Mirage™ full face mask This year, ResMed announced groundbreaking progress in its efforts to treat sleep-disordered breathing with the launch of the VPAP Adapt SV in the United States, trailing the success of the AutoSet CS 2, its European counterpart. It is the first and only positive airway pressure device cleared for homecare use in the US to treat central sleep apnea, periodic breathing (Cheyne-Stokes respiration) and mixed apnea. Previously, treatment options for these challenging respiratory disorders have been limited to in-hospital ventilation. The VPAP Adapt SV fulfills the need for comfortable and effective homecare treatment options across Awards and recognition • The UK Association for Respiratory Technology and Physiology (ARTP) named ResMed as its Manufacturer of the Year for 2006. • ResMed has been recognized by Forbes’ list of the 200 Best Small Companies in America for nine consecutive years. • Business 2.0 named ResMed one of the Top 100 Fastest Growing Technology Companies. • ResMed received the 2006 Australian Design Award for the S8 Series Flow Generator and HumidAire 3i.™ Judges praised the system as a high-quality product with “so much technology the sleep-disordered breathing spectrum. squeezed into such a small space.” 6 2 0 0 6 7 G R O W T H Manufacturing In response to the growing demand for ResMed products, we expanded our manufacturing space with a state-of-the-art campus in Sydney’s prestigious Norwest Business Park. Distribution partners We have broadened our distribution strategy by partnering with both Teijin Pharma Limited and Fukuda Denshi in Japan, providing ResMed with a much wider customer base in both the sleep and ventilation markets. China is preparing to become a direct marketing operation supporting our distri- bution partners, and we have increased staff in Hong Kong to provide support to China’s growing markets nearby. In addition, our office based in New Delhi gives us direct access to India’s burgeoning market. Making waves Increasing awareness of sleep- disordered breathing has created one of the fastest growing seg- ments of the respiratory industry. ResMed is well-positioned at the center of this industry to meet the growing challenges of this under- penetrated market with global investments in every link of the supply chain. Research and development We continue to invest approximately 6% of revenues in research and product development— that’s a growing dollar figure every year. ResMed’s team is focused on developing innovative therapies that increase patient comfort and convenience while improving health. We have more than 450 granted patents and 650 pending patents world- wide. Our growing body of proprietary technology reflects our commitment to product development. 8 2 0 0 6 People and operations Training and development With a team of approximately 2,500 employees and ResMed provides training and development to 18 direct offices across 67 countries, we continue all employees through its internal development to recruit the brightest and strongest talent around organization, the Learning Center. This year, the the world and professionally develop existing talent. Learning Center received a commendation from Our diverse team across the globe has strength- the American Society of Training and Development ened the company and driven growth. The opening for its sales training program. Following its success of our new European headquarters in Basel, in the US, the Learning Center is expanding globally Switzerland provides a home for future regional with a focus on Europe and Asia Pacific. conferences, educational programs and new opportunities for increasing awareness about sleep-disordered breathing in Europe. 9 A W A R E N E S S Ripple effect ResMed promotes industry growth by investing in programs to educate the medical commu- nity and the public about sleep- disordered breathing. A recent third-party survey shows the sleep apnea industry is expanding at a rapid rate: 53% of sleep centers reported that cardiologist referrals increased this past year and they expect this trend to continue. ResMed actively promotes clinician education and public awareness to fuel this growth and increase market share. Educating physicians ResMed is breaking through medical silos by reaching out to health- care professionals at scientific conferences and meetings. In 2006, we participated in multiple major medical conferences and educated nearly 50,000 clinicians on the comorbidities associated with sleep- disordered breathing, including diabetes, cardiovascular disease and obesity. ResMed has focused particularly on helping medical professionals develop relationships with sleep specialists in order to effectively screen, diagnose and treat undiagnosed sleep apnea sufferers among these new patient groups. 10 2 0 0 6 A new area of opportunity is in treating diabetes Research and philanthropy sufferers who also have sleep-disordered breathing. In continuing efforts to promote sleep and breathing Recent evidence shows that nearly 75% of patients research as well as physician and community aware- with type 2 diabetes suffer from sleep apnea,2 and ness, the ResMed US and Australia Foundations that blood glucose levels can be reduced with com- review and approve grants for non-profit organizations pliant CPAP therapy.3 This suggests that CPAP may each quarter. This year, the ResMed Foundations be an important therapeutic approach for diabetes pledged over $1.1M in grants, such as funding for the sufferers with sleep-disordered breathing. We will Mayo Clinic to study sleep-disordered breathing and focus on developing new ways to educate diabetes atrial fibrillation. clinicians on identifying and treating sleep- disordered breathing in their patients. Educating patients ResMed began a public relations campaign with other industry leaders in 2004 to reach millions of undiagnosed patients, and has succeeded in placing over 1,000 stories in local and national media. Sleep- disordered breathing has received coverage from multiple media giants in the past year, including ESPN, The New York Times, The Wall Street Journal, US News and World Report, the Today Show and Nikkei Sangyo (in Japan). 11 L E A D E R S H I P EXECUTIVE TEAM, STANDING FROM LEFT: Rob Douglas, Chief Operating Officer, Sydney • David Pendarvis, Sr. Vice President, Organizational Development and General Counsel Peter C. Farrell, Chief Executive Officer • Kieran T. Gallahue, President, ResMed Global • Brett Sandercock, Chief Financial Officer SEATED, FROM LEFT: Keith Serzen, Chief Operating Officer, Americas Paul Eisen, Sr. Vice President, Asia Pacific NOT PICTURED: Adrian Smith, Chief Operating Officer, Europe Charting the course A company can only be as successful as its people. The collective efforts of ResMed’s leaders and our strong, moti- vated and talented team of employees throughout the world are the reason for our continued success. Our executives have extensive experience in the field of sleep- disordered breathing and the medical device industry. Balancing out our management team is an independent board of directors, a body of advisors who represent shareholders and other stakehold- ers. The board of directors lends diverse insights to ResMed’s executive team. In addition, our Medical Advisory Board of physi- cians and scientists specializing in the field of sleep-disordered breathing contributed valuable clinical and industry guidance throughout 2006. Medical Advisory Board BOARD OF DIRECTORS, LEFT TO RIGHT: Gary W. Pace,2,3 Director • Ronald Taylor,2,3 Director • Christopher G. Roberts, Director Michael A. Quinn,1,3 Director • Peter C. Farrell, Chairman of the Board of Directors Donagh McCarthy,1,2,3 Director • John Wareham,1,3 Director • Richard Sulpizio,2,3 Director 1 Member of the Audit Committee 2 Member of the Compensation Committee 3 Member of the Nominating and Governance Committee Note: bold blue denotes committee chair. Claudio Bassetti, MD Michael Coppola, MD Terence M. Davidson, MD, FACS Anthony N. Demaria, MD Neil J. Douglas, MD, DSc, FRCP Nicholas Hill, MD Barry J. Make, MD Ralph Pascualy, MD Barbara Phillips, MD, MSPH, FCCP Jonathan R.L. Schwartz, MD Helmut Teschler, MD B. Tucker Woodson, MD, FACS 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2006 Commission file number: 001-15317 RESMED INC. (Exact name of Registrant as specified in its Charter) Delaware (State or other jurisdiction of incorporation or organization) 98-0152841 (IRS Employer Identification No) 14040 Danielson Street Poway, CA 92064-6857 United States Of America (Address of principal executive offices) (858) 746-2400 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act Title of each class Common Stock, $.004 Par Value Rights to Purchase Series A Junior Participating Preferred Stock Name of each exchange upon which registered New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [ x ] No [ ] Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes [ x ] No [ ] Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ x ] No [ ] Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulations S-K (S 229.405 of this Chapter) is not contained herein and will not be contained to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K [ ] Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. SE definition of accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act). Yes [ x ] No [ ] Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes [ ] No [ x ] The aggregate market value of the voting stock held by non-affiliates of registrant as of December 31, 2005 (the last business day of the registrant’s most recently completed second fiscal quarter), computed by reference to the closing sale price of such stock on the New York Stock Exchange, was approximately $2,632,489,000. (All directors, executive officers, and 10% stockholders of Registrant are considered affiliates.) At August 23, 2006, registrant had 75,932,458 shares of Common Stock, $.004 par value, issued and outstanding. This number excludes 2,254,918 shares held by the registrant as treasury shares. Portions of registrant’s definitive Proxy Statement for its November 9, 2006 meeting of stockholders are incorporated by reference into Part III of this report. CONTENTS Cautionary Note Regarding Forward Looking Statements Part I Item 1 Business Item 1A Risk Factors Item 2 Properties Item 3 Legal Proceedings Item 4 Submission of Matters to a Vote of Security Holders Part II Item 5 Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Item 6 Selected Financial Data Item 7 Management’s Discussion and Analysis of Financial Condition and Results of Operations Item 7A Quantitative and Qualitative Disclosures About Market and Business Risks Item 8 Consolidated Financial Statements and Supplementary Data Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Item 9A Controls and Procedures Item 9B Other Information Part III Item 10 Directors and Executive Officers of the Registrant Item 11 Executive Compensation 3 3 17 22 22 22 23 24 25 39 40 41 41 43 44 44 Item 12 Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 44 Item 13 Certain Relationships and Related Transactions Item 14 Principal Accountant Fees and Services Part IV Item 15 Exhibits and Consolidated Financial Statement Schedules Signatures 44 44 45 S-1 Activa, Aerial, Aero-Click, Aero-Fix, ApneaLink, AutoVPAP, AutoScan, AutoSet, AutoSet CS, AutoSet Spirit, AutoSet T, AutoSet.com, AutoSet-CS.com, AutoView, Bubble Cushion, Bubble Mask, Elisée, Eole, Helia, HumidAire, HumidAire 2i, IPAP MAX, IPAP MIN, MEDDTRAXX, MEPAL, MESAMIV, MicroMesam, minni Max, MaxNcpap, Mirage, Protégé, Moritz II biLEVEL, Poly-MESAM, ResCap, ResAlarm, ResControl, ResMed, SleepKIT Solutions, S6, S7, S8, SELFSET, SmartStart, Spiro+, Sullivan, Swift, TiControl, TRAXX, Twister remote, Ultra Mirage, Vential, VPAP, VPAP Adapt SV, VPAP MAX, VS Easyfit, Vsync, are our trademarks. As used in this 10-K, the terms “we”, “us”, “our” and “the Company” refer to ResMed Inc., a Delaware corporation, and its subsidiaries, on a consolidated basis, unless otherwise stated. - 2 - Forward-Looking Statements PART I This report contains or may contain certain forward-looking statements and information that are based on the beliefs of our management as well as estimates and assumptions made by, and information currently available to our management. All statements other than statements regarding historical facts are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “plan,” “future” and other similar expressions generally identify forward-looking statements, including, in particular, statements regarding the development and approval of new products and product applications, market expansion, pending litigation and the development of new markets for our products, such as cardiovascular and stroke markets. These forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned not to place undue reliance on these forward-looking statements each of which applies only as of the date of this report. Such forward- looking statements reflect the views of our management at the time such statements are made and are subject to a number of risks, uncertainties, estimates and assumptions, including, without limitation, and in addition to those identified in the text surrounding such statements, those identified in Item 1A “Risk Factors” and elsewhere in this report. In addition, important factors to consider in evaluating such forward-looking statements include changes or developments in social, economic, market, legal or regulatory circumstances, changes in our business or growth strategy or an inability to execute our strategy due to changes in our industry or the economy generally, the emergence of new or growing competitors, the actions or omissions of third parties, including suppliers, customers, competitors and governmental authorities, and various other factors. Should any one or more of these risks or uncertainties materialize, or the underlying estimates or assumptions prove incorrect, actual results may vary significantly from those expressed in such forward-looking statements, and there can be no assurance that the forward-looking statements contained in this report will in fact occur. ITEM 1 BUSINESS General We are a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing, or SDB, includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. When we were formed in 1989, our primary purpose was to commercialize a treatment for OSA developed by Professor Colin Sullivan. This treatment, nasal Continuous Positive Airway Pressure, or CPAP, was the first successful noninvasive treatment for OSA. CPAP systems deliver pressurized air, typically through a nasal mask, to prevent collapse of the upper airway during sleep. Since the development of CPAP, we have developed a number of innovative products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Our growth has been fuelled by geographic expansion, increased awareness of respiratory conditions as a significant health concern among physicians and patients, and our research and product development efforts. We employ approximately 2,500 people and sell our products in over 67 countries through a combination of wholly owned subsidiaries and independent distributors. Our web site address is www.resmed.com. We make our periodic reports, together with any amendments, available on our web site, free of charge, as soon as reasonably practicable after we electronically file or furnish the reports with the Securities and Exchange Commission. Corporate History ResMed Inc., a Delaware corporation, was formed in March 1994 as the ultimate holding company for our Americas, Asia-Pacific and European operating subsidiaries. On June 1, 1995, we completed an initial public offering of common stock and on June 2, 1995 our common stock commenced trading on the NASDAQ National Market. On September 30, 1999 we transferred our principal public listing to the New York Stock Exchange, or NYSE, trading under the ticker symbol RMD. On November 25, 1999, we established a secondary listing of our common stock via Chess Depositary Instruments, or CDI’s, on the Australian Stock Exchange, or ASX, also under the symbol RMD. Ten CDI’s on the ASX represent one share of our common stock on the NYSE. On July 1, 2002, we converted our ASX listing status from a foreign exempt listing to a full listing. - 3 - Our Australian subsidiary, ResMed Holdings Limited, was originally organized in 1989 by Dr. Peter Farrell to acquire from Baxter Center for Medical Research Pty Limited, or Baxter, the rights to certain technology relating to CPAP treatment as well as Baxter’s existing CPAP device business. Baxter had sold CPAP devices in Australia since 1988, having acquired the rights to the technology in 1987. Since formation we have acquired a number of operating businesses including: Name of Entity Dieter W. Priess Medtechnik Premium Medical SARL Innovmedics Pte Ltd EINAR Egnell AB MAP Medizin Technologie GmbH Labhardt AG Servo Magnetics Inc. John Stark and Associates Respro Medical Company Limited Resprecare BV Hoefner Medizintechnik GmbH Saime SA Pulmomed Medizinisch-Technische Geräte GmbH PolarMed Holding AS Date of Acquisition February 7, 1996 June 12, 1996 November 1, 1997 January 31, 2000 February 16, 2001 November 15, 2001 May 14, 2002 July 24, 2002 July 2, 2003 December 1, 2004 February 14, 2005 May 19, 2005 July 1, 2005 December 1, 2005 - 4 - The Market Sleep is a complex neurological process that includes two distinct states: rapid eye movement, or REM, sleep and non-rapid eye movement, or non-REM, sleep. REM sleep, which is about 20-25% of total sleep experienced by adults, is characterized by a high level of brain activity, bursts of rapid eye movement, increased heart and respiration rates, and paralysis of many muscles. Non-REM sleep is subdivided into four stages that generally parallel sleep depth; stage 1 is the lightest and stage 4 is the deepest. The upper airway has no rigid support and is held open by active contraction of upper airway muscles. Normally, during REM sleep and deeper levels of non-REM sleep, upper airway muscles relax and the airway narrows. Individuals with narrow upper airways or poor muscle tone are prone to temporary collapses of the upper airway during sleep, called apneas, and to near closures of the upper airway called hypopneas. These breathing irregularities result in a lowering of blood oxygen concentration, causing the central nervous system to react to the lack of oxygen or increased carbon dioxide and signaling the body to respond. Typically, the individual subconsciously arouses from sleep, causing the throat muscles to contract, opening the airway. After a few gasping breaths, blood oxygen levels increase and the individual can resume a deeper sleep until the cycle repeats itself. Sufferers of OSA typically experience ten or more such cycles per hour. While these awakenings greatly impair the quality of sleep, the individual is not normally aware of these disruptions. In addition, OSA has recently been recognized as a cause of hypertension and a significant co-morbidity for heart disease, stroke and diabetes. Scientists estimate that one in five adults have some form of obstructive sleep apnea. In the United States alone, this represents approximately 43 million people. Despite the high prevalence of OSA, there is a general lack of awareness of OSA among both the medical community and the general public. It is estimated that less than 10% of those with OSA have been diagnosed or treated. Many healthcare professionals are often unable to diagnose OSA because they are unaware that such non-specific symptoms as excessive daytime sleepiness, snoring, hypertension and irritability are characteristic of OSA. While OSA has been diagnosed in a broad cross-section of the population, it is predominant among middle-aged men and those who are obese, smoke, consume alcohol in excess or use muscle-relaxing and pain-killing drugs. A strong association has been discovered between OSA and a number of cardiovascular diseases. Recent studies have shown that SDB is present in approximately 80% of patients with drug-resistant hypertension, approximately 60% of stroke patients and approximately 50% of patients with congestive heart failure. More recently, studies have shown a connection between SDB and diabetes: recent studies indicate that SDB is independently associated with glucose intolerance and insulin resistance. Sleep-Disordered Breathing and Obstructive Sleep Apnea Sleep-disordered breathing encompasses all physiological processes that cause detrimental breathing patterns during sleep. Manifestations include OSA, central sleep apnea, or CSA, and hypoventilation syndromes that occur during sleep. Hypoventilation syndromes are generally associated with obesity, chronic obstructive lung disease and neuromuscular disease. OSA is the most common form of SDB. Sleep fragmentation and the loss of the deeper levels of sleep caused by OSA can lead to excessive daytime sleepiness, reduced cognitive function, including memory loss and lack of concentration, depression and irritability. OSA sufferers also experience an increase in heart rate and an elevation of blood pressure during the cycle of apneas. Several studies indicate that the oxygen desaturation, increased heart rate and elevated blood pressure caused by OSA may be associated with increased risk of cardiovascular morbidity and mortality due to angina, stroke and heart attack. Patients with OSA have been shown to have impaired daytime performance in a variety of cognitive functions including problem solving, response speed and visual motor coordination, and studies have linked OSA to increased occurrences of traffic and workplace accidents. Generally, an individual seeking treatment for the symptoms of OSA is referred by a general practitioner to a specialist for further evaluation. The diagnosis of OSA typically requires monitoring the patient during sleep at either a sleep clinic or the patient’s home. During overnight testing, respiratory parameters and sleep patterns may be monitored, along with other vital signs such as heart rate and blood oxygen levels. Simpler tests, using devices such as our Apnealink, or our automatic positive airway pressure devices, monitor airflow during sleep, and use computer programs to analyze airflow patterns. These tests allow sleep clinicians to detect any sleep disturbances such as apneas, hypopneas or subconscious awakenings. We estimate that there are currently around 3,000 sleep clinics in the United States, a substantial portion of which are affiliated with hospitals. The number of sleep clinics has expanded significantly from approximately 100 such facilities in 1985. - 5 - Existing Therapies to create a channel for airflow. Most recently, alternative Before 1981, the primary treatment for OSA was a tracheotomy, a surgical procedure to cut a hole in the patient’s involved either windpipe uvulopalatopharyngoplasty, or UPPP, in which surgery is performed on the upper airway to remove excess tissue and to streamline the shape of the airway, implanting a device to add support to the soft palate, or mandibular advancement, in which the lower jaw is moved forward to widen the patient’s airway. UPPP alone has a poor success rate; however, when performed in conjunction with multi-stage upper airway surgical procedures, a greater success rate has been claimed. These combined procedures, performed by highly specialized surgeons, are expensive and involve prolonged and often painful recovery periods. treatments have CPAP, by contrast, is a non-invasive means of treating OSA. CPAP was first used as a treatment for OSA in 1980 by Dr. Colin Sullivan, the past Chairman of our Medical Advisory Board. CPAP systems were commercialized for treatment of OSA in the United States in the mid 1980’s. Today, use of CPAP is generally acknowledged as the most effective and least invasive therapy for managing OSA. During CPAP treatment, a patient sleeps with a nasal interface connected to a small portable airflow generator that delivers room air at a positive pressure. The patient breathes in air from the flow generator and breathes out through an exhaust port in the interface. Continuous air pressure applied in this manner acts as a pneumatic splint to keep the upper airway open and unobstructed. Interfaces include nasal masks and nasal pillows. Sometimes, when a patient leaks air through their mouth, a full-face mask may need to be used, rather than a nasal interface. CPAP is not a cure and therefore, must be used on a nightly basis as long as treatment is required. Patient compliance has been a major factor in the efficacy of CPAP treatment. Early generations of CPAP units provided limited patient comfort and convenience. Patients experienced soreness from the repeated use of nasal masks and had difficulty falling asleep with the CPAP device operating at the prescribed pressure. In more recent years, product innovations to improve patient comfort and compliance have been developed. These include more comfortable patient interface systems; delay timers that gradually raise air pressure allowing the patient to fall asleep more easily; bilevel air flow generators, including Variable Positive Airway Pressure, or VPAP systems, which provide different air pressures for inhalation and exhalation; heated humidification systems to make the airflow more comfortable; and autotitration devices that reduce the average pressure delivered during the night. Business Strategy We believe that the SDB market will continue to grow in the future due to a number of factors including increasing awareness of OSA, improved understanding of the role of SDB treatment in the management of cardiac, neurologic, metabolic and related disorders, and an increase in home-based diagnosis. Our strategy for expanding our business operations and capitalizing on the growth of the SDB market consists of the following key elements: Continue Product Development and Innovation. We are committed to ongoing innovation in developing products for the diagnosis and treatment of SDB. We have been a leading innovator of products designed to more effectively treat SDB, increase patient comfort and encourage compliance with prescribed therapy. For example, in 1999 we introduced the Mirage Full Face Mask. This mask contains an inflatable air pocket, which conforms to the patient’s facial contours, creating a more comfortable and better seal. In 2002 we introduced the AutoSet Spirit flow generator, our second-generation autotitrating device that adapts to the patient’s breathing patterns to more effectively treat OSA. In 2003, we introduced the Mirage Activa nasal mask, with active cushion technology to automatically seal mask leaks. In 2004, we introduced the Mirage Swift nasal pillows system, a less obtrusive, lightweight, and flexible alternative to nasal masks. In 2005, we introduced the S8 range of CPAP, a small flow generator with optional integrated humidification. We believe that continued product development and innovation are key factors to our ongoing success. Approximately 12% of our employees are devoted to research and development activities. In fiscal year 2006, we invested $37.2 million, or 6% of our revenues, in research and development. Expand Geographic Presence. We market our products in over 67 countries to sleep clinics, home healthcare dealers and third party payers. We intend to increase our sales and marketing efforts in our principal markets, as well as expand the depth of our presence in other geographic regions. Increase Public and Clinical Awareness. We intend to continue to expand our existing promotional activities to increase awareness of SDB and our treatment alternatives. These promotional activities target the population with predisposition to SDB as well as primary care physicians and specialists, such as cardiologists, neurologists and pulmonologists. In addition, we also target special interest groups, including the National Stroke Association, the American Heart Association and the National Sleep Foundation. - 6 - During fiscal 2006, 2005 and 2004, we donated $0.8 million, $0.5 million and $0.5 million respectively to the ResMed Foundation in the United States, and the ResMed Foundation Limited in Australia, to further enhance research and awareness of SDB. The contributions to the Foundations reflect ResMed’s commitment to medical research into sleep-disordered breathing, particularly the treatment of obstructive sleep apnea. Expand into New Clinical Applications. We continually seek to identify new applications of our technology for significant unmet medical needs. Recent studies have established a clinical association between OSA and both stroke and congestive heart failure, and have recognized SDB as a cause of hypertension or high blood pressure. Research also indicates that SDB is independently associated with glucose intolerance and insulin resistance. We have developed a device for the treatment of Cheyne-Stokes breathing in patients with congestive heart failure. In addition, we maintain close working relationships with a number of prominent physicians to explore new medical applications for our products and technology. We have recently received FDA clearance and launched a new product in the United States for the treatment of respiratory insufficiency due to central sleep apnea, mixed apnea and periodic breathing, called the VPAP Adapt SV. The VPAP Adapt SV uses a technology known as adaptive servo-ventilation and was first made available to a select group of US key opinion leader sites beginning in the third quarter of fiscal 2006. Physicians have found tremendous benefit from this technology as it has successfully treated the complex breathing disorders of many patients who had previously tried and failed traditional PAP therapy. Leverage the Experience of our Management Team and Medical Advisory Board. Our senior management team has extensive experience in the medical device industry in general, and in the field of SDB in particular. Our Medical Advisory Board is comprised of experts in the field of SDB. We intend to continue to leverage the experience and expertise of these individuals to maintain our innovative approach to the development of products and increase awareness of the serious medical problems caused by SDB. Products Our portfolio of products for the treatment of OSA and other forms of SDB includes airflow generators, diagnostic products, mask systems, headgear and other accessories. Air Flow Generators We produce CPAP, VPAP and AutoSet systems for the titration and treatment of SDB. The flow generator systems deliver positive airway pressure through a patient interface, either a small nasal mask, nasal pillows system, or full- face mask. Our VPAP units deliver ultra-quiet, comfortable bilevel therapy. There are two preset pressures: a higher pressure as the patient breathes in, and a lower pressure as the patient breathes out. Breathing out against a lower pressure makes treatment more comfortable, particularly for patients who need high pressure levels or for those with impaired breathing ability. AutoSet systems are based on a proprietary technology to monitor breathing and can also be used in the diagnosis, treatment and management of OSA. CPAP and VPAP flow generators accounted for approximately 52%, 49% and 50% of our net revenues in fiscal years 2006, 2005 and 2004, respectively. With the acquisition of Saime in May 2005, we increased our presence in the European homecare ventilation market. The VS and Elisée range of products are sophisticated, yet easy to use for physicians, clinicians and patients. We believe these devices complement our VPAP III, VPAP Adapt SV and Autoset CS2 for patients who need ventilatory assistance. - 7 - AIR FLOW GENERATORS VPAP Products VPAP II DESCRIPTION DATE OF COMMERCIAL INTRODUCTION Bilevel portable device providing different pressure levels for inhalation and exhalation, improved pressure switching and reduced noise output and spontaneous breath triggering. March 1996 COMFORT Bilevel device with limited features. VPAP II ST Bilevel portable device with spontaneous and spontaneous/timed breath triggering modes of operation. VPAP II ST A Bilevel device with alarms. VPAP MAX Bilevel ventilatory support system for the treatment of adult patients with respiratory insufficiency or respiratory failure. March 1996 April 1996 August 1998 November 1998 Moritz S#* Moritz ST#* VPAP III Bilevel portable device providing different pressure levels for inhalation and exhalation with integrated humidifier. October 2001 Bilevel ST device with spontaneous and spontaneous/timed breath triggering modes of operation, and with power failure alarms, system with integrated humidifier. October 2001 Updated Bilevel portable device encompassing improved pressure synchronization, spontaneous breath triggering and reduced noise. April 2003 VPAP III ST Updated Bilevel ST portable device encompassing improved pressure synchronization, spontaneous and spontaneous/timed breath triggering modes of operation and reduced noise. April 2003 VPAP III STA An upgraded Bi-level device with alarm features. VPAP Adapt SV # The newest and most highly evolved bilevel device which uses adaptive servo-ventilation technology to treat patients with central sleep apnea, mixed apnea and periodic breathing. # Sold in United States only August 2004 March 2006 DATE OF COMMERCIAL INTRODUCTION AIR FLOW GENERATORS Ventilation Products Helia 2*# Eole 3 XLS*# VS Serena*# VS Ultra*# VS Integra*# Elisée 350*# Elisée 150*# Elisée 370*# DESCRIPTION Dual mode ventilator that combines volumetric and barometric ventilation modes. August 1998 Ventilator device providing conventional volumetric ventilation through both controlled and assisted- controlled ventilation with etv functions. December 1999 Bi-level ventilator providing all ventilation modes with two pressure levels. Dual mode ventilator that combines volumetric and barometric ventilation from leakage to valve type with single or double limb circuit. June 2001 March 2002 Pressure support ventilator that combines pressure modes with leakage or valve ventilators. March 2002 Ventilator for use in Intensive Care Unit combining all conventional ventilation modes, diagnostic and monitoring functions. December 2003 Ventilator device that combines volumetric and barometric ventilation modes with single or double limb circuit. June 2004 Ventilator for use in Intensive Care Unit combining all conventional ventilation modes, diagnostic functions with external monitoring interface for ventilation loops. September 2004 Elisée 250*# Ventilator for use in transport and emergency situations. April 2005 * Not cleared for marketing in the United States # Sold outside United States only - 8 - AIR FLOW GENERATORS Automatic Positive Airway Pressure Devices AutoSet CS*# DESCRIPTION DATE OF COMMERCIAL INTRODUCTION Automatic ventilatory assistance device specifically designed to normalize ventilation in congestive heart failure patients with Cheyne Stokes respiration. December 1998 AutoSet T Autotitrating device, which continually adjusts CPAP treatment pressure based on patient airway resistance. March 1999 AutoSet Spirit Modular, autotitrating device with advanced compliance monitoring and optional integrated humidifier. Magellan*# Autotitrating device using airway resistance measurement. September 2001 March 2003 AutoSet Respond Autotitrating device with basic compliance monitoring and optional integrated humidifier. September 2003 AutoSet CS2*# Modular, automatic device specifically designed to normalize ventilation in congestive heart failure patients with Cheyne Stokes respiration. The device has an optional integrated humidifier. August 2004 CPAP Max II nCPAP*# CPAP device with or without integrated humidifier. Features low noise and reduced pressure swings. April 1997 Mini Max nCPAP*# CPAP device with integrated and attachable humidifier and low noise levels. ResMed S6 series Quiet, compact CPAP device with various comfort features. ResMed S7 series A CPAP device with optional integrated humidifier. ResMed S8 Series A small CPAP device with optional integrated humidification. March 2000 June 2000 July 2002 June 2005 * Not cleared for marketing in the United States # Sold outside United States only - 9 - Mask Systems and Diagnostic Products Mask systems are one of the most important elements of SDB treatment systems. Masks are a primary determinant of patient comfort and as such may drive or impede patient compliance with therapy. We have been a consistent innovator in masks, improving patient comfort while minimizing size and weight. Masks, accessories, motors and diagnostic products accounted for approximately 48%, 51% and 50% of our net revenues in fiscal years 2006, 2005 and 2004, respectively. MASK PRODUCTS DESCRIPTION DATE OF COMMERCIAL INTRODUCTION Mirage Mask Ultra Mirage Mask Proprietary mask design with a contoured nasal cushion that adjusts to patient’s facial contours. Quiet, light and low profile. August 1997 Advanced version of the Mirage system with reduced noise characteristics and improved forehead bridge. Mirage Full Face Mask Series 2 Mirage-based full-face mask system. Provides an effective method of applying ventilatory assist Noninvasive Positive Pressure Ventilation therapy. Can be used to address mouth- breathing problems in conventional bilevel or CPAP therapy. Papillon Mask*# Nasal mask with only four major parts, allows simplified handling for patients and distributors. April 2002 Mirage Vista Mask Small nasal mask without forehead supports. November 2002 Ultra Mirage Full Face Mask Full-face mask incorporating our latest adjustable forehead support technology. August 2003 Mirage Activa Mask Nasal mask system utilizing Active Seal technology to mitigate leak and improve patient comfort. October 2003 Mirage Swift A light and unobtrusive nasal cannula mask system. Silent Papillon Mask*# A low noise nasal mask with simplified assembly. Hospital Full Face Mask Disposable full face mask specifically designed for hospital use. Hospital Nasal Mask Disposable nasal mask specifically designed for hospital use. June 2000 October 2001 August 2004 March 2005 April 2005 April 2005 July 2005 Ultra Mirage II Meridian Nasal Mask Advanced version of the Ultra Mirage Nasal System with improved comfort and ease of fit through enhanced forehead pads and support. A value line nasal mask. Effective therapy supplied through a simple yet comfortable mask February 2006 * Not cleared for marketing in the United States # Sold outside United States only We market sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. These diagnostic systems record relevant respiratory and sleep data, which can be analyzed by a sleep specialist or physician who can then tailor an appropriate OSA treatment regimen for the patient. DATE OF COMMERCIAL INTRODUCTION February 1995 February 1999 October 1999 DIAGNOSTIC PRODUCTS DESCRIPTION Poly-MESAM Portable Diagnostic System*(cid:31)# Configurable cardio-respiratory polygraphy system up to 8 channels, includes ECG, thorax and abdomen belts, PLMS sensor. MEPAL Diagnostic System *(cid:31)# Polysomnography system designed for use in the sleep laboratory. Embla(cid:31) Embletta(cid:31) Digital sleep recorder that provides comprehensive sleep diagnosis in a sleep laboratory. Pocket-size digital recorder that performs ambulatory sleep studies. November 2000 MEPAL mobil *(cid:31) Diagnostic System Ambulatory polysomnography system. ApneaLink (MicroMesam) A portable Sleep Apnea screening device for use by sleep professionals and primary care physicians. March 2001 April 2004 * Not cleared for marketing in the United States # Sold outside United States only (cid:31) Not manufactured by ResMed - 10 - Accessories and Other Products To enhance patient comfort, convenience and compliance, we market a variety of other products and accessories. These products include humidifiers, such as the HumidAire, H2i and H3i, which connect directly with the CPAP, VPAP and AutoSet flow generators to humidify and heat the air delivered to the patient. Their use helps prevent the drying of nasal passages that can cause discomfort. Other optional accessories include cold passover humidifiers, carry bags and breathing circuits. To assist those professionals diagnosing or managing the treatment of patients there are data communications and control products such as the ResLink, ResControl and ResControl II modules that facilitate the transfer of data and other information to and from the flow generators. MAP also offers a range of accessories, including the Twister remote, an intelligent remote control for use in the sleep laboratory environment to set and monitor flow generators, the Aero-Click connection system, which allows a quick, simple connect/disconnect between the mask and CPAP air delivery source and the AeroFix headgear, for the comfortable adjustment of masks for CPAP therapy. Since the May 2002 acquisition of Servo Magnetics Inc., we have also sold custom electric motors, primarily for use in data storage and aerospace applications, but we do not expect custom electric motor sales to contribute material revenues in the future. Product Development and Clinical Trials We have a strong track record in innovation in the sleep market. In 1989, we introduced our first CPAP device. Since then we have been committed to an ongoing program of product advancement and development. Currently, our product development efforts are focused on not only improving our current product offerings, but also expanding into new product applications. For example, in 1997, we introduced the Mirage Mask. This mask was based on the innovative Bubble Mask technology introduced in 1991, which used the principle of air inflation of the mask cushion to create a more comfortable and better seal by better conforming to patient facial contours. In 1999, we introduced the AutoSet T flow generator, an autotitrating device that adapts to the patient’s breathing patterns to effectively prevent apneas. In 2001, we introduced our next generation autotitrating device, the AutoSet Spirit. The AutoSet Spirit is an autotitrating modular device with optional integrated humidifier. In September 2003, we introduced the Activa nasal mask using our patented Active Cushion Technology, which automatically seals mask leaks. In August 2004, we launched our Mirage Swift mask, a light and unobtrusive nasal cannula mask system. Also, in August 2004 we launched an improved AutoSet CS 2 (outside the United States only) to treat congestive heart failure patients with significant central sleep apnea. In March 06 we launched the VPAP Adapt SV within the United States. This product is for the treatment of respiratory insufficiency due to central sleep apnea, mixed apnea and periodic breathing and uses a technology known as adaptive servo-ventilation. We continually seek to identify new applications of our technology for significant unmet medical needs. SDB is associated with a number of symptoms beyond excessive daytime sleepiness and irritability. Recent studies have established a clinical association between SDB and hypertension, stroke, congestive heart failure and diabetes. We support clinical trials in the United States, Germany, France, the United Kingdom, Italy, Switzerland and Australia to develop new clinical applications for our technology. We consult with physicians at major sleep centers throughout the world to identify technological trends in the treatment of SDB. Some of these physicians currently serve on our Medical Advisory Board. New product ideas are also identified by our marketing staff, direct sales force, network of distributors, manufacturers’ representatives, customers and patients. Typically, our internal development staff then develops these ideas, where appropriate, into new products. In fiscal years 2006, 2005 and 2004 we invested $37.2 million, $30.0 million and $26.2 million, respectively, on research and development. Sales and Marketing We currently market our products in over 67 countries using a network of distributors, independent manufacturers’ representatives and our direct sales force. We attempt to tailor our marketing approach to each national market, based on regional awareness of SDB as a health problem, physician referral patterns, consumer preferences and local reimbursement policies. - 11 - North America and Latin America. Our products are typically purchased by a home healthcare dealer who then sells the products to the patient. The decision to purchase our products, as opposed to those of our competitors, is made or influenced by one or more of the following individuals or organizations: the prescribing physician and his or her staff; the home healthcare dealer; the insurer and the patient. In the United States, our sales and marketing activities are conducted through a field sales organization made up of regional territory representatives, program development specialists, regional sales directors and independent manufacturers’ representatives. Our U.S. field sales organization markets and sells products to home healthcare dealer branch locations throughout the United States. Our direct sales force receives a base salary, plus commissions, while our independent sales representatives receive higher commissions, but no base salary. We also promote and market our products directly to sleep clinics. Patients who are diagnosed with OSA and prescribed CPAP treatment are typically referred by the diagnosing sleep clinic to a home healthcare dealer to fill the prescription. The home healthcare dealer, in consultation with the referring physician, will assist the patient in selecting the equipment, fit the patient with the appropriate mask and set the flow generator pressure to the prescribed level. In the United States, our sales employees and manufacturers’ representatives are managed by the Chief Operating Officer Americas and Vice President of Marketing. Our Canadian and Latin American sales are conducted through independent distributors. Sales in North and Latin America accounted for 52%, 51% and 49% of our net revenues for fiscal years 2006, 2005 and 2004, respectively. Europe. We market our products in most major European countries. We have wholly-owned subsidiaries in Austria, Finland, France, Germany, Spain, Sweden, Norway, Netherlands, Switzerland and the United Kingdom that sell our products directly into those countries. We use independent distributors to sell our products in other areas of Europe. Distributors are selected in each country based on their knowledge of respiratory medicine and a commitment to SDB therapy. In each country in which we have a subsidiary, a local senior manager is responsible for direct national sales. In many countries in Europe, we sell our products to home healthcare dealers who then sell the products to the patients. In Germany, we also operate a home healthcare company, in which we provide products and services directly to patients, and receive reimbursement directly from third party payers. Our European Chief Operating Officer is responsible for coordination of all European activities and, in conjunction with local management, the direct sales activity in Europe. Sales in Europe accounted for 39%, 41% and 43% of our total net revenues for fiscal years 2006, 2005 and 2004, respectively. Asia Pacific. Marketing in Asia Pacific and the rest of the world is the responsibility of our Senior Vice President Sales & Marketing Asia Pacific. We have wholly–owned subsidiaries in Australia, Hong Kong, Japan, Malaysia, New Zealand and Singapore that sell our products directly into those countries. We use a combination of our direct sales force and independent distributors in Australia and New Zealand, and use independent distributors to sell our products elsewhere in Asia Pacific. Sales in Asia Pacific and the rest of the world accounted for 9%, 8% and 8% of our total net revenues for the fiscal years 2006, 2005 and 2004, respectively. Other Marketing Efforts. In addition to our and our distributors’ sales efforts, we work with the following cardiovascular disease associations to raise awareness of the co-morbidity of SDB in cardiovascular disease patients, including coronary artery disease, congestive heart failure, hypertension and stroke: • American College of Cardiology. We work with the American College of Cardiology and its more than 20,000 cardiologist members to increase education and awareness in the cardiology community regarding the morbidity associated with sleep apnea in their patients. We have co-sponsored educational symposia with Guidant Corporation at ACC in 2003 and ACC 2004 on sleep apnea and cardiovascular disease. We have exhibited at ACC national conferences since 2001. Sleep apnea was included in the formal ACC scientific sessions in 2004. • American Heart Association. We have worked with the American Heart Association, or AHA, and we have attended the annual Scientific Sessions of the AHA since 2001. Sleep apnea has been on the official program of the Scientific Sessions since 2002. We work with various regional and local AHA affiliates to increase awareness regarding sleep apnea and cardiovascular disease. • Heart Failure Society of America. We have attended the Heart Failure Society of America national conferences since 2002. We have co-sponsored CME-level educational symposia with Guidant Corporation at HFSA 2003 and HFSA 2004 on sleep apnea and heart failure. We continue to see a very high level of interest amongst heart failure physicians, due to the significant (approximately 50%) prevalence of sleep apnea in heart failure patients, and the outcome improvements in blood pressure and ejection fraction observed in peer-reviewed studies using CPAP treatment. - 12 - We also continue to work to raise awareness of SDB in diabetes. Current research is increasingly showing an independent association between OSA and type 2 diabetes. Accordingly, we initiated a study investigating the prevalence of OSA in the type 2 diabetic population. Due to the high prevalence of the co-incidence of SDB and type 2 diabetes, we are now actively supporting the American Association of Diabetes Educators and are in the process of setting up further initiatives to develop the SDB market in the diabetic population. In addition to the above marketing efforts we have strategic alliances with the Guidant Corporation and the MedCath Corporation. The Guidant Corporation is a world leader in the treatment of cardiac and vascular disease. We have entered into an agreement with Guidant pursuant to which the companies will work together in the areas of sleep- disordered breathing and cardiac rhythm disorders, disease states with a significant patient population overlap. Currently the companies plan to collaborate on research and development projects, clinical studies, as well as physician and patient education. MedCath develops, owns and operates hospitals in partnership with cardiologists and cardiovascular surgeons. Our alliance allows MedCath to offer SDB screening, diagnosis and treatment in conjunction with services currently offered through the company’s cardiovascular diagnostic centers. We believe that our affiliations and continued work with these organizations raises the awareness of SDB as a significant health concern. Manufacturing Our principal manufacturing facility is located in Sydney, Australia and comprises a 215,000 square foot manufacturing facility. Our manufacturing operations consist primarily of assembly and testing of our flow generators, masks and accessories. Of the numerous raw materials, parts and components purchased for assembly of our therapeutic and diagnostic sleep disorder products, most are off-the-shelf items available from multiple vendors. We generally manufacture to our internal sales forecasts and fill orders as received. Over the last few years, the manufacturing processes have been transformed along lean manufacturing guidelines to flow lines staffed by dedicated teams. Each team is responsible for the manufacture and quality of their product group and decisions are based on performance and quality measures, including customer feedback. Our quality management system is based upon the requirements of ISO 9001, ISO 13485, FDA Quality System Regulations for Medical Devices and the Medical Device Directive (93/42/EEC). Our Sydney, Australia and San Diego, California facilities are each accredited to ISO 9001 and ISO 13485. These two sites have third party audits conducted by the ISO certification bodies at regular intervals. Our German manufacturing operation based in Munich operates in a facility of approximately 24,000 square feet. This facility is accredited to ISO 13485 and primarily assembles and tests flow generators for sale by our German subsidiary. Appropriate quality controls monitor and measure product assembly and performance. As part of the acquisition of Saime SA on May 19, 2005, we acquired a 7,000 square foot manufacturing facility in Paris, France. This facility is accredited to ISO 13485 and is primarily responsible for the assembly of the Saime brand of mechanical ventilators and associated accessories. We also manufacture high-quality electric motors for both our flow generator devices and external customers, primarily in the data storage sector, at our Servo Magnetics Inc., or SMI, facility at Canoga Park, California. The SMI facility is approximately 35,500 square feet. We have recently leased a larger site of 72,000 square feet within Chatsworth California and expect to move to this new SMI facility in October 2006. Third-Party Reimbursement The cost of medical care in many of the countries in which we operate is funded in substantial part by government and private insurance programs. In Germany, we receive payments directly from these payers. Outside Germany, although we do not generally receive payments for our products directly from these payers, our success in major markets is dependent upon the ability of patients to obtain adequate reimbursement for our products. In the United States, our products are purchased primarily by home healthcare dealers, hospitals or sleep clinics, which then invoice third-party payers directly for reimbursement. Domestic third-party payers include Medicare, Medicaid and corporate health insurance plans. These payers may deny reimbursement if they determine that a device is not used in accordance with cost-effective treatment methods, or is experimental, unnecessary or inappropriate. The long-term trend towards managed healthcare, or legislative proposals to reform healthcare, could control or significantly influence the purchase of healthcare services and products and could result in lower prices for our products. In some foreign markets, such as Spain, France and Germany, government reimbursement is currently available for purchase or rental of our products, however, subject to constraints such as price controls or unit sales limitations. In Australia and in some other foreign markets, there is currently limited or no reimbursement for devices that treat OSA. Even though we do not file claims or bill governmental programs and other third-party payers directly for reimbursement for our products sold in the United States, we are still subject to laws and regulations relating to governmental programs, and any violation of these laws and regulations could result in civil and criminal penalties, - 13 - including fines. In particular, the federal Anti-Kickback Law prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending or arranging for a good or service, for which payment may be made under a Federal healthcare program such as the Medicare and Medicaid programs. The government has interpreted this law broadly to apply to the marketing and sales activities of manufacturers and distributors like us. Many states have adopted laws similar to the federal Anti-Kickback Law. We are also subject to other federal and state fraud laws applicable to payment from any third-party payer. These laws prohibit persons from knowingly and willfully filing false claims or executing a scheme to defraud any healthcare benefit program, including private third-party payers. These laws may apply to manufacturers and distributors who provide information on coverage, coding and reimbursement of their products to persons who bill third-party payers. We continuously strive to comply with these laws and believe that our arrangements do not violate these laws. Liability may still arise from the intentions or actions of the parties with whom we do business or from a different governmental agency interpretation of the laws. Service and Warranty We generally offer one-year and two-year limited warranties on our flow generator products. Warranties on mask systems are for 90 days. In most markets, we rely on our distributors to repair our products with parts supplied by us. In the United States, home healthcare dealers generally arrange shipment of products to our San Diego facility for repair. We receive returns of our products from the field for various reasons. We believe that the level of returns experienced to date is consistent with levels typically experienced by manufacturers of similar devices. We provide for warranties and returns based on historical data. Competition The markets for our products are highly competitive. We believe that the principal competitive factors in all of our markets are product features, reliability and price. Customer support, reputation and efficient distribution are also important factors. We compete on a market-by-market basis with various companies, some of which have greater financial, research, manufacturing and marketing resources than us. In the United States, our principal market, Respironics Inc.; DeVilbiss, a division of Sunrise Medical Inc.; Nellcor Puritan Bennett, a subsidiary of Tyco Inc.; and Fisher & Paykel Healthcare Corporation Limited are the primary competitors for our products. Our principal European competitors are also Respironics, DeVilbiss, and Nellcor Puritan Bennett, as well as regional European manufacturers. The disparity between our resources and those of our competitors may increase as a result of the trend towards consolidation in the healthcare industry. In addition, our products compete with surgical procedures and dental appliances designed to treat OSA and other SDB related respiratory conditions. The development of new or innovative procedures or devices by others could result in our products becoming obsolete or noncompetitive, which would harm our revenues and financial condition. Any product developed by us that gains regulatory clearance will have to compete for market acceptance and market share. An important factor in such competition may be the timing of market introduction of competitive products. Accordingly, the relative speed with which we can develop products, complete clinical testing and regulatory clearance processes and supply commercial quantities of the product to the market are important competitive factors. In addition, our ability to compete will continue to be dependent on the extent to which we are successful in protecting our patents and other intellectual property. - 14 - Patents and Proprietary Rights and Related Litigation Through our subsidiaries ResMed Limited, Medizintechnik fur Arzt und Patient GmbH, SMI and Saime SA, we own or have licensed rights to 192 issued U.S. patents (including 56 design patents) and 242 issued foreign patents. In addition, there are 182 pending U.S. patent applications (including 41 design patent applications), 369 pending foreign patent applications, 312 registered foreign designs and 107 pending foreign designs. Some of these patents, patent applications and designs relate to significant aspects and features of our products. Of our patents, nine U.S. patents and four foreign patents are due to expire in the next five years, with one foreign patent due to expire in each of the years 2005, 2007, 2009 and U.S. patents in 2010. We believe that the expiration of these patents will not have a material adverse impact on our competitive position. We rely on a combination of patents, trade secrets, copyrights, trademarks and non-disclosure agreements to protect our proprietary technology and rights. Litigation may be necessary to attempt to enforce patents issued to us, to protect our rights, or to defend third-party claims of infringement by us of the proprietary rights of others. Patent laws regarding the enforceability of patents vary from country to country. Therefore, we cannot assure you that patent issues will be uniformly resolved, or that local laws will provide us with consistent rights and benefits. Government Regulations Our products are subject to extensive regulation particularly as to safety, efficacy and adherence to FDA Quality System Regulation, and related manufacturing standards. Medical device products are subject to rigorous FDA and other governmental agency regulations in the United States and regulations of relevant foreign agencies abroad. The FDA regulates the introduction, manufacture, advertising, labeling, packaging, marketing, distribution and record keeping for such products, in order to ensure that medical products distributed in the United States are safe and effective for their intended use. In addition, the FDA is authorized to establish special controls to provide reasonable assurance of the safety and effectiveness of most devices. Non-compliance with applicable requirements can result in import detentions, fines, civil penalties, injunctions, suspensions or losses of regulatory approvals, recall or seizure of products, operating restrictions, refusal of the government to approve product export applications or allow us to enter into supply contracts, and criminal prosecution. The FDA requires that a manufacturer introducing a new medical device or a new indication for use of an existing medical device obtain either a Section 510(k) premarket notification clearance or a premarket approval, or PMA, before introducing it into the U.S. market. Our products currently marketed in the United States are marketed in reliance on 510(k) pre-marketing clearances as either Class I or Class II devices. The process of obtaining a Section 510(k) clearance generally requires the submission of performance data and often clinical data, which in some cases can be extensive, to demonstrate that the device is “substantially equivalent” to a device that was on the market before 1976 or to a device that has been found by the FDA to be “substantially equivalent” to such a pre-1976 device. As a result, FDA approval requirements may extend the development process for a considerable length of time. In addition, in some cases, the FDA may require additional review by an advisory panel, which can further lengthen the process. The PMA process, which is reserved for new devices that are not substantially equivalent to any predicate device and for high-risk devices or those that are used to support or sustain human life, may take several years and requires the submission of extensive performance and clinical information. As a medical device manufacturer, all of our domestic and Australian manufacturing facilities are subject to inspection on a routine basis by the FDA. We believe that our design, manufacturing and quality control procedures are in substantial compliance with the FDA’s regulatory requirements. Sales of medical devices outside the United States are subject to regulatory requirements that vary widely from country to country. Approval for sale of our medical devices in Europe is through the CE mark process. Where appropriate, our products are CE marked to the European Union’s Medical Device Directive. Under the CE marketing scheme, our products are classified as either Class I or Class II. Our devices are listed in Australia with the Therapeutic Goods Administration, or TGA, and in Canada with Health Canada. - 15 - On August 16, 2005, the FDA authorized us to market our VPAP Adapt SV device in the United States pursuant to a 510(K) clearance. The device is indicated for the treatment of respiratory insufficiency due to central sleep apnea, mixed apnea and periodic breathing. This product is essentially the same device as the AutoSet CS2, which has been commercially available outside the U.S. for a number of years. The VPAP Adapt SV uses a technology known as adaptive servo-ventilation and was first made available to a select group of U.S. key opinion leader sites beginning in the third quarter of fiscal 2006. Physicians have found tremendous benefit from this technology as it has successfully treated the complex breathing disorders of many patients who had previously tried and failed traditional PAP therapy. Employees As of June 30, 2006, we had approximately 2,500 employees or full time consultants, of which approximately 900 persons were employed in warehousing and manufacturing, 300 in research and development, 1,300 in sales, marketing and administration. Of our employees and consultants approximately, 1,100 were located in Australia, 500 in the United States, 800 in Europe and 100 in Asia. We believe that the success of our business will depend, in part, on our ability to attract and retain qualified personnel. None of our employees is covered by a collective bargaining agreement. We believe that our relationship with our employees is good. Medical Advisory Board Our Medical Advisory Board, consists of physicians specializing in the field of sleep-disordered breathing and ventilation. During fiscal 2006 the Medical Advisory Board members met as a group with members of our senior management and members of our research and marketing departments to advise us on technology trends in SDB and other developments in sleep disorders medicine. Medical Advisory Board members are also available to consult on an as-needed basis with our senior management. In alphabetical order, Medical Advisory Board members during fiscal 2006 included: Claudio Bassetti, M.D. Michael Coppola, M.D. Terence M. Davidson, M.D. Anthony N. DeMaria, M.D. Neil J. Douglas, M.D. Nicholas Hill, M.D. Barry J. Make, M.D. Ralph Pascualy, M.D. Barbara Phillips, M.D. Bruce Robinson, M.D. Jonathan R. L. Schwartz, M.D. Helmut Teschler, M.D. B. Tucker Woodson, M.D. - 16 - ITEM 1A RISK FACTORS Before deciding to purchase, hold or sell our common stock, you should carefully consider the risks described below in addition to the other cautionary statements and risks described elsewhere, and the other information contained, in this Report and in our other filings with the SEC, including our subsequent reports on Forms 10-Q and 8-K. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our business. If any of these known or unknown risks or uncertainties actually occurs with material adverse effects on us, our business, financial condition and results of operations could be seriously harmed. In that event, the market price for our common stock will likely decline, and you may lose all or part of your investment. Our inability to compete successfully in our markets may harm our business. The markets for our sleep- disordered breathing products are highly competitive and are characterized by frequent product improvements and evolving technology. Our ability to compete successfully depends, in part, on our ability to develop, manufacture and market innovative new products. The development of innovative new products by our competitors or the discovery of alternative treatments or potential cures for the conditions that our products treat could make our products noncompetitive or obsolete. Additionally, some of our competitors have greater financial, research and development, manufacturing and marketing resources than we do. The past several years have seen a trend towards consolidation in the healthcare industry and in the markets for our products. Industry consolidation could result in greater competition if our competitors combine their resources or if our competitors are acquired by other companies with greater resources than ours. This competition could increase pressure on us to reduce the selling prices of our products or could cause us to increase our spending on research and development and sales and marketing. If we are unable to develop innovative new products, maintain competitive pricing, and offer products that consumers perceive to be as reliable as those of our competitors, our sales or gross margins could decrease which would harm our business. Our business depends on our ability to market effectively to dealers of home healthcare products and sleep clinics. We market our products primarily to home healthcare dealers and to sleep clinics that diagnose OSA and other sleep disorders. We believe that home healthcare dealers and sleep clinics play a significant role in determining which brand of product a patient will use. The success of our business depends on our ability to market effectively to home healthcare dealers and sleep clinics to ensure that our products are properly marketed and sold by these third parties. We have limited resources to market to approximately the 3,000 U.S. sleep clinics and the more than 6,000 home healthcare dealer branch locations, most of which use, sell or recommend several brands of products. In addition, home healthcare dealers have experienced price pressures as government and third-party reimbursement has declined for home healthcare products, and home healthcare dealers are requiring price discounts and longer periods of time to pay for products purchased from us. We cannot assure you that sleep clinic physicians will continue to prescribe our products, or that home healthcare dealers or patients will not substitute competing products when a prescription specifying our products has been written. We have expanded our marketing activities to target the population with a predisposition to sleep- disordered breathing as well as primary care physicians and various medical specialists. We cannot assure you that these marketing efforts will be successful in increasing awareness or sales of our products. inability to market Any impact our profitability. Approximately half our revenues are generated outside the U.S., in over 67 different countries. Many of these countries have unique regulatory, medical and business environments, which may adversely impact our ability to market our products. If we are unable to market effectively our products outside the U.S., our overall financial performance could decline. effectively our products outside the U.S. could Fluctuations in foreign currency exchange rates could result in declines in our reported sales and earnings. Since our international sales and a significant portion of our manufacturing costs are denominated in local currencies and not in U.S. dollars, our reported sales and earnings are subject to fluctuations in foreign exchange rates. We had foreign currency transaction losses in recent periods and may have further losses in the future. We expect that international sales will continue to be a significant portion of our business and that a significant portion of our manufacturing costs will continue to be denominated in Australian dollars. If we are unable to support our continued growth, our business could suffer. We have experienced rapid and substantial growth. As we continue to grow, the complexity of our operations increases, placing greater demands on our management. Our ability to manage our growth effectively depends on our ability to implement and improve our financial and management information systems on a timely basis and to effect other changes in our business. - 17 - Unexpected difficulties during expansion, the failure to attract and retain qualified employees, the failure to successfully replace or upgrade our management information systems, the failure to manage costs or our inability to respond effectively to growth or plan for future expansion could cause our growth to stop. If we fail to manage effectively and efficiently our growth, our costs could increase faster than our revenues and our business could suffer. If we fail to integrate our recent acquisitions with our operations, our business could suffer. During the year ended June 30, 2006, we acquired PolarMed and Pulmomed and during the fiscal year ended June 30, 2005, we acquired Saime, Hoefner and Resprecare. We are currently in the process of integrating our operations with these recent acquisitions. The integration will require significant efforts from each company. We may find it difficult to integrate the operations as personnel may leave and licensees, distributors or suppliers may terminate their arrangements or demand amended terms to these arrangements. Additionally, our management may have their attention diverted while trying to integrate these companies. If we are not able to successfully integrate the operations, we may not realize the anticipated benefits of these acquisitions. If we fail to implement our restructure plans successfully, our business could suffer. In fiscal year 2005, we merged the operations of ResMed Germany and MAP into a single operating unit as part of our German restructure plan. We will continue to monitor the progress of this restructure and adjust our business strategies and personnel accordingly to achieve maximum efficiencies, cost savings and success. If we are not able to integrate the operations successfully, we may not fully realize the anticipated benefits of the restructure. Changes in assumptions used in the purchase accounting of our recent acquisitions may impact our future operating results. The acquisitions noted above have been accounted for using purchase accounting and accordingly have been included in our operations since the date of acquisition. We allocate the purchase price according to the fair value of assets and liabilities assumed, intangible assets and in process research and development as at the date of acquisition. The excess of the purchase price over the fair values of acquired net assets is recorded as goodwill. We utilize independent appraisals with our own internal studies and management assumptions to estimate the fair values. If our estimates change due to inaccurate assumptions or other circumstances our future financial results maybe impacted. This may result in goodwill becoming impaired and changes to the amount of amortization charges of certain identifiable intangible assets. We are subject to various risks relating to international activities that could affect our overall profitability. We manufacture substantially all of our products outside the U.S. and sell a significant portion of our products in non-U.S. markets. Sales outside North and Latin America accounted for approximately 48% and 49% of our net revenues in the years ended June 30, 2006 and 2005, respectively. We expect that sales within these areas will account for approximately 50% of our net revenues in the foreseeable future. Our sales outside of North America and our operations in Europe, Australia and Asia are subject to several difficulties and risks that are separate and distinct from those we face in our U.S. operations, including: • • • • • • • • fluctuations in currency exchange rates; tariffs and other trade barriers; compliance with foreign medical device manufacturing regulations; reduction in third party payer reimbursement for our products; inability to obtain import licenses; changes in trade policies and in U.S. and foreign tax policies; possible changes in export or import restrictions; and the modification or introduction of other governmental policies with potentially adverse effects. Government and private insurance plans may not adequately reimburse patients for our products, which could result in reductions in sales or selling prices for our products. Our ability to sell our products depends in large part on the extent to which reimbursement for the cost of our products will be available from government health administration authorities, private health insurers and other organizations. These third party payers are increasingly challenging the prices charged for medical products and services. Therefore, even if a product is approved for marketing, we cannot assure you that reimbursement will be allowed for the product, that the reimbursement amount will be adequate or, that the reimbursement amount even if initially adequate, will not subsequently be reduced. For example, in some markets, such as Spain, France and Germany, government reimbursement is currently available for purchase or rental of our products but is subject to constraints such as price controls or unit sales limitations. In other markets, such as Australia and the United Kingdom, there is currently limited or no reimbursement for devices that treat sleep-disordered breathing conditions. Additionally, future legislation or regulation concerning the healthcare industry or third party or governmental coverage and reimbursement, particularly legislation or regulation limiting consumers’ reimbursement rights, may harm our business. As we continue to develop new products, those products will generally not qualify for reimbursement, if at all, until they are approved for marketing. In the United States, we sell our products primarily to home healthcare dealers and to - 18 - sleep clinics. We do not file claims and bill governmental programs and other third party payers directly for reimbursement for our products. However, we are still subject to laws and regulations relating to governmental reimbursement programs, particularly Medicaid and Medicare. In addition to reimbursement for our products, our customers depend in part on reimbursement by government and private health insurers for other products. Any proposed reductions in reimbursement, if they occur, may have a material impact on our customers. Any material impact on our customers may indirectly affect our sales to those customers, or the collectibility of receivables we have from those customers. Failure to comply with anti-kickback and fraud regulations could result in substantial penalties and changes in our business operations. In particular, the federal Anti-Kickback Law prohibits persons from knowingly and willfully soliciting, receiving, offering or providing remuneration, directly or indirectly, to induce either the referral of an individual, or the furnishing, recommending or arranging for a good or service, for which payment may be made under a federal healthcare program such as the Medicare and Medicaid programs. The U.S. government has interpreted this law broadly to apply to the marketing and sales activities of manufacturers and distributors like us. Many states and other governments have adopted laws similar to the federal Anti-Kickback Law. We are also subject to other federal and state fraud laws applicable to payment from any third party payer. These laws prohibit persons from knowingly and willfully filing false claims or executing a scheme to defraud any healthcare benefit program, including private third party payers. These laws may apply to manufacturers and distributors who provide information on coverage, coding, and reimbursement of their products to persons who do bill third party payers. Any violation of these laws and regulations could result in civil and criminal penalties (including fines), increased legal expenses and exlusions from governmental reimbursement programs, all of which could have a material adverse effect upon our business, financial conditions and results of operations. Complying with Food and Drug Administration, or FDA, and other regulations is an expensive and time- consuming process, and any failure to comply could result in substantial penalties. We are subject to various federal, state, local and international regulations regarding our business activities. Failure to comply with these regulations could result in, among other things, recalls of our products, substantial fines and criminal charges against us or against our employees. A recall or other regulatory action could increase our costs, damage our reputation, and materially affect our operating results. Product sales, introductions or modifications may be delayed or canceled as a result of FDA regulations or similar foreign regulations, which could cause our sales and profits to decline. Before we can market or sell a new medical device in the United States, we must obtain FDA clearance, which can be a lengthy and time-consuming process. We generally receive clearance from the FDA to market our products in the United States under Section 510(k) of the Federal Food, Drug, and Cosmetic Act or our products are exempt from the 510(k) clearance process. We have modified some of our 510(k) approved products without submitting new 510(k) notices, which we do not believe were required. However, if the FDA disagrees with us and requires us to submit new 510(k) notifications for modifications to our existing products, we may be required to stop marketing the products while the FDA reviews the 510(k) notification. Any new product introduction or existing product modification could be subjected to a lengthier, more rigorous FDA examination process. For example, in certain cases we may need to conduct clinical trials of a new product before submitting a 510(k) notice. Additionally, we may be required to obtain premarket approvals for our products. The requirements of these more rigorous processes could delay product introductions and increase the costs associated with FDA compliance. Marketing and sale of our products outside the United States are also subject to regulatory clearances and approvals, and if we fail to obtain these regulatory approvals, our sales could suffer. We cannot assure you that any new products we develop will receive required regulatory approvals from U.S. or foreign regulatory agencies. - 19 - Off-label marketing of our products could result in substantial penalties. Clearance under Section 510(k) only permits us to market our products for the uses indicated on the labeling cleared by the FDA. We may request additional label indications for our current products, and the FDA may deny those requests outright, require additional expensive clinical data to support any additional indications or impose limitations on the intended use of any cleared products as a condition of clearance. If the FDA determines that we have marketed our products for off-label use, we could be subject to fines, injunctions or other penalties. Disruptions in the supply of components from our single source suppliers could result in a significant reduction in sales and profitability. We purchase uniquely configured components for our devices from various suppliers, including some who are single-source suppliers for us. We cannot assure you that a replacement supplier would be able to configure its components for our devices on a timely basis or, in the alternative, that we would be able to reconfigure our devices to integrate the replacement part. A reduction or halt in supply while a replacement supplier reconfigures its components, or while we reconfigure our devices for the replacement part, would limit our ability to manufacture our devices, which could result in a significant reduction in sales and profitability. We cannot assure you that our inventories would be adequate to meet our production needs during any prolonged interruption of supply. Our intellectual property may not protect our products, and/or our products may infringe on the intellectual property rights of third parties. We rely on a combination of patents, trade secrets and non-disclosure agreements to protect our intellectual property. Our success depends, in part, on our ability to obtain and maintain United States and foreign patent protection for our products, their uses and our processes to preserve our trade secrets and to operate without infringing on the proprietary rights of third parties. We have a number of pending patent applications, and we do not know whether any patents will issue from any of these applications. We do not know whether any of the claims in our issued patents or pending applications will provide us with any significant protection against competitive products or otherwise be commercially valuable. Legal standards regarding the validity of patents and the proper scope of their claims are still evolving, and there is no consistent law or policy regarding the valid breadth of claims. Additionally, there may be third party patents, patent applications and other intellectual property relevant to our products and technology which are not known to us and that block or compete with our products. We face the risks that: • • third parties will infringe our intellectual property rights; our non-disclosure agreements will be breached; • we will not have adequate remedies for infringement; • • our trade secrets will become known to or independently developed by our competitors; or third parties will be issued patents that may prevent the sale of our products or require us to license and pay fees or royalties in order for us to be able to market some of our products. Litigation may be necessary to enforce patents issued to us, to protect our proprietary rights, or to defend third party claims that we have infringed upon proprietary rights of others. For example, we are currently appealing the decision of a court in Germany that entered judgment in favor of certain plaintiffs that had claimed they should be listed as co- inventors on two of our German patent applications. The defense and prosecution of patent claims, including these pending claims, as well as participation in other inter-party proceedings, can be expensive and time consuming, even in those instances in which the outcome is favorable to us. If the outcome of any litigation or proceeding brought against us were adverse, we could be subject to significant liabilities to third parties, could be required to obtain licenses from third parties, could be forced to design around the patents at issue or could be required to cease sales of the affected products. A license may not be available at all or on commercially viable terms, and we may not be able to redesign our products to avoid infringement. Additionally, the laws regarding the enforceability of patents vary from country to country, and we cannot assure you that any patent issues we face will be uniformly resolved, or that local laws will provide us with consistent rights and benefits. - 20 - We are subject to potential product liability claims that may exceed the scope and amount of our insurance coverage, which would expose us to liability for uninsured claims. We are subject to potential product liability claims as a result of the design, manufacture and marketing of medical devices. Any product liability claim brought against us, with or without merit, could result in the increase of our product liability insurance rates. In addition, we would have to pay any amount awarded by a court in excess of our policy limits. Our insurance policies have various exclusions, and thus we may be subject to a product liability claim for which we have no insurance coverage, in which case, we may have to pay the entire amount of any award. We cannot assure you that our insurance coverage will be adequate or that all claims brought against us will be covered by our insurance. Insurance varies in cost and can be difficult to obtain, and we cannot assure you that we will be able to obtain insurance in the future on terms acceptable to us or at all. A successful product liability claim brought against us in excess of our insurance coverage, if any, may require us to pay substantial amounts, which could harm our business. We are subject to tax audits by various tax authorities in many jurisdictions. From time to time we may be audited by the tax authorities and are still subject to an ongoing German tax audit. Any final assessment resulting from this audit could result in material changes to our past or future taxable income, tax payable or deferred tax assets, and could require us to pay penalties and interest that could materially adversely affect our financial results. Our quarterly operating results are subject to fluctuation for a variety of reasons. Our operating results have, from time to time, fluctuated on a quarterly basis and may be subject to similar fluctuations in the future. These fluctuations may result from a number of factors, including: • • • • • • • • • • • • the introduction of new products by us or our competitors; the geographic mix of product sales; the success of our marketing efforts in new regions; changes in third party reimbursement; timing of regulatory clearances and approvals; timing of orders by distributors; expenditures incurred for research and development; competitive pricing in different regions; seasonality; the cost and effect of promotional and marketing programs; the effect of foreign currency transaction gains or losses; and other activities of our competitors. Fluctuations in our quarterly operating results may cause the market price of our common stock to fluctuate. If a natural or man-made disaster strikes our manufacturing facilities, we will be unable to manufacture our products for a substantial amount of time and our sales and profitability will decline. Our facilities and the manufacturing equipment we use to produce our products would be costly to replace and could require substantial lead-time to repair or replace. The facilities may be affected by natural or man-made disasters and in the event they were affected by a disaster, we would be forced to rely on third party manufacturers. Although we believe we possess adequate insurance for damage to our property and the disruption of our business from casualties, such insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. Delaware law, provisions in our charter and our shareholder rights plan could make it difficult for another company to acquire us. Provisions of our certificate of incorporation may have the effect of delaying or preventing changes in control or management which might be beneficial to us or our security holders. In particular, our board of directors is divided into three classes, serving for staggered three-year terms. Because of this classification it will require at least two annual meetings to elect directors constituting a majority of our board of directors. Additionally, our board of directors has the authority to issue up to 2,000,000 shares of preferred stock and to determine the price, rights, preferences, privileges and restrictions, including voting rights, of those shares without further vote or action by the stockholders. Under our stockholder rights plan, we have also issued purchase rights to the holders of our common stock that entitle those holders to purchase our Series A Junior Participating Preferred Stock at a discount, under certain circumstances. The rights of the holders of our common stock will be subject to, and may be adversely affected by, the rights of the holders of any preferred stock that may be issued in the future. The issuance of preferred stock may have the effect of delaying, deferring or preventing a change in control, may discourage bids for our common stock at a premium over the market price of our common stock and may adversely affect the market price of our common stock and the voting and other rights of the holders of our common stock. You may not be able to enforce the judgments of U.S. courts against some of our assets or officers and directors. A substantial portion of our assets are located outside the United States. Additionally, two of our eight - 21 - directors and three of our seven executive officers reside outside the United States, along with all or a substantial portion of the assets of these persons. As a result, it may not be possible for investors to enforce judgments of U.S. courts relating to any liabilities under U.S. securities laws against our assets, those persons or their assets. In addition, we have been advised by our Australian counsel that some doubt exists as to the ability of investors to pursue claims based on U.S. securities laws against these assets or these persons in Australian courts. ITEM 2 PROPERTIES Our principal executive offices and U.S. distribution facilities, consisting of approximately 144,000 square feet, are located in Poway (North San Diego County), California in a building we own. We lease facilities consisting of approximately 120,000 square feet for our research and development operations at North Ryde, in Sydney, Australia. We own our principal manufacturing facility consisting of a 215,000 square foot complex at Norwest, also in Sydney, Australia and lease in Canoga Park, California a 35,500 square foot facility for manufacture of electronic motors. On July 7, 2005, we purchased a 9.78 acre parcel of land at Kearney Mesa, San Diego for $21.0 million to develop our new corporate headquarters. Sales and warehousing facilities are either leased or owned in Abingdon, England; Munich, Germany; Bremen, Germany; Hochstadt, Germany; Lyon, France; Paris, France; Basel, Switzerland; Trollhaettan, Sweden; Villach and Vienna, Austria; Helsinki, Finland; Den Haag, Netherlands; Oslo, Norway and Singapore. ITEM 3 LEGAL PROCEEDINGS In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not have a material adverse effect on our consolidated financial statements taken as a whole. During September and October 2004, we began receiving tax assessment notices for the audit of one of our German subsidiaries by the German tax authorities for the years 1996 through 1998. Certain of these adjustments are being contested and appealed to the German tax authority office. We believe no additional provision is necessary for any tax adjustment that may result from the tax audit. However, the outcome of the audit cannot be predicted with certainty. Should any tax audit issues be resolved in a manner not consistent with management’s expectations, we could be required to adjust our provision for income tax in the period of resolution. On December 23, 2002, three former contractors of our subsidiary MAP Medizin-Technologie GmbH initiated proceedings in Munich 1 Regional Court (Proceedings No. 7 O 23286/02), petitioning the Court for a declaration of inventorship with respect to MAP German Patent Applications identified as No. 100 31 079 and 101 92 802.5 and European Patent Application No. EP 01 967 819.7. On March 10, 2005, the Court entered judgement in favor of the plaintiffs, finding that they should be identified as co-inventors in place of certain individual defendants. In April 2005, MAP filed an appeal of that decision. We do not expect the outcome of this litigation to have an adverse material effect on our consolidated financial statements. In March 2006 an Australian university made a demand that we pay extra royalties pursuant to a current patent license agreement. We rejected the demand and the University has agreed to discuss our position. We do not consider the claim to have merit. We do not expect that the outcome of this demand to have an adverse material effect on our consolidated financial statements. ITEM 4 SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS None. - 22 - PART II ITEM 5 MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Our common stock is traded on the New York Stock Exchange (NYSE) under the symbol “RMD”. The following table sets forth for the fiscal periods indicated the high and low closing prices for the common stock as reported by the New York Stock Exchange. Quarter One, ended September 30 Quarter Two, ended December 31 Quarter Three, ended March 31 Quarter Four, ended June 30 2006 2005 High $40.03 42.72 44.31 48.50 Low $32.21 37.01 36.86 41.76 High $25.75 25.55 30.25 33.14 Low $21.95 21.73 24.91 28.15 As of August 23, 2006, there were 48 holders of record of our common stock. We have not paid any cash dividends on our common stock since the initial public offering of our common stock and we do not currently intend to pay cash dividends in the foreseeable future. We anticipate that all of our earnings and other cash resources, if any, will be retained for the operation and expansion of our business and for general corporate purposes. All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 10, 2005 and distributed on September 30, 2005. Sale of Unregistered Securities During fiscal year 2006, and pursuant to the Indenture dated June 20, 2001 between us and American Stock Transfer & Trust Company, as trustee, holders of all of our 4% Convertible Subordinated Notes (“the Notes”) due 2006 converted the Notes into an aggregate of approximately 3,737,593 shares of our common stock, par value $0.004, based on a conversion price of $30.30 per share. The shares of common stock were issued solely to existing security holders upon conversion of the Notes pursuant to the exemption from registration provided under Section 3(a)(9) of the Securities Exchange Act 1993, as amended. We did not pay or give, directly or indirectly, any commission or other remuneration for soliciting such conversion. Purchases of Equity Securities The following table summarizes purchases by us of our common stock during the year ended June 30, 2006: Period Opening Balance at July 1, 2005 July 2005 August 2005 September 2005 October 2005 November 2005 December 2005 January 2006 February 2006 March 2006 April 2006 May 2006 June 2006 Total to June 30, 2006 Total Number of Shares 2,254,918 Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 2,254,918 Average Price Paid per Share $18.36 Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (1) 2,254,918 Maximum Number of Shares that May yet be Purchased Under the Plans or Programs(1) 5,745,082 $18.36 2,254,918 5,745,082 (1) On June 6, 2002, the Board of Directors authorized us to repurchase up to 8.0 million shares of our outstanding common stock. There is no expiration date for the repurchase of these shares. For the years ended June 30, 2006 and 2005, we repurchased NIL and 482,000 shares at a cost of $NIL and $11.0 million respectively. At June 30, 2006, we have repurchased a total of 2,254,918 shares at a cost of $41.4 million. We may continue to repurchase shares of our common stock for cash in the open market, or in negotiated or block transactions, from time to time as market and business conditions warrant. - 23 - ITEM 6 SELECTED FINANCIAL DATA The following table summarizes certain selected consolidated financial data for, and as of the end of, each of the fiscal years in the five-year period ended June 30, 2006. The data set forth below should be read in conjunction with the Management’s Discussion and Analysis of Financial Condition and Results of Operations and our Consolidated Financial Statements and related Notes included elsewhere in this Report. The consolidated statements of operations data for the years ended June 30, 2006, 2005 and 2004 and the balance sheet data as of June 30, 2006 and 2005 are derived from our audited consolidated financial statements included elsewhere in this Report. The consolidated statements of operations data for the years ended June 30, 2003 and 2002 and the balance sheet data as of June 30, 2004, 2003 and 2002 are derived from our audited consolidated financial statements not included herein. Historical results are not necessarily indicative of the results to be expected in the future, and the results for the years presented should not be considered indicative of our future results of operations. Consolidated Statement of Income Data: (In thousands, except per share data) Net revenues Cost of sales Gross profit Selling, general and administrative expenses Research and development expenses Donations to Research Foundations In-process research and development charge Amortization of acquired intangible assets Restructuring expenses Other income (expenses): Interest income (expense), net Other, net Gain on extinguishment of debt Total other income (expenses) Income before income taxes Income taxes Net income Basic earnings per share Diluted earnings per share Basic shares outstanding Diluted shares outstanding 2006 2005 2004 2003 2002 Years Ended June 30 $606,996 230,101 $425,505 150,645 376,895 274,860 200,168 135,703 37,216 30,014 760 - 6,327 1,124 500 5,268 870 5,152 1,320 774 - 2,094 (808) 81 - (727) 133,394 (45,183) 96,626 (31,841) $339,338 122,602 216,736 104,706 26,169 500 - - - 131,375 85,361 (1,683) 990 - (693) 84,668 (27,384) $273,570 100,483 $204,076 70,827 173,087 133,249 85,313 20,534 - - - - 105,847 67,240 (2,549) 1,907 529 (113) 67,127 (21,398) 64,481 14,910 2,349 350 - - 82,090 51,159 (3,224) 108 6,549 3,433 54,592 (17,086) $88,211 $64,785 $57,284 $45,729 $37,506 $1.22 $1.16 72,307 77,162 $0.94 $0.91 68,643 74,942 $0.85 $0.82 67,389 70,251 $0.69 $0.66 66,108 68,878 $0.58 $0.55 64,348 68,161 Total operating expenses 245,595 177,507 Income from operations 131,300 97,353 All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 10, 2005 and distributed on September 30, 2005. - 24 - Consolidated Balance Sheet Data: (In thousands) Working capital Total assets Long-term debt, less current maturities 2006 $381,284 1,007,221 116,212 Total stockholders’ equity 738,148 2005 $141,659 774,146 58,934 474,065 As of June 30 2004 $222,230 549,151 113,250 361,499 2003 $191,322 459,595 113,250 286,433 2002 $142,809 376,191 123,250 192,930 ITEM 7 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Overview Management’s discussion and analysis of financial condition and results of operations should be read in conjunction with selected financial data and consolidated financial statements and notes, included herein. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements due to known and unknown risks, uncertainties and other factors, including those risks discussed in “Risk Factors” and elsewhere in this report. We are a leading developer, manufacturer and distributor of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. Sleep-disordered breathing, or SDB, includes obstructive sleep apnea, or OSA, and other respiratory disorders that occur during sleep. When we were formed in 1989, our primary purpose was to commercialize a treatment for OSA developed by Professor Colin Sullivan. This treatment, nasal Continuous Positive Airway Pressure, or CPAP, was the first successful noninvasive treatment for OSA. CPAP systems deliver pressurized air, typically through a nasal mask, to prevent collapse of the upper airway during sleep. We have invested significant resources in research and development and product enhancement. Since the development of CPAP, we have developed a number of innovative products for SDB and other respiratory disorders including airflow generators, diagnostic products, mask systems, headgear and other accessories. Our growth has been fuelled by geographic expansion, increased awareness of respiratory conditions as a significant health concern among physicians and patients, and our research and product development effort. We currently employ approximately 2,500 people and market our products in over 67 countries using a network of distributors, independent manufacturers’ representatives and our direct sales force. We market our products primarily to home health care dealers and sleep clinics. We attempt to tailor our marketing approach to each national market, based on regional awareness of SDB as a health problem, physician referral patterns, consumer preferences and local reimbursement policies. Our principal manufacturing facility is located in Sydney, Australia, and we have additional manufacturing facilities in Munich, Germany, Combs La Ville, France and Canoga Park, California. Our manufacturing operations consist primarily of assembly and testing of our flow generators, masks and accessories. Of the numerous raw materials, parts and components purchased for assembly of our therapeutic and diagnostic sleep disorder products, most are off-the- shelf items available from multiple vendors. We generally manufacture to our internal sales forecasts and fill orders as received. - 25 - Business Acquisitions Fiscal year ended June 30, 2006 PolarMed Holding AS (“PolarMed”). On December 1, 2005, we acquired 100% of the outstanding stock of PolarMed, the holding company for PolarMed AS and its affiliates, for net cash consideration of $6.5 million. This consisted of $6.8 million in consideration less $0.3 million of cash acquired. Additionally, as part of the acquisition we assumed debt of $1.5 million. Under the purchase agreement, we may also be required to make additional future payments of up to $3.0 million based on the achievement of certain performance milestones following the acquisition through December 31, 2008. The acquisition and the immediate repayment of the majority of the assumed debt were funded with cash on hand. PolarMed is predominantly a Norwegian based company, with affiliated operations based in Sweden and Denmark, which distributes medical equipment and associated services for the treatment of sleep and respiratory patients. PolarMed was our Norwegian distributor before the acquisition, and the acquisition is consistent with our strategy for ongoing expansion of our international operations. The acquisition has been accounted for using purchase accounting and has been included within our consolidated financial statements from December 1, 2005. An amount of $4.4 million, representing the excess of the purchase price over the fair value of identifiable net assets acquired of $2.4 million, has been recorded as goodwill, which will not be tax deductible under Norwegian tax law. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their respective fair values at the date of acquisition. We have not yet completed the purchase price allocation, as the appraisals associated with the valuation of certain tangible assets are not yet complete. We do not believe that the appraisals will materially modify the preliminary purchase price allocation. We expect to complete our purchase price allocation in the quarter ending September 30, 2006. Pulmomed Medizinisch-Technische Geräte GmbH (“Pulmomed”). On July 1, 2005, we acquired 100% of the outstanding stock of Pulmomed for net cash consideration of $2.5 million, including acquisition costs. Additionally, as part of the acquisition we assumed debt of $1.0 million. Under the purchase agreement, we may also be required to make additional future payments of up to $0.9 million based on the achievement of certain performance milestones following the acquisition through June 30, 2007. Pulmomed is an Austrian based company that distributes medical equipment and associated services for the treatment of sleep and respiratory patients. The acquisition of Pulmomed is consistent with our strategy for ongoing expansion of our international operations. The acquisition has been accounted for using purchase accounting and has been included within our consolidated financial statements from July 1, 2005. An amount of $1.8 million, representing the excess of the purchase price over the fair value of identifiable net assets acquired of $0.7 million, has been recorded as goodwill, which will not be tax deductible under Austrian tax law. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their respective fair values at the date of acquisition. The fair values were determined by an independent appraisal and internal studies. Of the potential additional future payments included within the purchase agreement, $0.3 million was accrued at June 30, 2006 as a result of the successful achievement of a performance milestone. The impact of this accrual was to increase the total acquisition consideration to $2.8 million from $2.5 million and to increase the amount recorded as goodwill by $0.3 million to $2.1 million. Fiscal year ended June 30, 2005 Saime SAS (“Saime”). We acquired 100% of the outstanding stock of Financiere ACE SAS, the holding company for Saime and its affiliates, on May 19, 2005, for net cash consideration of $40.6 million. This consisted of $51.1 million in consideration, including acquisition costs, less $10.5 million of cash acquired. At June 30, 2005, we had not yet completed the purchase price allocation as the appraisals associated with the valuation of certain tangible assets were not yet complete. The fair values have now been finalized based on independent appraisals and internal studies. The impact of the completion of the purchase price allocation was to increase the fair value of the acquired fixed assets by approximately $0.7 million to $2.9 million, increase the fair value of acquired liabilities, including deferred tax liabilities, by approximately $0.4 million to $91.7 million, increase the fair value of acquired deferred tax assets by approximately $1.2 million to $2.0 million and to decrease the amount recorded as goodwill by $1.5 million to $64.8 million. - 26 - Hoefner Medizintechnick GmbH (“Hoefner”). We acquired 100% of the outstanding stock of Hoefner on February 14, 2005, for net cash consideration of $8.2 million. This consisted of the $10.7 million in total consideration, including acquisition costs, less $2.5 million of cash acquired. Under the purchase agreement, additional future payments of up to $0.9 million are possible based on the achievement of certain performance milestones following the acquisition through December 31, 2006. Of these potential additional payments, $0.6 million, which was paid during the year ended June 30, 2006 as a result of the successful achievement of a performance milestone. The impact of this payment was to increase the total acquisition consideration to $11.3 million from $10.7 million and to increase the amount recorded as goodwill by $0.6 million to $8.8 million. Resprecare BV (“Resprecare”). On December 1, 2004, we acquired substantially all the assets of Resprecare BV, our Dutch distributor, for initial consideration of $5.9 million in cash, including acquisition costs. The acquisition of the exclusive Dutch distributor is consistent with our strategy for ongoing expansion of our international operations. Under the purchase agreement, we potentially were also required to make up to $1.4 million of additional future payments based on the achievement of certain milestones. Of these potential additional payments, $0.6 million was paid in January 2005 as a result of the successful achievement of a performance milestone and a further $0.7 million was accrued at June 30, 2005 as a result of the integration of the Dutch subsidiary of our subsidiary MAP with the newly-acquired Resprecare business. The decision to integrate these operations determined the amount of the final future payment, which was paid in January 2006. The acquisition was accounted for using purchase accounting and accordingly, the results of operations of Resprecare were included within our consolidated financial statements from December 1, 2004. An amount of $4.4 million, representing the excess of the purchase price over the fair value of identifiable net assets acquired of $2.8 million, was recorded as goodwill, which is tax deductible. An independent third party has completed a valuation of identifiable intangible assets associated with the Resprecare acquisition. As a result of this valuation, $1.7 million was recorded as a customer relationship intangible asset and is being amortized over its estimated useful life of seven years. Fiscal year ended June 30, 2004 Respro Medical Company Limited (“Respro”). On July 2, 2003 we acquired the assets of Respro, our Hong Kong distributor, for total consideration of $184,000 in cash. The acquisition has been accounted for using purchase accounting and accordingly, the results of operations of Respro have been included within our consolidated financial statements from July 2, 2003. An amount of $89,000, representing the excess of the purchase price over the fair value of net identifiable assets acquired of $95,000, has been recorded as goodwill. - 27 - In-Process Research and Development Charge (“IPR&D”) On acquisition of Saime in May 2005, we recognized as an expense a charge of $5.3 million with respect to IPR&D programs under active development by Saime that, at date of acquisition, had not reached technological feasibility and had no alternative future use. The estimated fair value assigned to IPR&D was based on an independent appraisal and was comprised of the following projects (in thousands): Project Upgrade of the Elisee Series of ventilators Next generation of portable ventilators Total Value of IPR&D $1,379 $3,889 $5,268 The value of IPR&D was calculated by identifying research projects in areas for which technological feasibility had not been established, estimating the costs to develop the purchased in-process technology into commercially viable products, estimating the resulting net cash flows from such products, discounting the net cash flows to present value, and applying the reduced percentage completion of the projects thereto. The discount rate used in the analysis was 25%, which was based on the risk profile of the acquired assets. As of the date of acquisition, these projects had estimated costs to complete totaling approximately $5.3 million. The projects were in various stages of development but are expected to reach completion at various dates ranging from one to three years. We believe that the assumptions used to value the acquired intangible assets were reasonable at the time of acquisition. No assurance can be given, however, that the underlying assumptions used to estimate expected project revenues, development costs or profitability, or events associated with such projects, will transpire as estimated. For these reasons, among others, actual results may vary from the projected results. Stock Based Compensation Costs We have granted stock options to personnel, including officers and directors, under both our 1995 Option Plan and our 1997 Equity Participation Plan, which we refer to collectively as the Plans. These options have expiration dates of ten years from the date of grant and vest over three or four years. We granted these options with an exercise price equal to the market value as determined at the date of grant. We have also offered to our personnel, including officers and directors, the right to purchase shares of our common stock at a discount under our employee stock purchase plan, or ESPP. Prior to July 1, 2005, we applied APB Opinion No. 25, “Accounting for Stock Issued to Employees” and related Interpretations, in accounting for our equity plans. For periods prior to July 1, 2005, we complied with the disclosure only provisions of SFAS No. 123, “Accounting for Stock Based Compensation”, or SFAS 123. No stock-based employee compensation cost was reflected in net income, as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant (or within permitted discounted prices as it pertains to the ESPP). Results for periods before July 1, 2005 have not been restated to reflect, and do not include the impact of, SFAS No. 123(R), “Share Based Payment”, or SFAS 123(R). While our financial statements through June 30, 2005 account for stock option grants pursuant to APB No. 25, in accordance with SFAS No. 123, we disclose in the notes to our financial statements the pro forma impact on our net income had we accounted for stock option grants using the minimum value method of accounting. As of July 1, 2005, we adopted SFAS No. 123(R), using the modified prospective method, which requires measurement of compensation expense of all stock-based awards at fair value on the date of grant and amortization of the fair value over the vesting period of the award. We have elected to use the straight-line method of amortization. Under the prospective method, the provisions of SFAS 123(R) apply to all awards granted or modified after the date of adoption. In addition, the unrecognized expense of awards not yet vested at the date of adoption, determined under the original provisions of SFAS No. 123 shall be recognized in net income in the periods after adoption. The fair value of stock options is determined using the Black-Scholes valuation model, which is consistent with valuation techniques previously utilized for options in footnote disclosures required under SFAS No. 123, as amended by SFAS No. 148 “Accounting for Stock-Based Compensation – Transition and Disclosure”. Such value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method under SFAS 123(R). - 28 - The application of SFAS 123(R) had the following effect on reported amounts relative to amounts that would have been reported under previous accounting (in thousands, except per share data): Cost of sales Operating expenses: Selling, general and administration Research and development Income from operations Income before income taxes Net income Inventories, net Earnings per share: Basic Diluted Cashflow from operating activities Cashflow from financing activities 2006 Under Previous Accounting SFAS 123(R) Adjustments As Reported $229,210 $891 $230,101 187,796 35,174 146,605 148,699 100,183 115,787 $1.39 $1.30 $108,781 $88,014 12,372 2,042 (15,305) (15,305) (11,972) 407 ($0.17) ($0.14) $(9,753) $9,753 200,168 37,216 131,300 133,394 88,211 116,194 $1.22 $1.16 $99,028 $97,767 The fair value of stock options granted under our stock option plans and purchase rights granted under our ESPP is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: Stock Options: Weighted average fair value Weighted average risk-free interest rate Dividend yield Expected option life in years Volatility ESPP Purchase rights: Weighted average risk-free interest rate Dividend yield Expected option life in years Volatility Years ended June 30 2005 2006 12.75 3.9-4.5% - 3.9-5.2 29-31% 3.2-4.9% - 6 months 29-41% 8.49 4.0% - 3.5-4.6 31% 2.3% - 6 months 31-38% 2004 7.44 2.9% 3.3-4.2 43% - - - - Expected volatilities are based on a combination of historical volatilities of our stock and implied volatilities from traded options of our stock. The expected life represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and our historical exercise patterns. The risk- free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. The guidance in SFAS No. 123(R) is relatively new, and best practices are not well established. The application of these principles may be subject to further interpretation and refinement over time. There are significant differences among option valuation models, and this may result in a lack of comparability with other companies that use different models, methods and assumptions. If factors change and we employ different assumptions in the application of SFAS No. 123(R) in future periods, or if we decide to use a different valuation model, the compensation expense that we record in the future under SFAS No. 123(R) may differ significantly from what we have recorded in the current period and could materially affect our operating income, net income and net income per share. - 29 - Tax Expense Our income tax rate is governed by the laws of the regions in which our income is recognized. To date, a substantial portion of our income has been subject to income tax in Australia where the statutory rate was 30% in fiscal year 2006, 2005 and 2004. During fiscal years 2006, 2005 and 2004, our effective tax rate has fluctuated between approximately 32.3% and approximately 33.9%. These fluctuations have resulted from, and future effective tax rates will depend upon, numerous factors, including the amount of research and development expenditures for which a 125% Australian tax deduction is available, the level of non-deductible expenses, and other tax credits or benefits available to us under applicable tax laws. During the fourth quarter of fiscal year 2006, we made the decision to repatriate earnings from certain foreign subsidiaries to take advantage of a temporary incentive under the American Jobs Creation Act of 2004. This temporary incentive provides an 85% exclusion from U.S. taxable income for qualifying dividends received from controlled foreign corporations. The repatriation of $75 million resulted in a one-time additional income tax expense of $3.5 million for the year ended June 30, 2006. The repatriation of these funds to the United States provides us with increased flexibility in the utilization of cash to further its strategic objectives. We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Fiscal Year Ended June 30, 2006 Compared to Fiscal Year Ended June 30, 2005 Net Revenues. Net revenue increased for the year ended June 30, 2006 to $607.0 million from $425.5 million for the year ended June 30, 2005, an increase of $181.5 million or 43%. The increase in net revenue was attributable to an increase in unit sales of our flow generators, masks and accessories and incremental sales contributed from acquisitions. Sales were negatively impacted by the appreciation of international currencies against the U.S. dollar (decreasing sales by approximately $11.3 million). Excluding the impact of acquisitions and unfavourable foreign currency movements sales for the year ended June 30, 2006 increased by 32% compared to the year ended June 30, 2005. Net revenue in North and Latin America increased for the year ended June 30, 2006 to $321.0 million from $218.1 million for the year ended June 30, 2005, an increase of $102.9 million or 47%. This growth has been generated by increased public and physician awareness of sleep- disordered breathing together with our continued investment in our sales force and marketing initiatives. Recent product releases, in particular our Mirage Swift mask and S8 flow generator platform, have also contributed strongly to our sales growth. Net revenue in markets outside the Americas increased for the year ended June 30, 2006 to $286.0 million from $207.4 million for the years ended June 30, 2006 and 2005 respectively, an increase of 38%. International sales growth for the year ended June 30, 2006 reflects organic growth in the overall sleep-disordered breathing market and the recent acquisitions of Resprecare, Hoefner, Saime, PolarMed and Pulmomed. These acquisitions contributed incremental revenue of $52.7 million for the year ended June 30, 2006. Excluding the impact of acquisitions and unfavourable foreign currency movements, international sales for the year ended June 30, 2006 grew by 17% compared to the year ended June 30, 2005. Sales of flow generators for the year ended June 30, 2006 totaled $316.6 million, an increase of 51% compared to the year ended June 30, 2005, including increases of 47% in North and Latin America and 53% elsewhere. Sales of mask systems, motors and other accessories totaled $290.4 million, an increase of 35%, including increases of 47% in North and Latin America and 16% elsewhere, for the year ended June 30, 2006, compared to the year ended June 30, 2005. These increases primarily reflect growth in the overall sleep-disordered breathing market, acquisitions during the year, and new product releases, particularly the Mirage Swift and our new flow generator platform, the S8. - 30 - Gross Profit. Gross profit increased for the year ended June 30, 2006 to $376.9 million from $274.9 million for the year ended June 30, 2005, an increase of $102.0 million or 37%. Gross profit as a percentage of net revenue decreased for the year ended June 30, 2006 to 62% from 65% for the year ended June 30, 2005. The reduction in gross margin reflects the change in product and geographical mix of sales with a higher proportion of sales in flow generators, which generate lower margins relative to our mask sales, and higher North and Latin American sales, which also typically generate lower margins relative to our international sales, as well as the additional stock-based compensation costs. Stock based compensation expenses of $0.9 million have been included within cost of sales for the year ended June 30, 2006 as compared to no stock-based compensation expense for the year ended June 30, 2005. Selling, General and Administrative Expenses. Selling, general and administrative expenses increased for the year ended June 30, 2006 to $200.2 million from $135.7 million for the year ended June 30, 2005, an increase of $64.5 million or 48%. As a percentage of net revenue, selling, general and administrative expenses for the year ended June 30, 2006 was 33%, marginally higher than 32% in the year ended June 30, 2005. Stock based compensation expenses of $12.4 million have been included within selling, general and administrative expenses for the year ended June 30, 2006. Excluding the impact of stock-based compensation expenses, as a percentage of net revenue, selling, general and administrative expenses for the year ended June 30, 2006 were 31%, which is marginally lower than 32% in the year ended June 30, 2005. The increase in selling, general and administrative expenses was primarily due to stock-based compensation costs, an increase in the number of sales and administrative personnel to support our growth, the acquisitions of Resprecare, Hoefner, Saime, PolarMed and Pulmomed, continued infrastructure investment, particularly in our European businesses, and other expenses related to the increase in our sales. As a percentage of net revenue, we expect our future selling, general and administrative expense to continue in the historical range of 31% to 34%. Donations to Foundations. In the years ended June 30, 2006 and 2005 we donated $0.8 million and $0.5 million, respectively, to the ResMed Foundation in the United States, and the ResMed Foundation in Australia. The Foundations’ overall mission includes the education of both the public and physicians about the inherent dangers of untreated SDB/OSA, particularly as it relates to cerebrovascular and cardiovascular disease. Research and Development Expenses. Research and development expenses increased for the year ended June 30, 2006 to $37.2 million from $30.0 million for the year ended June 30, 2005, an increase of $7.2 million or 24%. As a percentage of net revenue, research and development expenses were 6% for the year ended June 30, 2006 compared to 7% for the year ended June 30, 2005. Stock-based compensation costs of $2.0 million have been included within research and development expenses for the year ended June 30, 2006. As a percentage of net revenue, we expect our future research and development expense to continue in the range of 5% to 7%. In-process Research and Development Charge. No in-process research and development charge was incurred for the year ended June 30, 2006. For the year ended June 30, 2005, purchased in-process research and development of $5.3 million was expensed upon the acquisition of Saime as technological feasibility of the products under development had not been established and no further alternative uses existed. The nature of this charge is explained in further detail in note 20 to the consolidated financial statements. Amortization of Acquired Intangible Assets. Amortization of acquired intangible assets for the year ended June 30, 2006 totaled $6.3 million compared to $0.9 million for the year ended June 30, 2005. The amortized amounts in 2006 related to acquired intangible assets associated with the acquisitions of Pulmomed, PolarMed, Saime, Hoefner and Resprecare. Restructure. Restructuring expenses incurred for the year ended June 30, 2006 were $1.1 million compared to $5.2 million for the year ended June 30, 2005. Restructuring expenses for 2006 consisted of restructure charges associated with our integration of the separate operations of ResMed Germany and MAP into a single operating unit. We have completed the relocation of our ResMed Germany operation, previously located in Moenchengladbach, to Munich and associated integration of the back office functions including customer service, logistics and administration. We plan to continue to monitor the progress of this restructure and adjust our business strategies and personnel accordingly in an effort to maximize efficiencies and cost savings. Other Income (Expense), Net. Other income, net for the year ended June 30, 2006 was $2.1 million, an increase of $2.8 million from other expense, net of $0.7 million for the year ended June 30, 2005. In fiscal year 2006 other income was predominantly due to higher interest income on additional cash balances. This was partially offset by lower interest expense due to the reduction in our convertible debt, which was converted into equity during the quarter ended March 31, 2006. Other factors included higher foreign currency gains on foreign currency transactions and hedging offset by an impairment loss of $1.2 million on one of our cost method investments. - 31 - Income Taxes. Our effective income tax rate increased to approximately 34% for the year ended June 30, 2006 from approximately 33% for the year ended June 30, 2005. This was primarily due to the one-time additional income tax expense of $3.5 million associated with the repatriation of $75 million in dividends received from certain controlled foreign corporations. These dividend payments were made to take advantage of a temporary tax incentive under the American Jobs Creation Act of 2004, which provides an 85% exclusion from U.S. taxable income for qualifying dividends. The repatriation of these funds to the United States provides us with increased flexibility in the utilization of cash to further our strategic objectives. Excluding the impact of the one-time additional income tax expense of $3.5 million relating to the dividend repatriation, the effective tax rate for the year ended June 30, 2006 was 31%. This compares to an adjusted effective tax rate of approximately 31% for the year ended June 30, 2005 when excluding the impact of the non-deductible in- process research and development charge of $5.3 million incurred in the prior year. We continue to benefit from the Australian corporate tax rate of 30% and certain Australian research and development tax benefits because we generate a majority of our taxable income in Australia. Net Income. As a result of the factors above, our net income for the year ended June 30, 2006 was $88.2 million or $1.16 per diluted share compared to net income of $64.8 million or $0.91 per diluted share for the year ended June 30, 2005. The net after tax impact of stock-based compensation costs, restructuring expenses, in-process research and development charge, amortization of acquired intangible assets and the repatriation of funds described above resulted in a reduction of diluted earnings per share of $0.26 and $0.12 on an after-tax basis, respectively, for the years ended June 30, 2006 and 2005. Fiscal Year Ended June 30, 2005 Compared to Fiscal Year Ended June 30, 2004 Net Revenues. Net revenue increased for the year ended June 30, 2005 to $425.5 million from $339.3 million for the year ended June 30, 2004, an increase of $86.2 million or 25%. The increase in net revenue was attributable to an increase in unit sales of our flow generators, masks and accessories. Sales also benefited from an appreciation of international currencies against the U.S. dollar (increasing sales by approximately $10.4 million). Net revenue in North and Latin America increased for the year ended June 30, 2005 to $218.1 million from $166.1 million for the year ended June 30, 2004, an increase of $52.0 million or 31%. This growth has been generated by increased public and physician awareness of sleep-disordered breathing together with our continued investment in our sales force and marketing initiatives. Product releases during the year, in particular our Mirage Swift mask, have also contributed strongly to our sales growth. Net revenue in markets outside the Americas increased for the year ended June 30, 2005 to $207.4 million from $173.2 million for the years ended June 30, 2005 and 2004 respectively, an increase of 20%. International sales growth for the year ended June 30, 2005 reflects organic growth in the overall sleep-disordered breathing market, appreciation of international currencies against the U.S. dollar and the acquisition during the year of Resprecare, Hoefner and Saime. These acquisitions contributed incremental revenue of $11.5 million for the year ended June 30, 2005. Excluding the impact of acquisitions, international sales grew by 13%. Sales of flow generators for the year ended June 30, 2005 totaled $209.8 million, an increase of 24% compared to the year ended June 30, 2004, including increases of 22% in North and Latin America and 25% elsewhere. Sales of mask systems, motors and other accessories totaled $215.7 million, an increase of 27%, including increases of 38% in North and Latin America and 12% elsewhere, for the year ended June 30, 2005, compared to the year ended June 30, 2004. These increases primarily reflect growth in the overall sleep-disordered breathing market, acquisitions during the year, appreciation of international currencies against the U.S. dollar and new product releases. Gross Profit. Gross profit increased for the year ended June 30, 2005 to $274.9 million from $216.7 million for the year ended June 30, 2004, an increase of $58.2 million or 27%. Gross profit as a percentage of net revenue increased for the year ended June 30, 2005 to 65% from 64% for the year ended June 30, 2004. The improvement in gross margin reflects a more favorable product mix due to increased sales of higher margin mask products and new product introductions. - 32 - Selling, General and Administrative Expenses. Selling, general and administrative expenses increased for the year ended June 30, 2005 to $135.7 million from $104.7 million for the year ended June 30, 2004, an increase of $31.0 million or 30%. As a percentage of net revenue, selling, general and administrative expenses for the year ended June 30, 2005 was 32%, marginally higher than 31% in the year ended June 30, 2004. The increase in selling, general and administrative expenses was primarily due to an increase in the number of sales and administrative personnel to support our growth, the acquisitions of Resprecare, Hoefner and Saime, continued infrastructure investment, particularly in our European businesses, and other expenses related to the increase in our sales. The increase in selling, general and administrative expenses was also attributable to appreciation of international currencies against the U.S. dollar, which added approximately $4.0 million to our expenses as reported in U.S. dollars. Donations to Foundations. In the years ended June 30, 2005 and 2004 we donated $0.5 million and $0.5 million, respectively, to the ResMed Foundation in the U.S., and the Resmed Foundation in Australia. The Foundations’ overall mission includes the education of both the public and physicians about the inherent dangers of untreated SDB/OSA, particularly as it relates to cerebrovascular and cardiovascular disease. Research and Development Expenses. Research and development expenses increased for the year ended June 30, 2005 to $30.0 million from $26.2 million for the year ended June 30, 2004, an increase of $3.8 million or 15%. As a percentage of net revenue, research and development expenses were 7% for the year ended June 30, 2005 compared to 8% for the year ended June 30, 2004. The increase in research and development expenses was primarily due to higher employee compensation and increased charges for consulting fees and technical assessments incurred to facilitate development of new products. The increase also reflects an appreciation of the Australian dollar against the U.S. dollar, as the majority of research and development costs are incurred in Australian dollars. The appreciation of international currencies against the U.S. dollar added approximately $1.3 million to our research and development expenses as reported in U.S. dollars. In-process Research and Development Charge. Purchased in-process research and development of $5.3 million was expensed upon acquisition of Saime as technological feasibility of the products under development had not been established and no further alternative uses existed. The nature of this charge is explained more fully in note 20 to the consolidated financial statements. Amortization of Acquired Intangible Assets. Amortization of acquired intangible assets for the year ended June 30, 2005 totaled $0.9 million compared to $nil for the year ended June 30, 2004, and related to acquired intangible assets totaling $46.0 million associated with the acquisitions of Saime, Hoefner and Resprecare. Restructure. Restructuring expenses incurred for the year ended June 30, 2005 were $5.2 million and consisted of restructure charges associated with our integration of the separate operations of ResMed Germany and MAP into a single operating unit. We have completed the relocation of our ResMed Germany operation, previously located in Moenchengladbach, to Munich and associated integration of the back office functions including customer service, logistics and administration. We will continue to monitor the progress of this restructure and adjust our business strategies and personnel accordingly to achieve maximum efficiencies and cost savings. Other Income (Expense), Net. Other expense, net for the year ended June 30, 2005 was $0.7 million, consistent with the year ended June 30, 2004. In fiscal year 2005, other expense, net reflected lower net foreign currency exchange gains, partially offset by lower interest expense due to the reduction in our convertible note debt that occurred in the 2004 fiscal year. Income Taxes. Our effective income tax rate increased to approximately 33% for the year ended June 30, 2005 from approximately 32% for the year ended June 30, 2004. However, adding back the impact of the non-deductible in- process research and development charge of $5.3 million taken in the year ended June 30, 2005 would result in an adjusted effective tax rate of approximately 31%. The lower adjusted effective tax rate was primarily due to our geographical mix of taxable income. In particular, we continue to benefit from the Australian corporate tax rate of 30% and certain Australian R&D tax benefits because we generate a majority of our taxable income in Australia. Net Income. As a result of the factors above, our net income for the year ended June 30, 2005 was $64.8 million or $0.91 per diluted share compared to net income of $57.3 million or $0.82 per diluted share for the year ended June 30, 2004. The restructuring expenses, in-process research and development charge and amortization of acquired intangible assets described above resulted in a reduction of earnings per diluted share of $0.12 and $0.00 on an after-tax basis, respectively, for the years ended June 30, 2005 and 2004. - 33 - Liquidity and Capital Resources As of June 30, 2006 and June 30, 2005, we had cash and cash equivalents and marketable securities available-for-sale of $219.5 million and $142.2 million, respectively. Working capital was $381.3 million and $141.7 million at June 30, 2006 and June 30, 2005 respectively. The increase in working capital predominantly reflects the conversion of our convertible subordinated notes into equity in March 2006 as well as the growth and profitability of the business during the year. Inventories at June 30, 2006 increased by $27.1 million or 30% to $116.2 million compared to June 30, 2005 inventories of $89.1 million. The increase in inventories was lower than the increase of 43% in revenues in the year ended June 30, 2006 compared to the year ended June 30, 2005, which we believe reflects strong sales growth and improved working capital management. Accounts receivable at June 30, 2006 were $138.1 million, an increase of $34.2 million or 33% over the June 30, 2005 accounts receivable balance of $104.0 million. Excluding the incremental increase from acquisitions, our accounts receivables have increased by $31.3 million or 30%. The increase was lower than the 43% incremental increase in revenues for the year ended June 30, 2006 compared to the year ended June 30, 2005 and predominantly reflects the impact of our acquisitions, as sales increased by 30% on an ex-acquisition basis. Accounts receivable days 70 days for the year ended June 30, 2006 decreased by 1 day compared to 71 days for the year ended June 30, 2005. Our allowance for doubtful accounts as a percentage of total accounts receivable at June 30, 2006 and 2005 was 3.3% and 3.0%, respectively. The credit quality of our customers remains consistent with our past experience. During the year ended June 30, 2006, we generated cash of $99.0 million from operations. This was higher than the cash generated from operations for the year ended June 30, 2005 of $71.1 million and was primarily the result of the increase in net income and improved working capital management. In addition, cash generated from operations for the year end June 30, 2006 was reduced by $9.8 million due to the initial adoption of SFAS 123(R) as tax benefits associated with employee stock options exercised during the year are required to be included within cash flows from financing activities. Prior to the adoption of SFAS 123(R), cash retained as a result of tax deductions relating to stock-based compensation was presented in operating cash flows, along with other tax cash flows. Capital expenditures for the years ended June 30, 2006 and 2005 aggregated $102.7 million and $39.7 million respectively. The capital expenditures in the year ended June 30, 2006 primarily reflected the construction of our new manufacturing, research and development building, purchase of land in San Diego, office facilities, computer hardware and software, rental and loan equipment and purchase of production tooling equipment and machinery. As a result of these capital expenditures, our balance sheet reflects net property, plant and equipment of approximately $245.4 million at June 30, 2006 compared to $174.2 million at June 30, 2005. We are currently building our new research and development and office facilities at our existing site in Sydney, Australia and expect to have this completed in September 2006. We estimate that the additional building and fit-out costs for the new research and development and office facilities will be approximately $12.9 million. We expect to fund the project through a combination of cash on hand and cash generated from operations. On July 7, 2005, we purchased a 9.78-acre parcel of land in San Diego for $21.0 million. The new location at Kearney Mesa, San Diego will allow us to develop a new corporate headquarters. We are currently evaluating building options in relation to our new corporate headquarters. Details of contractual obligations at June 30, 2006 are as follows: In $000’s Total 2007 2008 2009 2010 Long-Term Debt $120,441 $4,796 $38,782 $13,110 $35,173 Operating Leases 22,511 7,586 5,431 Capital Leases 641 73 73 3,799 73 3,066 73 2011 $- 1,972 73 Thereafter $28,580 657 276 Payments Due by Period Unconditional Purchase Obligations Total Contractual Cash Obligations 12,926 12,926 $156,519 $25,381 $44,286 $16,982 $38,312 $2,045 $29,513 - 34 - Details of other commercial commitments at June 30, 2006 are as follows: In $000’s Standby Letters of Credit Guarantees* Total Commercial Commitments Total Amounts Committed 2007 2008 2009 2010 2011 Thereafter Amount of Commitment Expiration Per Period $34 2,457 $34 263 $2,491 $297 $- - $- $- - $- $- - $- $- - $- $- 2,194 $2,194 *The above guarantees relate to guarantees required by statutory authorities as a pre-requisite to developing our site at Norwest and requirements under contractual obligations with insurance companies transacting with our German subsidiaries. During fiscal year 2006, and pursuant to the Indenture dated June 20, 2001 between us and American Stock Transfer & Trust Company, as trustee, holders of all of the 4% Convertible Subordinated Notes (“the Notes”) due 2006 converted the Notes into an aggregate of 3,737,593 shares of our common stock, par value $0.004. The Notes were converted into 33 shares of our common stock for each $1,000 principal amount of the Notes, at a conversion price of $30.30 per share. The dilutive impact of these conversions has been reflected in the reported earnings per share. With the conversion of the Notes we expect to realize interest expense savings in the future of approximately $2.2 million per annum. On March 13, 2006, our wholly-owned subsidiaries ResMed Corp., Servo Magnetics Inc. and ResMed EAP Holdings Inc. entered into a Second Amended and Restated Revolving Loan Agreement with Union Bank of California, N.A. as administrative agent for the Lenders (the “Loan Agreement”), that provides for a revolving loan of up to $75 million. The Loan Agreement also contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum ratio of total debt to EBITDA (as defined in the Loan Agreement), a fixed charge coverage ratio, a minimum tangible net worth, and that certain of our subsidiaries maintain a minimum EBITDA and liquidity. We believe we are currently in compliance with all of these covenants. Draws under the revolving loans must be made before March 1, 2011, at which time all unpaid principal and interest under both loans must be repaid. The outstanding principal amount due under the loans will bear interest at a rate equal to LIBOR plus 0.75% to 1.00% (depending on the applicable leverage ratio). At June 30, 2006 there were no amounts outstanding under the Loan Agreement. On June 8, 2006, our wholly-owned Australian subsidiary, ResMed Limited, entered into a Syndicated Facility Agreement with HSBC Bank Australia Limited as original financier, facility agent and security trustee, that provides for a loan in three tranches. Tranche A is a EUR 50 million term loan facility that refinances all amounts outstanding under a previous syndicated facility agreement dated May 16, 2005 between ResMed Limited and HSBC Bank Australia Limited, to fund the obligations of our wholly-owned French subsidiary Resmed SA under its agreement to acquire Saime). Tranche A bears interest at a rate equal to LIBOR for deposits denominated in EUR plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of ResMed Inc. and its subsidiaries, which we refer to as the ResMed Group, for the most recently completed fiscal year for the applicable interest period. Payments of principal must be made to reduce the total outstanding principal amount of Tranche A to EUR 44.5 million on June 30, 2007, EUR 37.75 million on June 30, 2008, EUR 27.5 million on June 30, 2009, EUR 15 million on December 31, 2009, and the entire outstanding principal amount must be repaid in full on June 8, 2011. At June 30, 2006, the Tranche A facility loan had an amount outstanding of $61.7 million. Tranche B is a USD 15 million term loan facility that may only be used for the purpose of financing capital expenditures and other asset acquisitions by the ResMed Group. Tranche B bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars, USD, or Sterling plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. The entire principal amount must be repaid in full on June 8, 2011. At June 30, 2006, there were no amounts outstanding under the Tranche B facility loan agreement. - 35 - Tranche C is a USD 60 million term loan facility that may only be used for the purpose of the payment by ResMed Limited of a dividend to ResMed Holdings Limited, which will ultimately be paid to ResMed Inc. Tranche C bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars or USD plus a margin of 0.70% or 0.80%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. Payments of principal must be made to reduce the total outstanding principal amount of Tranche C to USD 30 million on December 31, 2007 and the entire outstanding principle amount must be repaid in full by June 8, 2009. At June 30, 2006, the Tranche C facility loan had an amount outstanding of $58.6 million. The Loan is secured by a pledge of one hundred percent of the shares of ResMed Inc.’s subsidiary, Saime SAS, pursuant to a Pledge Agreement. The Syndicated Facility Agreement also contains customary covenants, including certain financial covenants and an obligation that ResMed Limited maintain certain financial ratios, including a minimum debt service cover ratio, a maximum ratio of total debt to EBITDA and a minimum tangible net worth. The entire principal amount of the Loan and any accrued but unpaid interest may be declared immediately due and payable in the event of the occurrence of an event of default as defined in the Syndicated Facility Agreement. Events of default include, among other items, failure to make payments when due, breaches of representations, warranties or covenants, the occurrence of certain insolvency events, the occurrence of an event or change which could have a material adverse effect on ResMed Limited and its subsidiaries, and if ResMed Inc. ceases to control ResMed Limited, ResMed Corp., ResMed SAS, ResMed GmbH & Co. KG, ResMed (UK) Limited, Take Air Medical Handels-GmbH or Saime SAS. The Syndicated Facility Agreement contains customary covenants, including certain financial covenants and an obligation that ResMed Limited maintain certain financial ratios, including a minimum debt service cover ratio, a maximum ratio of total debt to EBITDA and a minimum tangible net worth. The entire principal amount of the Loan and any accrued but unpaid interest may be declared immediately due and payable in the event of the occurrence of an event of default as defined in the Syndicated Facility Agreement, which includes, among other items, failure to make payments when due, breaches of representations, warranties or covenants, the occurrence of certain insolvency events, the occurrence of an event or change which could have a material adverse effect on ResMed Limited and its subsidiaries, and if ResMed Inc. ceases to control ResMed Limited, ResMed Corp., ResMed SAS, ResMed GmbH & Co. KG, ResMed (UK) Limited, Take Air Medical Handels-GmbH or Saime SAS. Simultaneous with the Syndicated Facility Agreement, ResMed Limited entered into a working capital agreement with HSBC Bank Australia Limited for revolving, letter of credit and overdraft facilities up to a total commitment of 6.5 million Australian dollars for one year, and ResMed (UK) Limited entered into a working capital agreement with HSBC Bank plc for a revolving cash advance facility up to a total commitment of 3 million Sterling for one year. We expect to satisfy all of our short-term liquidity requirements through a combination of cash on hand, cash generated from operations, our $75 million undrawn revolving line of credit with Union Bank of California and our $18.6 million undrawn syndicated facility with HSBC. The results of our international operations are affected by changes in exchange rates between currencies. Changes in exchange rates may negatively affect our consolidated net revenue and gross profit margins from international operations. We are exposed to the risk that the dollar value equivalent of anticipated cash flows would be adversely affected by changes in foreign currency exchange rates. We manage this risk through foreign currency option contracts. Stock Split On August 10, 2005, our Board of Directors declared a two-for-one split of our common stock which was effected in the form of a 100% stock dividend. Stockholders received one additional share of common stock for every share held of record on September 15, 2005. All share numbers and per share amounts contained in the condensed consolidated financial statements and accompanying notes have been retroactively adjusted to reflect this stock split. Critical Accounting Principles and Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires us to make estimates and judgments that affect our reported amounts of assets and liabilities, revenues and expenses and related disclosures of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, including those related to allowance for doubtful accounts, inventory reserves, warranty obligations, goodwill, impaired assets, intangible assets, income taxes, deferred tax valuation allowances and contingencies. - 36 - We state these accounting policies in the notes to the financial statements and at relevant sections in this discussion and analysis. The estimates are based on the information that is currently available to us and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could vary from those estimates under different assumptions or conditions. We believe that the following critical accounting policies affect the more significant judgments and estimates used in the preparation of our financial statements: (1) Allowance for Doubtful Accounts. We maintain an allowance for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments, which results in bad debt expense. We determine the adequacy of this allowance by continually evaluating individual customer receivables, considering a customer’s financial condition, credit history and current economic conditions. If the financial condition of our customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. (2) Inventory Adjustments. Inventories are stated at lower of cost or market and are determined by the first-in, first-out method. We review the components of inventory on a regular basis for excess, obsolete and impaired inventory based on estimated future usage and sales. The likelihood of any material inventory write-downs is dependent on changes in competitive conditions, new product introductions by us or our competitors, or rapid changes in customer demand. (3) Valuation of Goodwill, Intangible and Other Long-Lived Assets. We use assumptions in establishing the carrying value, fair value and estimated lives of our goodwill, intangibles and other long-lived assets. The criteria used for these evaluations include management’s estimate of the asset’s continuing ability to generate positive income from operations and positive cash flow in future periods compared to the carrying value of the asset, as well as the strategic significance of any identifiable intangible asset in our business objectives. If assets are considered to be impaired, the impairment recognized is the amount by which the carrying value of the assets exceeds the fair value of the assets. Useful lives and related amortization or depreciation expense are based on our estimate of the period that the assets will generate revenues or otherwise be used by us. Factors that would influence the likelihood of a material change in our reported results include significant changes in the asset’s ability to generate positive cash flow, loss of legal ownership or title to the asset, a significant decline in the economic and competitive environment on which the asset depends, significant changes in our strategic business objectives, utilization of the asset, and a significant change in the economic and/or political conditions in certain countries. (4) Valuation of Deferred Income Taxes. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. The likelihood of a material change in our expected realization of these assets is dependent on future taxable income, our ability to deduct tax loss carryforwards against future taxable income, the effectiveness of our tax planning and strategies among the various tax jurisdictions that we operate in, and any significant changes in the tax treatment received on our business combinations. (5) Provision for Warranty. We provide for the estimated cost of product warranties at the time the related revenue is recognized. The amount of this provision is determined by using a financial model, which takes into consideration actual, historical expenses and potential risks associated with our different products. This financial model is then used to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, revisions to our estimated warranty provision would be required. (6) Revenue Recognition. Revenue on product sales is recorded at the time of shipment, at which time title transfers to the customer. Revenue on product sales which require customer acceptance is not recorded until acceptance is received. Royalty revenue from license agreements is recorded when earned. Service revenue received in advance from service contracts is initially deferred and recognized ratably over the life of the service contract. Revenue received in advance from rental unit contracts is initially deferred and recognized ratably over the life of the rental contract. Revenue from sale of marketing and distribution rights is initially deferred and recognized ratably as revenue over the life of the contract. Freight charges billed to customers are included in revenue. All freight-related expenses are charged to cost of sales. - 37 - We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products or similarly offer variable sale prices for subsequent events or activities. However, as part of our sales processes we may provide upfront discounts for large orders, one time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. The costs of all such programs are recorded as an adjustment to revenue. In our domestic sales activities we use a number of Manufacturer representatives to sell our products. These representatives are paid a direct commission on sales and act as an integral component of our domestic sales force. We do not sell our products to these representatives, and do not recognize revenue on such shipments. Our products are predominantly therapy-based equipment and require no installation. As such, we have no significant installation obligations. (7) Stock-Based Compensation. In accordance with the modified prospective method of SFAS 123(R), we measure the compensation of all stock-based awards at fair value on date of grant. Such value is recognized as compensation expense over the service period, net of estimated forfeitures. The estimation of stock awards that will ultimately vest requires judgment, and to the extent actual results differ from our estimates, such amounts will be recorded as a cumulative adjustment in the period estimates are revised. We consider many factors when estimating expected forfeitures, including the type of awards, employee class, and historical experience. Actual results may differ substantially from these estimates. Recently Issued Accounting Pronouncements In November 2005, the FASB issued FSP FAS123(R)-3, “Transition Election to Accounting for the Tax Effects of Share-Based Payment Awards”. This FSP requires an entity to follow either the transition guidance for the additional- paid-in-capital pool as prescribed in SFAS 123(R), or the alternative transition method as described in the FSP. We have made a one-time election to adopt the transition method described in this FSP which did not have a material impact on our financial statements. In November 2005, the FASB issued FSP FAS115-1/124-1, “The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments”, which addresses the determination as to when an investment is considered impaired, whether that impairment is other than temporary, and the measurement of an impairment loss. This FSP also includes accounting considerations subsequent to the recognition of an other-than-temporary impairment and requires certain disclosures about unrealized losses that have not been recognized as other-than-temporary impairments. The guidance in this FSP amends FASB Statements No. 115, “Accounting for Certain Investments in Debt and Equity Securities”, and No. 124, and APB Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock”. We adopted this FSP during the fiscal year ended June 30, 2006 and it did not have a material impact on our financial statements. In June 2006, the FASB issued FIN No. 48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109”, which clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FASB Statement No. 109, “Accounting for Income Taxes”. The interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN No. 48 requires recognition of tax benefits that satisfy a greater than 50% probability threshold. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. FIN No. 48 is effective for us beginning July 1, 2007. We are assessing the potential impact that the adoption of FIN No. 48 will have on our financial statements. - 38 - ITEM 7A QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET AND BUSINESS RISKS Foreign Currency Market Risk Our functional currency is the U.S. dollar, although the financial statements of our non-U.S. subsidiaries are maintained in their respective local currencies. We transact business in various foreign currencies, including a number of major European currencies as well as the Australian dollar. We have significant foreign currency exposure through both our Australian manufacturing activities and international sales operations. We have established a foreign currency hedging program using purchased currency options to hedge foreign- currency-denominated financial assets, liabilities and manufacturing expenditure. The goal of this hedging program is to economically guarantee or lock-in the exchange rates on our foreign currency exposures denominated in Euro’s and the Australian dollar. Under this program, increases or decreases in our foreign-currency-denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We have determined our hedge program to be a non-effective hedge as defined under SFAS 133. The foreign currency derivatives portfolio is recorded in the consolidated balance sheets at fair value and included in other assets or other liabilities. All movements in the fair value of the foreign currency derivatives are recorded within other income, net on our consolidated statements of income. The table below provides information (in U.S. dollars) on our foreign-currency-denominated financial assets by legal entity functional currency as of June 30, 2006 (in thousands): AUD Functional Currency Entities: Assets Liability Net Total USD Functional Currency Entities: Assets Liability Net Total EURO Functional Currency Entities: Assets Liability Net Total GBP Functional Currency Entities: Assets Liability Net Total CHF Functional Currency Entities: Assets Liability Net Total SEK Functional Currency Entities: Assets Liability Net Total Australian Dollar (AUD) US Dollar (USD) Euro (EUR) Foreign Currency Financial Assets Great Britain Pound (GBP) Singapore Dollar (SGD) New Zealand Dollar (NZD) Swedish Krona (SEK) Swiss Franc (CHF) Norwegian Krone (NOK) $- - - $92,703 (56,224) 36,479 $93,586 (88,994) 4,592 $9,640 (5,198) 4,442 $830 (64) 766 $1,002 (315) 687 $537 - 537 $1,523 (29) 1,494 $1,092 - 1,092 - - - - (1,010) (1,010) - - - 2 (218) (216) - (141) (141) - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - (15) (15) - (1,708) (1,708) 41,007 - 41,007 - - - - - - - - - - - - - - - 4,104 (155) 3,949 193 - 193 9 (133) (124) 2 (1,330) (1,328) - - - - - - 1,730 - 1,730 1 (635) (634) - (187) (187) - 39 - The table below provides information about our foreign currency derivative financial instruments and presents the information in U.S. dollar equivalents. The table summarizes information on instruments and transactions that are sensitive to foreign currency exchange rates, including foreign currency call options held at June 30, 2006. The table presents the notional amounts and weighted average exchange rates by contractual maturity dates for our foreign currency derivative financial instruments. These notional amounts generally are used to calculate payments to be exchanged under the options contracts. FY 2007 FY 2008 Total Fair Value Assets / (Liabilities) As of June 30 2006 2005 $123,000 AUD $1 = USD 0.778 $9,000 AUD $1 = USD 0.767 $132,000 AUD $1 = USD 0.777 $1,035 $2,240 $7,674 AUD $1 = Euro 0.656 AUD $1 = Euro 0.660 AUD $1 = Euro 0.656 $53,718 $61,392 $144 $758 (In thousands except exchange rates) Foreign Exchange Call Options (Receive AUD$/Pay U.S.$) Option amount Average contractual exchange rate (Receive AUD$/Pay Euro) Option amount Average contractual exchange rate Interest Rate Risk We are exposed to risk associated with changes in interest rates affecting the return on our cash and cash equivalents and debt. At June 30, 2006 we had total long-term debt, including the current portion of those obligations, of $121.1 million. Of this debt, $0.6 million is at fixed interest rates and $120.4 million is subject to variable interest rates. A hypothetical 10% change in interest rates during the year ended June 30, 2006, would not have a material impact on pretax income. We have no interest rate hedging agreements. ITEM 8 CONSOLIDATED FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA a) Index to Consolidated Financial Statements Report of Independent Registered Public Accounting Firm Consolidated Balance Sheets as of June 30, 2006 and 2005 Consolidated Statements of Income for the years ended June 30, 2006, 2005 and 2004 Consolidated Statements of Stockholders’ Equity for the years ended June 30, 2006, 2005 and 2004 Consolidated Statements of Cash Flows for the years ended June 30, 2006, 2005 and 2004 Notes to Consolidated Financial Statements for the years ended June 30, 2006 and 2005 Schedule II – Valuation and Qualifying Accounts and Reserves F1 F2 F3 F4 F5 F6 b) Supplementary Data Quarterly Financial Information (unaudited)—The quarterly results for the years ended June 30, 2006 and 2005 are summarized below (in thousands, except per share amounts): 2006 First Quarter Second Quarter Third Quarter Fourth Quarter FiscalYear Net revenues Gross profit Net income Basic earnings per share Diluted earnings per share $127,127 80,119 16,442 $0.23 $0.23 $146,416 91,726 22,314 $0.31 $0.30 $162,281 100,866 26,362 $0.36 $0.34 $171,172 104,184 23,093 $0.31 $0.30 $606,996 376,895 88,211 $1.22 $1.16 2005 Net revenues First Quarter Second Quarter Third Quarter $87,733 $103,893 $108,454 Fourth Quarter $125,425 Fiscal Year $425,505 Gross profit Net income Basic earnings per share Diluted earnings per share 56,411 13,926 $0.21 $0.20 68,378 17,404 $0.26 $0.25 70,295 17,877 $0.26 $0.25 79,776 15,578 $0.22 $0.22 274,860 64,785 $0.94 $0.91 NB. Per share amounts for each quarter are computed independently, and, due to the computation formula, the sum of the four quarters may not equal the year. All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 10, 2005 and distributed on September 30, 2005. - 40 - ITEM 9 CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None. ITEM 9A CONTROLS AND PROCEDURES We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. As required by SEC Rule 13a-15(b), we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2006. Based on the foregoing, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level. There has been no change in our internal controls over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal controls over financial reporting. - 41 - MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. The Company’s internal control over financial reporting includes those policies and procedures that: (i) (ii) Pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company’s internal control over financial reporting as of June 30, 2006. Management based this assessment on criteria for effective internal control over financial reporting described in “Internal Control – Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management’s assessment included an evaluation of the design of ResMed Inc.’s internal control over financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Management reviewed the results of its assessment with the Audit Committee of our Board of Directors. Based on our assessment and those criteria, management has concluded that the Company did maintain effective internal control over financial reporting as of June 30, 2006. KPMG LLP, independent registered public accounting firm, who audited and reported on the consolidated financial statements of ResMed, Inc. included in this report, has issued an attestation report on management’s assessment of internal control over financial reporting. - 42 - RESMED INC. AND SUBSIDIARIES REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors and Stockholders ResMed Inc.: We have audited management’s assessment, included in the accompanying Management’s Report on Internal Control Over Financial Reporting, that ResMed Inc. maintained effective internal control over financial reporting as of June 30, 2006, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). ResMed Inc.’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting. Our responsibility is to express an opinion on management’s assessment and an opinion on the effectiveness of the Company’s internal control over financial reporting based on our audit. We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, evaluating management’s assessment, testing and evaluating the design and operating effectiveness of internal control, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. In our opinion, management’s assessment that ResMed Inc. maintained effective internal control over financial reporting as of June 30, 2006, is fairly stated, in all material respects, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Also, in our opinion, ResMed Inc. maintained, in all material respects, effective internal control over financial reporting as of June 30, 2006, based on criteria established in Internal Control – Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheets of ResMed Inc. and subsidiaries as of June 30, 2006 and 2005, and the related consolidated statements of income, stockholders’ equity and comprehensive income, and cash flows for each of the years in the three-year period ended June 30, 2006, and our report dated September 8, 2006 expressed an unqualified opinion on those consolidated financial statements. /s/ KPMG LLP …………………………………………… San Diego, California September 8, 2006 ITEM 9B OTHER INFORMATION None. - 43 - PART III ITEM 10 DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT Incorporated by reference to our definitive Proxy Statement for our November 9, 2006, meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June 30, 2006. The Company has filed, as exhibits to this Annual Report on Form 10-K for the year ended June 30, 2006, the certifications of its Principal Executive Officer and Principal Financial Officer required pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. On December 15, 2005, the Company submitted to the New York Stock Exchange the Annual CEO Certification required pursuant to Section 303A.12(a) of the New York Stock Exchange Listed Company Manual. ITEM 11 EXECUTIVE COMPENSATION Incorporated by reference to our definitive Proxy Statement for our November 9, 2006, meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June 30, 2006. ITEM 12 SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Incorporated by reference to our definitive Proxy Statement for our November 9, 2006, meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June 30, 2006. ITEM 13 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS No material transactions. ITEM 14 PRINCIPAL ACCOUNTANT FEES AND SERVICES Incorporated by reference to our definitive Proxy Statement for our November 9, 2006, meeting of stockholders, which will be filed with the Securities and Exchange Commission within 120 days after June 30, 2006. - 44 - ITEM 15 EXHIBITS AND CONSOLIDATED FINANCIAL STATEMENT SCHEDULES The following documents are filed as part of this report: PART IV 1. Consolidated Financial Statements and Schedule – The consolidated financial statements and schedule of the Company and its consolidated subsidiaries are set forth in the “Index to Consolidated Financial Statements” under Item 8 of this report. 2. Exhibits 3.1 Certificate of Incorporation of Registrant, as amended(1) 3.2 By-laws of Registrant(1) 4.1 Form of certificate evidencing shares of Common Stock(1) 4.2 Rights agreement dated as of April 23, 1997(2) 4.3 Indenture dated as of June 20, 2001, between ResMed Inc. and American Stock Transfer & Trust Company(5) 4.4 Registration Rights Agreement dated as of June 20, 2001, by and between ResMed Inc., Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Deutsche Banc Alex Brown Inc., William Blair & Company, L.L.C., Macquarie Bank Limited and UBS Warburg LLC(5) 4.5 Registration Rights Agreement dated as of May 14, 2002 between ResMed Inc., and Mr Leslie Hoffman(6) 10.1 1995 Stock Option Plan(1) 10.2 1997 Equity Participation Plan(3) 10.3 Licensing Agreement between the University of Sydney and ResMed Ltd dated May 17, 1991, as amended(1) 10.5 Loan Agreement between the Australian Trade Commission and ResMed Limited dated May 3, 1994(1) 10.6 Lease for 10121 Carroll Canyon Road, San Diego CA 92131-1109, USA(4) 10.7 Sale and Leaseback Agreements for 97 Waterloo Rd, North Ryde, Australia(5) 10.8 Employment Agreement dated as of May 14, 2002, between Servo Magnetics Acquisition Inc., and Mr Leslie Hoffman(6) 10.9 Agreement for the purchase of Lot 6001, Norwest Business Park, Baulkham Hills, Australia(6) 10.10 2003 Employee Stock Purchase Plan(7) 10.11 Loan Agreement between ResMed Limited and HSBC Bank Australia Limited - 45 - 10.12 Saime Purchase Agreement 10.13 First Amended and Restated Loan Agreement, dated as of November 1, 2005, by and among ResMed Corp., ResMed EAP Holdings Inc. and Union Bank of California, N.A. (8) 10.14 Security Agreement, dated as of November 1, 2005, by and between ResMed EAP Holdings Inc. and Union Bank of California, N.A. (8) 10.15 Continuing Guaranty, dated as of November 1, 2005, by and between ResMed Inc and Union Bank of California, N.A. (8) 10.16 Commercial Promissory Note, dated as of November 1, 2005, made by ResMed Corp. and ResMed EAP Holdings Inc. (8) 10.17 Commercial Promissory Note, dated as of November 1, 2005, made by ResMed Corp. and ResMed EAP Holdings Inc. (8) 10.18 Second Amended and Restated Loan Agreement (9) 10.19 Syndicated Facility Agreement, dated as of June 8, 2006, by and between ResMed Limited and HSBC Bank Australia Limited (10) 10.20 Deed of Guaranty and Indemnity, dated as of June 8, 2006, by and among HSBC Bank Australia Limited, ResMed Limited, ResMed SAS, ResMed GmbH & Co. KG, ResMed (UK) Limited and Take Air Medical Handels-GmbH (10) 10.21 Deed of Guaranty and Indemnity, dated as of June 8, 2006, by and among HSBC Bank Australia Limited, ResMed Inc., ResMed Corp. and ResMed Limited (10) 10.22 Working Capital Agreement, dated as of June 8, 2006, by and among ResMed (UK) Limited and HSBC Bank plc (10) 10.23 Working Capital Agreement, dated as of June 8, 2006, by and among ResMed Limited and HSBC Bank Australia Limited (10) 21.1 Subsidiaries of the Registrant 23.1 Independent Registered Public Accounting Firm’s Consent and Report on Schedule 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1) Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (No. 33-91094) declared effective on June 1, 1995. (2) Incorporated by reference to the Registrant’s Registration Statement on Form 8-A12G filed on April 25, 1997. (3) Incorporated by reference to the Registrant’s 1997 Proxy Statement. (4) Incorporated by reference to the Registrant’s Report on Form 10-K dated June 30, 1998. (5) Incorporated by reference to the Registrant’s Report on Form 10-K for the year ended June 30, 2001. (6) Incorporated by reference to the Registrant’s Report on Form 10-K for the year ended June 30, 2002. (7) Incorporated by reference to the Registrant’s 2003 Proxy Statement. (8) Incorporated by reference to the Registrant’s Form 8-K dated November 8, 2005. (9) Incorporated by reference to the Registrant’s Form 8-K dated March 13, 2006. (10) Incorporated by reference to the Registrant’s Form 8-K dated June 8, 2006. - 46 - RESMED INC. AND SUBSIDIARIES REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM The Board of Directors and Stockholders ResMed Inc.: We have audited the accompanying consolidated balance sheets of ResMed Inc. and subsidiaries as of June 30, 2006, and 2005, and the related consolidated statements of income, stockholders’ equity, and cash flows for each of the years in the three- year period ended June 30, 2006. In connection with our audits of the consolidated financial statements, we also have audited financial statement schedule II. These consolidated financial statements and financial statement schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements and financial statement schedule based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of ResMed Inc. and subsidiaries as of June 30, 2006 and 2005, and the results of their operations and their cash flows for each of the years in the three-year period ended June 30, 2006, in conformity with U.S. generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the basic consolidated financial statements, taken as a whole, presents fairly, in all material respects, the information set forth therein. We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the effectiveness of ResMed Inc.’s internal control over financial reporting as of June 30, 2006, based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated September 8, 2006, expressed an unqualified opinion on management’s assessment of, and the effective operation of, internal control over financial reporting. /s/ KPMG LLP ……………………………. San Diego, California September 8, 2006 - F1 - RESMED INC. AND SUBSIDIARIES Consolidated Balance Sheets June 30, 2006 and 2005 (In thousands, except share and per share data) Assets Current assets: Cash and cash equivalents Accounts receivable, net of allowance for doubtful accounts of $4,645 and $3,199 at June 30, 2006 and 2005, respectively Inventories, net (note 5) Deferred income taxes (note 14) Prepaid expenses and other current assets Total current assets Property, plant and equipment, net of accumulated depreciation of $115,471 and $88,970 at June 30, 2006 and 2005, respectively (note 7) Goodwill (note 8) Other intangibles (note 8) Other assets Total non-current assets Total assets Liabilities and Stockholders’ Equity Current liabilities: Accounts payable Accrued expenses (note 9) Deferred revenue Income taxes payable Current portion of long-term debt (note 10) Total current liabilities Non-current liabilities: Deferred income taxes (note 14) Deferred revenue Long-term debt (note 10) Total non-current liabilities Total liabilities Commitments and contingencies (notes 17, 18 and 19) Stockholders’ equity: (note 12) Preferred stock, $.01 par value, 2,000,000 shares authorized; none issued Series A Junior Participating preferred stock, $0.01 par value, 250,000 shares authorized; none issued Common stock, $.004 par value, 200,000,000 shares authorized; Issued and outstanding 75,670,316 at June 30, 2006 and 70,001,080 at June 30, 2005 (excluding 2,254,918 and 2,254,918 shares held as Treasury Stock respectively) Additional paid-in capital Retained earnings (note 6) Treasury stock, at cost Accumulated other comprehensive income (note 6) Total stockholders’ equity Total liabilities and stockholders’ equity June 30, 2006 June 30, 2005 $219,544 138,147 116,194 26,636 9,763 $142,185 103,951 89,107 15,230 9,737 510,284 360,210 245,376 195,612 48,897 7,052 174,168 181,106 49,371 9,291 496,937 413,936 $1,007,221 $774,146 $45,045 40,901 15,344 22,841 4,869 $34,416 34,414 12,327 21,959 115,435 129,000 218,551 12,377 11,484 116,212 140,073 11,695 10,901 58,934 81,530 269,073 300,081 - - - - - - 303 280 353,464 370,652 (41,405) 55,134 179,865 282,441 (41,405) 52,884 738,148 474,065 $1,007,221 $774,146 All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 10, 2005 and distributed on September 30, 2005. See accompanying notes to consolidated financial statements. - F2 - RESMED INC. AND SUBSIDIARIES Consolidated Statements of Income Years Ended June 30, 2006, 2005 and 2004 (In thousands, except per share data) Net revenues Cost of sales (A) Gross profit Operating expenses: Selling, general and administrative (A) Research and development (A) Donations to Research Foundations In-process research and development charge (note 20) Amortization of acquired intangible assets Restructuring expenses (note 11) Total operating expenses Income from operations Other income (expenses): Interest income (expense), net Other, net (note 13) Total other income (expenses), net Income before income taxes Income taxes (note 14) Net income Basic earnings per share Diluted earnings per share (note 2-j) Basic shares outstanding Diluted shares outstanding (A) Includes stock-based compensation costs as follows (note 3): Cost of sales Selling, general and administrative Research and development Total stock-based compensation costs June 30, 2006 June 30, 2005 June 30, 2004 $606,996 230,101 376,895 $425,505 150,645 274,860 $339,338 122,602 216,736 200,168 37,216 760 - 6,327 1,124 245,595 135,703 30,014 500 5,268 870 5,152 177,507 104,706 26,169 500 - - - 131,375 131,300 97,353 85,361 1,320 774 2,094 133,394 45,183 $88,211 $1.22 $1.16 72,307 77,162 $891 12,372 2,042 $15,305 (808) 81 (727) 96,626 31,841 (1,683) 990 (693) 84,668 27,384 $64,785 $57,284 $0.94 $0.91 68,643 74,942 $- - - $- $0.85 $0.82 67,389 70,251 $- - - $- All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 10, 2005 and distributed on September 30, 2005. See accompanying notes to consolidated financial statements. - F3 - RESMED INC. AND SUBSIDIARIES Consolidated Statements of Stockholders’ Equity Years ended June 30, 2006, 2005 and 2004 (In thousands) Common Stock Shares Amount 67,572 Additional Paid-in Capital $268 $107,300 Treasury Stock Shares (830) Amount ($11,417) Retained Earnings $160,372 Accumulated Other Comprehensive Income (loss) $29,910 1,916 6 (4) 20,335 5,105 (942) (19,023) 57,284 11,366 (3) Total $286,433 20,341 (19,027) 5,105 57,284 11,366 (3) 69,488 2,634 134 $270 $132,740 (1,772) ($30,440) $217,656 $41,273 $361,499 9 2 (1) 36,766 2,649 7,710 (482) (10,965) 36,775 2,651 (10,966) 7,710 64,785 11,617 (6) 64,785 11,617 (6) Balance, June 30, 2003 Common stock issued on exercise of options Treasury stock purchases Tax benefit from exercise of options Comprehensive income: Net income Other comprehensive income Foreign currency translation adjustments Unrealized losses on marketable securities Comprehensive income/(loss) Balance, June 30, 2004 Common stock issued on exercise of options Common stock issued on employee share purchase plan Treasury stock purchases Tax benefit from exercise of options Comprehensive income: Net income Other comprehensive income Foreign currency translation adjustments Unrealized losses on marketable securities Comprehensive income/(loss) Balance, June 30, 2005 72,256 $280 $179,865 (2,254) ($41,405) $282,441 $52,884 $474,065 Common stock issued on exercise of options (note 12) Common stock issued on employee share purchase plan (note 12) Treasury stock purchases Tax benefit from stock-based compensation costs Common stock issued on conversion of convertible subordinated notes 1,805 126 7 1 30,790 3,755 10,107 3,738 15 113,235 FAS123(R) stock-based compensation costs 15,712 Comprehensive income (note 6): Net income Other comprehensive income Foreign currency translation adjustments Comprehensive income/(loss) 30,797 3,756 - 10,107 113,250 15,712 88,211 - 2,250 88,211 2,250 Comprehensive Income 57,284 11,366 (3) $68,647 64,785 11,617 (6) $76,396 88,211 2,250 $90,461 Balance, June 30, 2006 77,925 $303 $353,464 (2,254) ($41,405) $370,652 $55,134 $738,148 All share and per share information has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 10, 2005 and distributed on September 30, 2005. See accompanying notes to consolidated financial statements. - F4 - RESMED INC. AND SUBSIDIARIES Consolidated Statements of Cash Flows Years ended June 30, 2006, 2005 and 2004 (In thousands) Cash flows from operating activities: Net income Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization Provision for service warranties Deferred income taxes Foreign currency options revaluation Amortization of deferred borrowing costs Stock-based compensation costs Tax benefit from stock options exercised Write-down of cost-method investment Release of profit on sale of building Purchased in-process research and development write off Changes in operating assets and liabilities, net of effect of acquisitions: Accounts receivable, net Inventories, net Prepaid expenses and other current assets Accounts payable, accrued expenses and other liabilities June 30, 2006 June 30, 2005 June 30, 2004 $88,211 $64,785 $57,284 40,970 1,437 (11,915) 3,796 649 15,305 - 1,156 - - (28,287) (25,041) (2,432) 15,179 28,292 501 (7,997) 293 834 - 7,710 - (2,371) 5,268 17,867 213 1,259 982 804 - 5,105 - (2,440) - (27,996) (22,562) 558 23,764 (13,129) (6,722) 15 15,303 Net cash provided by operating activities 99,028 71,079 76,541 Cash flows from investing activities: Purchases of property, plant and equipment Capitalized Interest Purchases of marketable securities - available for sale Proceeds from sale of marketable securities - available for sale Patent registration costs Business acquisitions, net of cash acquired of $262 ($12,982 in 2005 and $Nil in 2004) Purchases of non-trading investments Net cash used in investing activities Cash flows from financing activities: Proceeds from issuance of common stock, net Repayment of assumed borrowings from acquisitions Repayment of borrowings Proceeds from borrowings, net of borrowing costs Tax benefit from stock option exercises Purchases of treasury stock Net cash provided by financing activities Effect of exchange rate changes on cash Net increase in cash and cash equivalents Cash and cash equivalents at beginning of the year Cash and cash equivalents at end of the year Supplemental disclosure of cash flow information: Income taxes paid, net of refunds Interest paid, net of capitalized interest Fair value of assets acquired in acquisitions Liabilities assumed Goodwill on acquisition Acquisition costs accrued Acquisition costs paid Cash paid for acquisition, including acquisition costs (102,749) (1,100) (2,000) 2,002 (3,115) (10,526) (2,386) (39,691) - (401,546) 413,576 (2,819) (54,425) (1,873) (57,246) - (78,890) 73,376 (2,358) (184) (1,535) (119,874) (86,778) (66,837) 34,389 (2,195) (46,308) 102,128 9,753 - 39,426 (65,764) - 62,500 - (10,966) 20,341 - - - - (19,027) 97,767 25,196 1,314 438 3,781 3,398 77,359 142,185 13,278 128,907 14,416 114,491 $219,544 $142,185 $128,907 $44,873 4,566 11,517 (6,816) 5,553 (1,279) 1,813 $10,788 $24,747 4,530 $15,141 4,530 89,188 (99,270) 78,949 (1,726) 266 $67,407 95 - 89 - - $184 See accompanying notes to consolidated financial statements. - F5 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (1) Organization and Basis of Presentation ResMed Inc. (referred to herein as “we”, “us”, “our” or the "Company") is a Delaware Corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Germany, France and the United States of America. Major distribution and sales sites are located in the United States of America, Germany, France, the United Kingdom, Switzerland, Australia and Sweden. All share and per share information in the notes has been adjusted to reflect the two-for-one stock split effected in the form of a 100% stock dividend that was declared on August 10, 2005 and distributed on September 30, 2005. (2) Summary of Significant Accounting Policies (a) Basis of Consolidation The consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries. All significant inter-company transactions and balances have been eliminated in consolidation. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management estimates and assumptions that affect amounts reported in the financial statements and accompanying notes. Actual results could differ from management’s estimates. (b) Revenue Recognition Revenue on product sales is generally recorded upon shipment, at which time title transfers to the customer. Revenue on product sales which require customer acceptance is not recorded until acceptance is received. Royalty revenue from license agreements is recorded when earned. Service revenue received in advance from service contracts is initially deferred and recognized ratably over the life of the service contract. Revenue received in advance from rental unit contracts is initially deferred and recognized ratably over the life of the rental contract. Revenue from sale of marketing or distribution rights is initially deferred and recognized ratably as revenue over the life of the contract. Freight charges billed to customers are included in revenue. All shipping and handling related expenses are charged to cost of sales. We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products, other than returns for product defects or other warranty claims, nor do we recognize revenues if we offer variable sale prices for subsequent events or activities. However, as part of our sales processes we may provide upfront discounts for large orders, one time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. The costs of all such programs are recorded as an adjustment to revenue. In our U.S. sales activities we use a number of manufacturer representatives to sell our products. These representatives are paid a direct commission on sales and act as an integral component of our U.S. sales force. We do not sell our products to these representatives and do not recognize revenue on such shipments. Our products are predominantly therapy-based equipment and require no installation. As such, we have no significant installation obligations. (c) Cash and Cash Equivalents Cash equivalents include certificates of deposit, commercial paper, and other highly liquid investments and are stated at cost, which approximates market. Investments with original maturities of 90 days or less are considered to be cash equivalents for purposes of the consolidated statements of cash flows. (d) Inventories Inventories are stated at the lower of cost, determined principally by the first-in, first-out method, or net realizable value. We review and provide for any product obsolescence in our manufacturing and distribution operations with assessments of individual products and components (based on estimated future usage and sales) being performed throughout the year. - F6 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (2) Summary of Significant Accounting Policies, Continued (e) Property, Plant and Equipment Property, plant and equipment, including rental equipment, is recorded at cost. Depreciation expense is computed using the straight–line method over the estimated useful lives of the assets, generally two to ten years except for buildings which are depreciated over an estimated useful life of 40 years. Straight–line and accelerated methods of depreciation are used for tax purposes. Maintenance and repairs are charged to expense as incurred. We capitalize interest in connection with the construction of facilities. Actual construction costs incurred relating to facilities under active development qualify for interest capitalization. Interest capitalization ceases when the construction of a facility is complete and available for use. During the year ended June 30, 2006, we capitalized $1.1 million of interest relating to such construction costs. (f) Intangible Assets The registration costs for new patents are capitalized and amortized over the estimated useful life of the patent, generally five years. In the event of a patent being superseded, the unamortized costs are written off immediately. Other intangible assets are amortized on a straight-line basis over their estimated useful lives, which range from seven to nine years. We evaluate the recoverability of intangible assets periodically and take into account events or circumstances that warrant revised estimates of useful lives or that indicate that impairment exists. All of our intangible assets are subject to amortization. No impairment of intangible assets has been identified during any of the periods presented. (g) Goodwill We conducted our annual review for goodwill impairment during the final quarter of fiscal 2006. In conducting our review of goodwill impairment, we identified reporting units, being components of our operating segment, as each of the entities acquired and giving rise to the goodwill. The fair value for each reporting unit was determined based on estimated discounted cash flows. Our goodwill impairment review involved a two-step process as follows: Step 1- Step 2- Compare the fair value for each reporting unit to its carrying value, including goodwill. For each reporting unit where the carrying value, including goodwill, exceeds the reporting unit’s fair value, move on to step 2. If a reporting unit’s fair value exceeds the carrying value, no further work is performed and no impairment charge is necessary. Allocate the fair value of the reporting unit to its identifiable tangible and non-goodwill intangible assets and liabilities. This will derive an implied fair value for the goodwill. Then, compare the implied fair value of the reporting unit’s goodwill with the carrying amount of the reporting unit’s goodwill. If the carrying amount of the reporting unit’s goodwill is greater than the implied fair value of its goodwill, an impairment loss must be recognized for the excess. The results of the review indicated that no impaired goodwill exists. (h) Foreign Currency The consolidated financial statements of our non–U.S. subsidiaries, whose functional currencies are other than U.S. dollars, are translated into U.S. dollars for financial reporting purposes. Assets and liabilities of non–U.S. subsidiaries whose functional currencies are other than the U.S. dollar are translated at period end exchange rates, and revenue and expense transactions are translated at average exchange rates for the period. Cumulative translation adjustments are recognized as part of comprehensive income, as described in Note 6, and are included in accumulated other comprehensive income in the consolidated balance sheet until such time as the subsidiary is sold or substantially or completely liquidated. Gains and losses on transactions denominated in other than the functional currency of the entity are reflected in operations. - F7 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (2) Summary of Significant Accounting Policies, Continued (i) Research and Development All research and development costs are expensed in the period incurred. (j) Earnings Per Share We calculate earnings per share in accordance with Statement of Financial Accounting Standards (“SFAS”) No. 128, “Earnings per Share” (“SFAS 128”), as amended by SFAS No. 123(R), “Share Based Payments” (“SFAS 123(R)”). SFAS 128 requires the presentation of “basic” earnings per share and “diluted” earnings per share. Basic earnings per share is computed by dividing the net income available to common shareholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, net income is adjusted for the after-tax amount of interest associated with convertible debt, and the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and convertible notes. The weighted average shares used to calculate basic earnings per share were 72,307,000, 68,643,000, and 67,389,000 for the years ended June 30, 2006, 2005 and 2004, respectively. The difference between basic earnings per share and diluted earnings per share is attributable to the impact of outstanding stock options during the periods presented and the assumed conversion of our convertible notes. Stock options had the effect of increasing the number of shares used in the calculation (by application of the treasury stock method) by 2,346,000, 2,561,000 and 2,862,000 for the years ended June 30, 2006, 2005 and 2004, respectively. The conversion of our convertible notes had the effect of increasing the number of shares used in the calculation by 2,509,000, 3,738,000 and NIL for the years ended June 30, 2006, 2005 and 2004, respectively. During the year ended June 30, 2006 all of our convertible notes were converted to common stock. Stock options of 1,103,000, 568,000 and 1,502,000 for the years ended June 30, 2006, 2005 and 2004 respectively, were not included in the computation of diluted earnings per share as the effect of exercising these options would have been anti-dilutive. Basic and diluted earnings per share for the periods ended 30 June 2006, 2005 and 2004 are calculated as follows (in thousands except per share data): 2006 2005 2004 Numerator: Net income Adjustment for interest and deferred borrowing costs, net of income tax effect (1) Net income, used in calculating diluted earnings per share $88,211 $64,785 $57,284 1,660 3,285 - $89,871 $68,070 $57,284 Denominator: Basic weighted-average common shares outstanding 72,307 68,643 67,389 Effect of dilutive securities: Stock options Convertible subordinated notes Diluted potential common shares Diluted weighted average shares Basic earnings per share Diluted earnings per share(1) 2,346 2,509 4,855 77,162 $1.22 $1.16 2,561 3,738 6,299 74,942 $0.94 $0.91 2,862 - 2,862 70,251 $0.85 $0.82 (1) Diluted earnings per share has been calculated after adjusting the numerator (net income) by $1,660,000, $3,285,000 and $NIL for the years ended June 30, 2006, 2005 and 2004, respectively for the effect of assumed conversion of our convertible notes, and the related reduction in interest expense, net of tax. - F8 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (2) Summary of Significant Accounting Policies, Continued (k) Financial Instruments The carrying value of financial instruments, such as cash and cash equivalents, marketable securities available-for-sale, accounts receivable and accounts payable approximate their fair value because of their short-term nature. Foreign currency option contracts are marked to market and therefore reflect their fair value. We do not hold or issue financial instruments for trading purposes. The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. (l) Foreign Exchange Risk Management We enter into various types of foreign exchange contracts in managing our foreign exchange risk, including derivative financial instruments encompassing forward exchange contracts and foreign currency options. The purpose of our foreign currency hedging activities is to protect us from adverse exchange rate fluctuations with respect to net cash movements resulting from the sales of products to foreign customers and Australian manufacturing activities. We enter into foreign currency option contracts to hedge anticipated sales and manufacturing costs, principally denominated in Australian dollars and Euros. The terms of such foreign currency option contracts generally do not exceed three years. Our foreign currency derivatives portfolio represents a cash flow hedge program against the net cash flow of our international manufacturing operations. We have determined our hedge program to be a non-effective hedge as defined under SFAS 133. The foreign currency derivatives portfolio is recorded in the consolidated balance sheets at fair value and included in other assets or other liabilities. All movements in the fair value of the foreign currency derivatives are recorded within other income, net of our consolidated statements of income. We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. The credit exposure of foreign exchange options at June 30, 2006 and June 30, 2005 was $1.2 million and $3.0 million, respectively, which represents the positive fair value of options held by us. We held foreign currency option contracts with notional amounts totaling $193.4 million and $145.5 million at June 30, 2006 and 2005, respectively, to hedge foreign currency items. These contracts mature at various dates before December 2007. (m) Income Taxes We account for income taxes under the asset and liability method. We recognize deferred tax assets and liabilities for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. - F9 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (2) Summary of Significant Accounting Policies, Continued (n) Marketable Securities Management determines the appropriate classification of our investments in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. Debt securities for which we do not have the intent or ability to hold to maturity are classified as available-for-sale. Securities available- for-sale are carried at fair value, with the unrealized gains and losses, net of tax, reported in accumulated other comprehensive income. At June 30, 2006 and 2005, there were no investments in debt securities that were classified on the accompanying consolidated balance sheet as marketable securities-available-for-sale. (o) Warranty Estimated future warranty costs related to certain products are charged to operations in the period in which the related revenue is recognized. The liability for warranty costs are included in accrued expenses in our condensed consolidated balance sheet. Changes in the liability for product warranty for the year ended June 30, 2006 are as follows (in thousands): Balance as at June 30, 2005 Warranty accruals for the year ended June 30, 2006 Warranty costs incurred for the year ended June 30, 2006 Foreign currency translation adjustments Balance as at June 30, 2006 $2,912 1,964 (527) (149) $4,200 (p) Impairment of Long-Lived Assets We periodically evaluate the carrying value of long-lived assets to be held and used, including certain identifiable intangible assets, when events and circumstances indicate that the carrying amount of an asset may not be recovered. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. (q) Cost-Method Investments The aggregate carrying amount of our cost-method investments at June 30, 2006 and June 30, 2005 was $4.1 million and $5.3 million respectively. At June 30, 2006 we reviewed the carrying value of these investments. In fiscal 2006 and 2005, we recognized $1.2 million and $0.1 respectively of impairment losses related to our cost method investments, which include investments in privately held service companies, research companies and public companies. The expense associated with this impairment has been included in the other income (expense) line within the statement of income. - F10 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (2) Summary of Significant Accounting Policies, Continued In addition to the impairment loss recognized an unrealized loss of $1.4 million was identified in relation to an investment in a public company. The severity of the impairment (fair value is approximately 40% less than the cost) and the duration of the impairment (less than 6 months) correlates with a devaluation in both the currency of the shares against the U.S. dollar and the actual share price. Because we have the ability and intent to hold this investment until a recovery of the fair value and the decline in fair value is partly attributable to exchange rate movements, we do not consider this investment to be other-than-temporarily impaired at June 30, 2006. Except for the unrealized loss, we have determined that the fair value of the investments exceeded the carrying values. (3) New Accounting Pronouncements In November 2005, the FASB issued FSP FAS123(R)-3, “Transition Election to Accounting for the Tax Effects of Share-Based Payment Awards”. This FSP requires an entity to follow either the transition guidance for the additional- paid-in-capital pool as prescribed in SFAS 123(R), or the alternative transition method as described in the FSP. We have made a one-time election to adopt the transition method described in this FSP which did not have a material impact on our financial statements. In November 2005, the FASB issued FSP FAS115-1/124-1, “The Meaning of Other-Than-Temporary Impairment and Its Application to Certain Investments”, which addresses the determination as to when an investment is considered impaired, whether that impairment is other than temporary, and the measurement of an impairment loss. This FSP also includes accounting considerations subsequent to the recognition of an other-than-temporary impairment and requires certain disclosures about unrealized losses that have not been recognized as other-than-temporary impairments. The guidance in this FSP amends FASB Statements No. 115, “Accounting for Certain Investments in Debt and Equity Securities”, and No. 124, and APB Opinion No. 18, “The Equity Method of Accounting for Investments in Common Stock”. We adopted this FSP during the fiscal year ended June 30, 2006 and it did not have a material impact on our financial statements. In June 2006, the FASB issued FIN No. 48, “Accounting for Uncertainty in Income Taxes – an interpretation of FASB Statement No. 109”, which clarifies the accounting for uncertainty in income taxes recognized in the financial statements in accordance with FASB Statement No. 109, “Accounting for Income Taxes”. The interpretation prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. FIN No. 48 requires recognition of tax benefits that satisfy a greater than 50% probability threshold. It also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. FIN No. 48 is effective for us beginning July 1, 2007. We are currently assessing the potential impact that the adoption of FIN No. 48 will have on our financial statements. - F11 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (4) Stock-based Employee Compensation We have granted stock options to personnel, including officers and directors, under both our 1995 Option Plan and our 1997 Equity Participation Plan, which we refer to collectively as the Plans. These options have expiration dates of ten years from the date of grant and vest over three or four years. We granted these options with an exercise price equal to the market value as determined at the date of grant. We have also offered to our personnel, including officers and directors, the right to purchase shares of our common stock at a discount under our employee stock purchase plan, or ESPP. Prior to July 1, 2005, we applied APB Opinion No. 25, “Accounting for Stock Issued to Employees” and related Interpretations, in accounting for our equity plans. For periods prior to July 1, 2005, we complied with the disclosure only provisions of SFAS No. 123, “Accounting for Stock Based Compensation”, or SFAS 123. No stock-based employee compensation cost was reflected in net income, as all options granted under those plans had an exercise price equal to the market value of the underlying common stock on the date of grant (or within permitted discounted prices as it pertains to the ESPP). Results for periods before July 1, 2005 have not been restated to reflect, and do not include the impact of, SFAS No. 123(R), “Share Based Payment”, or SFAS 123(R). The following table illustrates the effect on net income and earnings per share if we had applied the fair value recognition provisions of SFAS 123 for stock option grants using the minimum value method of accounting: In thousands, except per share data Net income, as reported Deduct: Stock-based employee compensation expense determined under fair value based method, net of related tax effects Pro forma net income Adjustment for interest and deferred borrowing costs, net of related tax effects Pro forma net income used in calculating diluted earnings per share Earnings per share: Basic - as reported Basic - pro forma Diluted - as reported Diluted - pro forma Years Ended June 30 2005 $64,785 2004 $57,284 10,323 $54,462 9,394 $47,890 3,285 $57,747 3,285 $51,175 $0.94 $0.80 $0.91 $0.77 $0.85 $0.71 $0.82 $0.68 As of July 1, 2005, we adopted SFAS No. 123(R), using the modified prospective method, which requires measurement of compensation expense of all stock-based awards at fair value on the date of grant and amortization of the fair value over the vesting period of the award. We have elected to use the straight-line method of amortization. Under the prospective method, the provisions of SFAS 123(R) apply to all awards granted or modified after the date of adoption. In addition, the unrecognized expense of awards not yet vested at the date of adoption, determined under the original provisions of SFAS No. 123 shall be recognized in net income in the periods after adoption. The fair value of stock options is determined using the Black-Scholes valuation model, which is consistent with valuation techniques previously utilized for options in footnote disclosures required under SFAS No. 123, as amended by SFAS No. 148 “Accounting for Stock-Based Compensation – Transition and Disclosure”. Such value is recognized as expense over the service period, net of estimated forfeitures, using the straight-line method under SFAS 123(R). - F12 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (4) Stock-based Employee Compensation, Continued The application of SFAS 123(R) had the following effect on reported amounts relative to amounts that would have been reported under previous accounting (in thousands, except per share data): Cost of sales Operating expenses: Selling, general and administration Research and development Income from operations Income before income taxes Net income Inventories, net Earnings per share: Basic Diluted Cashflow from operating activities Cashflow from financing activities 2006 Under Previous Accounting SFAS 123(R) Adjustments As Reported $229,210 $891 $230,101 187,796 35,174 146,605 148,699 100,183 115,787 $1.39 $1.30 $108,781 $88,014 12,372 2,042 (15,305) (15,305) (11,972) 407 ($0.17) ($0.14) $(9,753) $9,753 200,168 37,216 131,300 133,394 88,211 116,194 $1.22 $1.16 $99,028 $97,767 The fair value of stock options granted under our stock option plans and purchase rights granted under our ESPP is estimated on the date of the grant using the Black-Scholes option-pricing model with the following weighted average assumptions: Stock Options: Weighted average fair value Weighted average risk-free interest rate Dividend yield Expected option life in years Volatility ESPP Purchase rights: Weighted average risk-free interest rate Dividend yield Expected option life in years Volatility Years ended June 30 2005 2006 12.75 3.9-4.5% - 3.9-5.2 28-30% 3.2-4.9% - 6 months 29-41% 8.49 4.0% - 3.5-4.6 31% 2.3% - 6 months 31-38% 2004 7.44 2.9% 3.3-4.2 43% - - - - Expected volatilities are based on a combination of historical volatilities of our stock and implied volatilities from traded options of our stock. The expected life represents the weighted average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and our historical exercise patterns. The risk- free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. - F13 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (5) Inventories Inventories, net were comprised of the following as of June 30, 2006 and 2005 (in thousands): Raw materials Work in progress Finished goods 2006 $41,979 3,520 70,695 $116,194 2005 $29,857 1,820 57,430 $89,107 (6) Comprehensive Income The components of comprehensive income, net of tax, were as follows (in thousands): Net income Foreign currency translation gains/(losses) Unrealized gains/(losses) on marketable securities Comprehensive income 2006 $88,211 2,250 - $90,461 2005 $64,785 11,617 (6) $76,396 We do not provide for U.S. income taxes on foreign currency translation adjustments since we do not provide for such taxes on undistributed earnings of foreign subsidiaries. (7) Property, Plant and Equipment Property, plant and equipment is comprised of the following as of June 30, 2006 and 2005 (in thousands): Machinery and equipment Computer equipment Furniture and fixtures Vehicles Clinical, demonstration and rental equipment Leasehold improvements Land Buildings Construction in Progress Accumulated depreciation and amortization 2006 $51,854 52,277 21,572 2,795 40,615 11,604 55,946 77,474 46,710 360,847 (115,471) $245,376 (8) Goodwill and Other Intangible Assets Changes in the carrying amount of goodwill for the year ended June 30, 2006, were as follows: (In thousands) Balance at June 30, 2005 Foreign currency translation adjustments Acquisition of PolarMed (note 18) Acquisition of Pulmomed (note 18) Payment of earn-out relating to Hoefner acquisition (note 18) Adjustment to purchase price allocation relating to Saime acquisition (note 18) Balance at June 30, 2006 - F14 - 2005 $42,623 44,011 18,174 2,266 29,211 4,940 35,492 77,101 9,320 263,138 (88,970) $174,168 2006 $181,106 8,952 4,351 2,104 594 (1,495) $195,612 RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (8) Goodwill and Other Intangible Assets, Continued Patents and other intangibles is comprised of the following as of June 30, 2006 and June 30, 2005: (In thousands) Developed/Core Product Technology Accumulated amortization Developed/Core Product Technology, net of accumulated amortization Trade names Accumulated amortization Trade names, net of accumulated amortization Customer relationships Accumulated amortization Customer relationships, net of accumulated amortization Patents Accumulated amortization Patents, net of accumulated amortization Patents and other intangibles, net of accumulated amortization June 30, 2006 $31,336 (4,992) 26,344 1,663 (265) 1,398 16,362 (2,094) 14,268 16,151 (9,264) 6,887 $48,897 June 30, 2005 $29,620 (487) 29,133 1,572 (26) 1,546 12,936 (345) 12,591 13,200 (7,099) 6,101 $49,371 Intangible assets consist of patents, customer relationships, trade names, developed/core product technology and are amortized over the estimated useful life of the assets, generally between five and nine years. There are no expected residual values related to these intangible assets. In fiscal year 2005, as part of the acquisition of Saime, we recognized an intangible asset with respect to developed/core product technology. Specifically, this technology related to the design and architecture of the hardware and algorithms that formed part of Saime’s ventilation products and is the subject of patents and other intellectual property protections. This technology is separable from goodwill as it is capable of being sold, transferred or licensed. This represents proprietary know-how predominantly associated with the following portfolio of products that were technologically feasible at the date of acquisition: (i) Elisee Series: Combines all conventional ventilation modes and monitoring functions; and (iii) VS Series (including Serena, Ultra and Integra): A new generation of ventilators using new blower technology. Both of these series of products continue to generate revenue which is consistent with the original expectations. Although no assurance can be given that the underlying assumptions used to value the acquired developed/core product technology will transpire as estimated, we remain confident in the assumptions used and, as a result, the net return of the Saime acquisition. Amortization expense related to identifiable intangible assets for the year ended June 30, 2006 was $8.5 million. Estimated annual amortization expense for the years ending June 30, 2007 through June 30, 2010, including the effect of the Resprecare, Hoefner, Saime, Pulmomed and PolarMed acquisitions is shown below (in thousands): Fiscal Year 2007 2008 2009 2010 2011 Amortization expense $9,067 8,695 8,304 7,754 $7,200 - F15 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (9) Accrued expenses Accrued expenses at June 30, 2006 and 2005 consist of the following (in thousands): Service warranties Consulting and professional fees Value added taxes and other taxes due Employee related costs Accrued interest Marketing and promotional programs Restructuring Acquisition costs Customer advance Other 2006 $4,653 2,851 3,199 20,804 868 3,024 138 320 1,102 3,942 $40,901 2005 $2,912 3,207 4,139 16,793 358 1,887 474 0 1,042 3,602 $34,414 (10) Long-term debt Long-term debt at June 30, 2006 and 2005 consists of the following (in thousands): Convertible subordinated notes Long-term loan Capital lease Current portion of long-term debt Long-term loan Capital lease Non-current portion of long-term debt Convertible Subordinated notes June 30, 2006 $- 4,796 73 $4,869 $115,644 568 $116,212 June 30, 2005 $113,250 2,116 69 $115,435 $58,328 606 $58,934 During the year ended June 30, 2006 and pursuant to the Indenture dated June 20, 2001 between us and American Stock Transfer & Trust Company, as trustee, holders of all of the 4% Convertible Subordinated Notes (“the Notes”) due 2006 converted the Notes into an aggregate of 3,737,593 shares of our common stock, par value $0.004. The Notes were converted into 33 shares of our common stock for each $1,000 principal amount of the Notes, at a conversion price of $30.30 per share. No payment was made for accrued interest on Notes surrendered for conversion and the dilutive impact of these conversions has been reflected in the reported earnings per share. Previous to the conversion, on January 5, 2006, we had exercised our right to call for an early redemption of all of the Notes, which at that time had an outstanding balance of $113.25 million. We provided notice to the trustee and the holders of the Notes that we were to redeem the Notes on March 3, 2006 at a redemption price of approximately $1,008 per $1,000 principal amount of Notes, or 100.8% of the principal amount thereof plus accrued and unpaid interest to the redemption date. However, as noted above, holders of all of the Notes exercised their option to convert the Notes into our common stock. Revolving Facility On March 13, 2006, our wholly-owned subsidiaries ResMed Corp., Servo Magnetics Inc. and ResMed EAP Holdings Inc. entered into a Second Amended and Restated Revolving Loan Agreement with Union Bank of California, N.A. as administrative agent for the Lenders (the “Loan Agreement”), that provides for a revolving loan of up to $75 million. Draws under the revolving loans must be made before March 1, 2011, at which time all unpaid principal and interest under both loans must be repaid. The outstanding principal amount due under the loans will bear interest at a rate equal to LIBOR plus 0.75% to 1.00% (depending on the applicable leverage ratio). At June 30, 2006 there were no amounts outstanding under the Loan Agreement. - F16 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (10) Long-term debt, Continued The obligations of ResMed Corp., Servo Magnetics Inc. and ResMed EAP Holdings Inc. under the Loan Agreement are secured by substantially all of the personal property of each of ResMed Corp., Servo Magnetics Inc. and ResMed EAP Holdings Inc., and are guaranteed by ResMed Inc. under an Amended and Restated Continuing Guaranty and Pledge Agreement, which guaranty is secured by a pledge of the equity interests in ResMed Corp., Servo Magnetics Inc. and ResMed EAP Holdings Inc. held by ResMed Inc. The Loan Agreement also contains customary covenants, including certain financial covenants and an obligation that ResMed Inc. maintain certain financial ratios, including a maximum ratio of total debt to EBITDA (as defined in the Loan Agreement), a fixed charge coverage ratio, a minimum tangible net worth, and a minimum ResMed Corp., Servo Magnetics Inc. and ResMed EAP Holdings Inc. EBITDA and liquidity. The entire principal amount of the Loan and any accrued but unpaid interest may be declared immediately due and payable in the event of the occurrence of an event of default as defined in the Loan Agreement. Events of default include, among other items, failure to make payments when due, the occurrence of a material default in the performance of any covenants in the Loan Agreement or related document or a 35% or more change in control of ResMed Inc., ResMed Corp., Servo Magnetics Inc. or ResMed EAP Holdings Inc. At June 30, 2006, we were in compliance with our debt covenants. Syndicated Facility On June 8, 2006, our wholly-owned Australian subsidiary, ResMed Limited, entered into a Syndicated Facility Agreement with HSBC Bank Australia Limited as original financier, facility agent and security trustee, that provides for a loan in three tranches. Tranche A is a EUR 50 million term loan facility that refinances all amounts outstanding under a previous syndicated facility agreement dated May 16, 2005 between ResMed Limited and HSBC Bank Australia Limited, to fund the obligations of our wholly owned French subsidiary Resmed SAS under its agreement to acquire Saime SA). Tranche A bears interest at a rate equal to LIBOR for deposits denominated in EUR plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of ResMed Inc. and its subsidiaries (the “ResMed Group”) for the most recently completed fiscal year for the applicable interest period. Payments of principal must be made to reduce the total outstanding principal amount of Tranche A to EUR 48.25 million on June 30, 2006, EUR 44.5 million on June 30, 2007, EUR 37.75 million on June 30, 2008, EUR 27.5 million on June 30, 2009, EUR 15 million on December 31, 2009, and the entire outstanding principal amount must be repaid in full on June 8, 2011. At June 30, 2006, the Tranche A facility loan had an amount outstanding of $61.7 million. Tranche B is a USD 15 million term loan facility that may only be used for the purpose of financing capital expenditures and other asset acquisitions by the ResMed Group. Tranche B bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars, USD, or Sterling plus a margin of 0.80% or 0.90%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. The entire principal amount must be repaid in full on June 8, 2011. At June 30, 2006, there were no amounts outstanding under the Tranche B facility loan agreement. Tranche C is a USD 60 million term loan facility that may only be used for the purpose of the payment by ResMed Limited of a dividend to ResMed Holdings Limited, which will ultimately be paid to ResMed Inc. Tranche C bears interest at a rate equal to LIBOR for deposits denominated in EUR, Australian dollars or USD plus a margin of 0.70% or 0.80%, depending on the ratio of the total debt to EBITDA of the ResMed Group for the most recently completed fiscal year for the applicable interest period. Payments of principal must be made to reduce the total outstanding principal amount of Tranche C to USD 30 million on December 31, 2007 and the entire outstanding principle amount must be repaid in full by June 8, 2009. At June 30, 2006, the Tranche C facility loan had an amount outstanding of $58.6 million. Simultaneous with the Syndicated Facility Agreement, ResMed Limited entered into a working capital agreement with HSBC Bank Australia Limited for revolving, letter of credit and overdraft facilities up to a total commitment of 6.5 million Australian dollars for one year, and ResMed (UK) Limited entered into a working capital agreement with HSBC Bank plc for a revolving cash advance facility up to a total commitment of 3 million Sterling for one year. - F17 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (10) Long-term debt, Continued The Loan is secured by a pledge of one hundred percent of the shares of ResMed Inc.’s subsidiary, Saime SAS, pursuant to a Pledge Agreement. The Syndicated Facility Agreement also contains customary covenants, including certain financial covenants and an obligation that ResMed Limited maintain certain financial ratios, including a minimum debt service cover ratio, a maximum ratio of total debt to EBITDA and a minimum tangible net worth. The entire principal amount of the Loan and any accrued but unpaid interest may be declared immediately due and payable in the event of the occurrence of an event of default as defined in the Syndicated Facility Agreement. Events of default include, among other items, failure to make payments when due, breaches of representations, warranties or covenants, the occurrence of certain insolvency events, the occurrence of an event or change which could have a material adverse effect on ResMed Limited and its subsidiaries, and if ResMed Inc. ceases to control ResMed Limited, ResMed Corp., ResMed SAS, ResMed GmbH & Co. KG, ResMed (UK) Limited, Take Air Medical Handels-GmbH or Saime SAS. The obligations of ResMed Limited under the Loan are subject to two guarantee and indemnity agreements, one on behalf of ResMed and its U.S. subsidiary, ResMed Corp., and another on behalf of ResMed’s international subsidiaries, ResMed SAS (other than Tranche C), ResMed GmbH & Co. KG, ResMed (UK) Limited and Take Air Medical Handels-GmbH. At June 30, 2006 we were in compliance with our debt covenants. Capital Lease As part of the acquisition of Saime we assumed a capital lease over land and buildings. This lease contains an option to purchase the property, for nominal consideration, at the end of the lease term in September 2014. Details of contractual debt maturities at June 30, 2006 are as follows (in thousands): Long-Term Debt Capital Leases Total Total $120,441 641 $121,082 2007 $4,796 73 $4,869 (11) Restructuring Expenses 2008 $38,782 73 $38,855 Payments Due by Period 2009 $13,110 73 $13,183 2010 $35,173 73 $35,246 Thereafter $28,580 349 $28,929 Restructuring expenses incurred during the year ended June 30, 2006 were $1.2 million ($0.7 million net of tax) and are recorded in the consolidated statement of income as restructure expenses. Restructuring expenses (predominantly one-time employee termination benefits) are associated with the integration of the separate operations of ResMed Germany and MAP into a single operating unit. We have substantially completed the relocation of our ResMed Germany operation (previously located in Moenchengladbach) to Munich and integration of the back office functions including customer service, logistics and administration. We will continue to monitor the progress of this restructure and adjust our business strategies and personnel accordingly to achieve maximum efficiencies and cost savings. Following is a summary of the restructuring liabilities related to the restructure and integration of the separate operations of ResMed Germany and MAP into a single operating unit, that were recorded during the year ended June 30, 2006 (in thousands): Balance at June 30, 2005 Restructuring expenses Cash payments Foreign Currency translation Balance at June 30, 2006 Accrued employee costs $222 888 (1,044) (28) $38 Other accrued costs $252 236 (408) 20 $100 Total accrued costs $474 1,124 (1,452) (8) $138 - F18 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (12) Stockholders’ Equity Stock Options. The Company has granted stock options to personnel, including officers and directors in accordance with both the 1995 Option Plan and the 1997 Equity Participation Plan (collectively the “Plans”). These options have expiration dates of ten years from the date of grant and vest over three or four years. The Company granted these options with the exercise price equal to the market value as determined at the date of grant. The total number of shares of Common Stock authorized for issuance upon exercise of options and other awards, or upon vesting of restricted or deferred stock awards, under the 1997 Plan was initially established at 2,000,000 and increases at the beginning of each fiscal year, commencing on July 1, 1998, by an amount equal to 4% of the outstanding Common Stock on the last day of the preceding fiscal year. The maximum number of shares of Common Stock issuable upon exercise of incentive stock options granted under the 1997 Plan, however, cannot exceed 16,000,000. Furthermore, the maximum number of shares which may be subject to options, rights or other awards granted under the 1997 Plan to any individual in any calendar year cannot exceed 600,000. At June 30, 2006, there was $26.5 million in unrecognized compensation costs, related to unvested stock options. This is expected to be recognized over a weighted average period of 2.9 years. The aggregate intrinsic value of the options outstanding and the options exercisable at June 30, 2006 was $183.8 million and $123.3 million, respectively. The aggregate intrinsic value of the options exercised during the year ended June 30, 2006 was $40.5 million. The total fair value of options that vested during the year ended June 30, 2006 was $17.1 million. The following table summarizes option activity during the year ended June 30, 2006: The following table summarizes option activity: Weighted Average Exercise Price 2006 2005 8,301,408 2,030,700 (1,805,648) (423,568) $19.38 38.17 17.06 26.09 8,832,712 2,336,650 (2,633,246) (234,708) Weighted Average Exercise Price $16.27 25.30 13.97 18.34 2004 9,490,356 1,820,474 (1,916,782) (561,336) Weighted Average Exercise Price $14.52 20.66 10.62 20.28 8,102,892 $24.26 8,301,408 $19.38 8,832,712 $16.27 $32.99-45.46 $21.95–31.24 $19.60–25.78 4,262,743 $18.03 3,987,754 $16.86 4,813,162 $14.35 Outstanding at beginning of year Granted Exercised Forfeited Outstanding at end of year Exercise price range of granted options Options exercisable at end of year - F19 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (12) Stockholders’ Equity, Continued The following table summarizes information about stock options outstanding at June 30, 2006. Exercise Prices $ 0 - $10 $11 - $20 $21 - $30 $31 - $40 $41 - $50 Number Outstanding at June 30, 2006 500,590 2,697,755 2,823,947 2,062,100 18,500 8,102,892 Weighted Average Remaining Contractual Life In Years 2.46 6.32 7.31 9.50 9.80 7.24 Number Exercisable at June 30, 2006 500,590 2,192,760 1,530,589 38,804 Nil 4,262,743 Employee Stock Purchase Plan (the “ESPP”). The ESPP was approved by our shareholders at the Annual General Meeting in November 2003. Under the ESPP, participants are offered the right to purchase shares of our common stock at a discount during successive offering periods. Each offering period under the ESPP will be for a period of time determined by the Board of Directors’ Compensation Committee of no less than 3 months and no more than 27 months. The purchase price for our common stock under the ESPP will be the lower of 85% of the fair market value of our common stock on the date of grant or 85% of the fair market value of our common stock on the date of purchase. An individual participant cannot subscribe for more than $25,000 in common stock during any calendar year. There is a maximum of 7,500,000 shares of our common stock authorized for sale under the ESPP. During fiscal year 2006, the company issued 125,995 shares in two offerings at an average share price of $29.81 to our employees. We recognized $1.2 million of stock compensation expense associated with the ESPP. Preferred Stock. In April 1997, the board of directors authorized 2,000,000 shares of $0.01 par value preferred stock. No such shares were issued or outstanding at June 30, 2006. Stock Purchase Rights. In April 1997, the Company implemented a plan to protect stockholders’ rights in the event of a proposed takeover of the Company. Under the plan, each share of the Company’s outstanding common stock carries one right to purchase Series A Junior Participating Preferred Stock (the “Right”). The Right enables the holder, under certain circumstances, to purchase common stock of the Company or of the acquiring person at a substantially discounted price ten days after a person or group publicly announces it has acquired or has tendered an offer for 20% or more of the Company’s outstanding common stock. The Rights are redeemable at $0.01 per Right and expire in 2007. Common Stock. On June 6, 2002, the Board of Directors authorized the Company to repurchase up to 8.0 million shares of outstanding common stock. During fiscal year 2006 and 2005, the Company repurchased NIL and 482,000 shares at a cost of $NIL million and $11.0 million respectively. As of June 30, 2006, we have repurchased a total of 2,254,918 shares at a cost of $41.4 million. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. Convertible Subordinated Notes. During the year ended June 30, 2006, and pursuant to the Indenture dated June 20, 2001 between us and American Stock Transfer & Trust Company, as trustee, holders of all of the 4% Convertible Subordinated Notes due 2006 converted the notes into an aggregate of 3,737,593 shares of the Company’s common stock, par value $0.004. The notes were converted into 33 shares of our common stock for each $1,000 principal amount of the notes, at a conversion price of $30.30 per share. The dilutive impact of these conversions has been reflected in the reported earnings per share. Stock Split. On August 10, 2005, our Board of Directors declared a two-for-one split of our Common Stock to be payable in the form of a 100% stock dividend. Shareholders received one additional share of Common Stock for every share held on September 30, 2005. All share and per share information has been adjusted for this stock split. - F20 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (13) Other, net Other, net in the statement of operations is comprised of the following at June 30, 2006, 2005 and 2004 (in thousands): Gain/(loss) on foreign currency transactions and hedging Realized gain (loss) on sale of marketable securities Write down of Cost method Investment Other 2006 $1,853 - (1,156) 77 $774 2005 $36 (34) - 79 $81 2004 $655 (11) - 346 $990 (14) Income Taxes Income before income taxes for the years ended June 30, 2006, 2005, and 2004, was taxed under the following jurisdictions (in thousands): U.S. Non-U.S. The provision for income taxes is presented below (in thousands): Current: Federal State Non-U.S. Deferred: Federal State Non-U.S. Provision for income taxes 2006 $5,472 127,922 $133,394 2005 ($54) 96,680 $96,626 2006 2005 $7,507 1,370 48,221 57,098 (3,353) (390) (8,172) (11,915) $45,183 $799 246 38,793 39,838 618 (29) (8,586) (7,997) $31,841 2004 $1,290 83,378 $84,668 2004 $3,567 372 22,186 26,125 1,293 (84) 50 1,259 $27,384 The provision for income taxes differs from the amount of income tax determined by applying the applicable U.S. federal income tax rate of 35% (34% for 2005 and 2004) to pretax income as a result of the following (in thousands): Taxes computed at statutory U.S. rate Increase (decrease) in income taxes resulting from: Effect of AJCA repatriation State income taxes, net of U.S. tax benefit Non-deductible expenses Research and development credit Tax effect of deemed dividends Change in valuation allowance Effect of non-U.S. tax rates In-process research and development write-off Foreign tax credits Stock-based compensation expense Other 2006 $46,688 3,537 939 777 (3,085) 1,846 1,665 (6,731) - (1,204) 2,006 (1,255) $45,183 2005 $32,853 - 165 580 (2,743) 590 637 (3,419) 1,791 - - 1,387 $31,841 2004 $28,787 - 254 312 (2,582) 129 5,074 (2,930) - (772) - (888) $27,384 - F21 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (14) Income Taxes, Continued Deferred tax assets and liabilities are classified as current or non-current according to the classification of the related asset or liability. The components of the Company’s deferred tax assets and liabilities at June 30, 2006 and 2005 are as follows (in thousands): Deferred tax assets: Employee benefit obligations Inventory Provision for service warranties Provision for doubtful debts Net operating loss carryforwards Foreign tax credits AMT tax credit Unrealized foreign exchange losses Capital loss carryover Intercompany profit in inventories Stock-based compensation expense Other Less valuation allowance Deferred tax assets Deferred tax liabilities: Unrealized gain on foreign currency options Unrealized foreign exchange gains Property, plant and equipment Goodwill and other intangibles Other Deferred tax liabilities Net deferred tax asset 2006 2005 $3,274 1,408 992 1,024 2,598 9,626 - 970 521 18,611 2,833 2,448 44,305 (10,989) $33,316 (353) - (1,673) (16,500) (531) (19,057) $14,259 $2,306 301 596 692 4,505 8,422 399 - - 14,376 - 2,031 33,628 (9,096) $24,532 (905) (1,905) (2,366) (15,062) (759) (20,997) $3,535 The net deferred tax assets and liabilities have been reported in the consolidated balance sheet at June 30, 2006 and 2005 as follows (in thousands): Current deferred tax asset Non-current deferred tax liability Net deferred tax asset 2006 $26,636 (12,377) $14,259 2005 $15,230 (11,695) $3,535 As of June 30, 2006, the Company had $1,776,000 and $14,082,000 of U.S. state and non-U.S. net operating loss carryforwards, respectively, which expire in various years through 2025 or carry forward indefinitely. The Company also had foreign tax credit carryforwards of $9,626,000. The foreign tax credit carryforwards have expiration dates through 2016. - F22 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (14) Income Taxes, Continued The valuation allowance at June 30, 2006, relates to a provision for uncertainty as to the utilization of foreign tax credits of $9,626,000, net operating loss carryforwards for certain non-U.S. countries of $842,000 and capital loss items of $521,000. We believe that it is more likely than not that the benefits of deferred tax assets, net of any valuation allowance, will be realized. The Company has not provided for U.S. income and foreign withholding taxes on undistributed earnings from non- U.S. subsidiaries indefinitely invested outside the United States as of June 30, 2006. The total amount of these undistributed earnings at June 30, 2006 amounted to approximately $266 million. Should the Company repatriate foreign earnings, the Company would have to adjust the income tax provision in the period management determined that the Company would repatriate earnings. The American Jobs Creation Act of 2004, or AJCA, enacted on October 22, 2004, provides for a one-time 85% dividends received deduction for certain foreign earnings repatriated. During the fourth quarter of fiscal 2006, ResMed repatriated $75 million of foreign earnings under the AJCA and recorded a related tax expense of $3.5 million. This distribution does not change the Company’s intention to indefinitely reinvest undistributed earnings of its non-U.S. subsidiaries outside the United States. (15) Employee Retirement Plans The Company contributes to a number of employee retirement plans for the benefit of its employees. These plans are detailed as follows: (1) Australia - The Company contributes to defined contribution pension plans for each employee resident in Australia. All Australian employees after serving a qualifying period, are entitled to benefits on retirement, disability or death. Employees may contribute additional funds to the plans. The Company contributes to the plans at the rate of 9% of the salaries of all Australian employees. Total Company contributions to the plans for the years ended June 30, 2006, 2005 and 2004, were $3,846,000, $2,849,000 and $2,410,000, respectively. (2) United Kingdom - The Company contributes to a defined contribution plan for each permanent United Kingdom employee. All employees, after serving a three-month qualifying period, are entitled to benefit on retirement, disability or death. Employees may contribute additional funds to the plan. The Company contributes to the plans at the rate of 5% of the salaries of all United Kingdom employees. Total Company contributions to the plan were $109,000, $67,000 and $33,000 in fiscal 2006, 2005 and 2004, respectively. (3) United States - The Company sponsors a defined contribution pension plan available to substantially all domestic employees. Company contributions to this plan are based on a percentage of employee contributions to a maximum of 3% of the employee’s salary. Total Company contributions to the plan were $531,000, $514,000 and $362,000 in fiscal 2006, 2005 and 2004, respectively. (4) Switzerland - The Company sponsors a fixed return defined contribution fund for each permanent Swiss employee. As part of the Company’s contribution to the fund the company guarantees a fixed 3% net return on accumulated contributions per annum. The Company contributes to the plans at variable rates that have averaged 10% of salaries over the last three years. Total Company contributions to the plan were $182,000, $85,000 and $139,000 in fiscal 2006, 2005 and 2004, respectively. (16) Segment Information The Company operates solely in the sleep-disordered breathing sector of the respiratory medicine industry. The Company therefore believes that, given the single market focus of its operations and the inter-dependence of its products, the Company operates as a single operating segment. The Company assesses performance and allocates resources on the basis of a single operating entity. - F23 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (16) Segment Information, Continued Financial information by geographic area for the years ended June 30, 2006, 2005 and 2004, is summarized below (in thousands): U.S.A Germany Australia France Rest of World Total 2006 Revenue from external customers Long lived assets 2005 Revenue from external customers Long lived assets 2004 Revenue from external customers Long lived assets $320,941 96,436 18,709 59,402 111,508 $606,996 $54,118 17,190 162,520 7,080 11,518 $252,426 $210,495 72,824 14,160 47,537 80,489 $425,505 $32,090 11,615 130,310 2,544 6,900 $183,459 $159,283 67,253 10,293 34,629 67,880 $339,338 $33,010 6,842 108,683 1,075 5,831 $155,441 Net revenues from external customers are based on the location of the customer. Long-lived assets of geographic areas are those assets used in the Company’s operations in each geographical area and excludes intangibles, deferred tax assets and goodwill. (17) Commitments The Company leases buildings, motor vehicles and office equipment under operating leases. As part of the acquisition of Saime the Company assumed a capital lease for land and buildings. This lease contains an option to purchase the property at the end of the lease term. Rental charges for operating leases are expensed as incurred. At June 30, 2006 the Company had the following future minimum lease payments under non-cancelable operating leases and capital leases (in thousands): Years 2007 2008 2009 2010 2011 Thereafter Total minimum lease payments Less: Sublease rental income Less: Interest portion Present value of net minimum lease payments Capital Leases Operating Leases $97 94 91 88 85 292 $747 - 106 $641 $7,586 5,431 3,799 3,066 1,972 657 $22,511 - - $22,511 Rent expenses under operating leases for the years ended June 30, 2006, 2005 and 2004 were approximately $7.5 million, $6.2 million and $5.5 million, respectively. - F24 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (17) Commitments, Continued Details of other commercial commitments at June 30, 2006 are as follows (in thousands): Total Amounts Committed $34 2,457 Standby Letters of Credit Guarantees* Total Commercial Commitments Amount of Commitment Expiration Per Period 2008 2009 2007 2010 2011 Thereafter $34 263 $- - $- $- - $- $- - $- $- - $- $- 2,194 $2,194 $2,491 $297 *The above guarantees relate to guarantees required by statutory authorities as a pre-requisite to developing our site at Norwest Business Park, near Sydney, Australia, and to guarantees required by contracts with insurance companies transacting with our German subsidiaries. (18) Business Acquisitions Fiscal year ended June 30, 2006 PolarMed Holding AS (“PolarMed”). On December 1, 2005, we acquired 100% of the outstanding stock of PolarMed, the holding company for PolarMed AS and its affiliates, for net cash consideration of $6.5 million. This was comprised of $6.8 million in consideration less $0.3 million of cash acquired. Additionally, as part of the acquisition we assumed debt of $1.5 million. Under the purchase agreement, we may also be required to make additional future payments of up to $3.0 million based on the achievement of certain performance milestones following the acquisition through December 31, 2008. The acquisition and the immediate repayment of the majority of the assumed debt were funded with cash on hand. PolarMed is predominantly a Norwegian based company, with affiliated operations based in Sweden and Denmark, which distributes medical equipment and associated services for the treatment of sleep and respiratory patients. PolarMed was our Norwegian distributor before the acquisition, and the acquisition is consistent with our strategy for ongoing expansion of our international operations. The acquisition has been accounted for using purchase accounting and has been included within our consolidated financial statements from December 1, 2005. An amount of $4.4 million, representing the excess of the purchase price over the fair value of identifiable net assets acquired of $2.4 million, has been recorded as goodwill, which will not be tax deductible under Norwegian tax law. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their respective fair values at the date of acquisition. We have not yet completed the purchase price allocation, as the appraisals associated with the valuation of certain tangible assets are not yet complete. We do not believe that the appraisals will materially modify the preliminary purchase price allocation. We expect to complete our purchase price allocation in the quarter ending September 30, 2006. The following table summarizes the purchase price allocation of the assets acquired and liabilities assumed from PolarMed at the date of acquisition based on a preliminary independent appraisal and internal studies (in thousands): At December 1, 2005 Cash Accounts receivable Inventory Other assets Property, plant & equipment Customer relationships (useful life of 7 years) Goodwill (non-amortizing, non-tax deductible) Total assets acquired Current liabilities, primarily consisting of accounts payable, accrued expenses, taxes payable and deferred revenue Non current liabilities, primarily consisting of deferred tax liabilities Net assets acquired $262 2,473 2,170 27 321 1,780 4,351 $11,384 (4,179) (427) $6,778 - F25 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (18) Business Acquisitions Pulmomed Medizinisch-Technische Geräte GmbH (“Pulmomed”). On July 1, 2005, we acquired 100% of the outstanding stock of Pulmomed for net cash consideration of $2.5 million, including acquisition costs. Additionally, as part of the acquisition we assumed debt of $1.0 million. Under the purchase agreement, we may also be required to make additional future payments of up to $0.9 million based on the achievement of certain performance milestones following the acquisition through June 30, 2007. Pulmomed is an Austrian based company that distributes medical equipment and associated services for the treatment of sleep and respiratory patients. The acquisition of Pulmomed is consistent with our strategy for ongoing expansion of our international operations. The acquisition has been accounted for using purchase accounting and has been included within our consolidated financial statements from July 1, 2005. An amount of $1.8 million, representing the excess of the purchase price over the fair value of identifiable net assets acquired of $0.7 million, has been recorded as goodwill, which will not be tax deductible under Austrian tax law. The cost of the acquisition was allocated to the assets acquired and liabilities assumed based on estimates of their respective fair values at the date of acquisition. The fair values were determined by an independent appraisal and internal studies. The following table summarizes the purchase price allocation of the assets acquired and liabilities assumed from Pulmomed at the date of acquisition (in thousands): Cash Accounts receivable Inventory Other assets Property, plant & equipment Customer relationships (useful life of 7 years) Goodwill (non-amortizing, non-tax deductible) Total assets acquired Current liabilities, primarily consisting of accounts payable, accrued expenses, loans and deferred tax liabilities Non-current liabilities, primarily consisting of deferred tax liabilities Net assets acquired At July 1, 2005 $1 377 592 217 458 907 1,785 $4,337 (1,668) (203) $2,466 Of the potential additional future payments included within the purchase agreement, $0.3 million was accrued at June 30, 2006 as a result of the successful achievement of a performance milestone. The impact of this accrual was to increase the total acquisition consideration to $2.8 million from $2.5 million and to increase the amount recorded as goodwill by $0.3 million to $2.1 million. Fiscal year ended June 30, 2005 Saime SAS (“Saime”). As disclosed in our financial statements and Form 10-K for the year ended June 30, 2005, we acquired 100% of the outstanding stock of Financiere ACE SAS, the holding company for Saime SAS and its affiliates, on May 19, 2005, for net cash consideration of $40.6 million. This was comprised of $51.1 million in consideration, including acquisition costs, less $10.5 million of cash acquired. At June 30, 2005, we had not yet completed the purchase price allocation as the appraisals associated with the valuation of certain tangible assets were not yet complete. The fair values have now been finalized based on independent appraisals and internal studies. The impact of the completion of the purchase price allocation was to increase the fair value of the acquired fixed assets by approximately $0.7 million to $2.9 million, increase the fair value of acquired liabilities, including deferred tax liabilities, by approximately $0.4 million to $91.7 million, increase the fair value of acquired deferred tax assets by approximately $1.2 million to $2.0 million and to decrease the amount recorded as goodwill by $1.5 million to $64.8 million. - F26 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (18) Business Acquisitions Hoefner Medizintechnick GmbH (“Hoefner”). As disclosed in our financial statements and Form 10-K for the year ended June 30, 2005, we acquired 100% of the outstanding stock of Hoefner Medizintechnick GmbH (“Hoefner”) on February 14, 2005, for net cash consideration of $8.2 million. This was comprised of the $10.7 million in total consideration, including acquisition costs, less $2.5 million of cash acquired. Under the purchase agreement, additional future payments of up to $0.9 million are possible based on the achievement of certain performance milestones following the acquisition through December 31, 2006. Of these potential additional payments, $0.6 million, which was paid during the year ended June 30, 2006 as a result of the successful achievement of a performance milestone. The impact of this payment was to increase the total acquisition consideration to $11.3 million from $10.7 million and to increase the amount recorded as goodwill by $0.6 million to $8.8 million. Resprecare BV. On December 1, 2004 we acquired substantially all the assets of Resprecare BV, our Dutch distributor, for initial consideration of $5.9 million in cash, including acquisition costs. The acquisition of the exclusive Dutch distributor is consistent with our strategy for ongoing expansion of our international operations. Under the purchase agreement, we potentially were also required to make up to $1.4 million of additional future payments based on the achievement of certain milestones. Of these potential additional payments, $0.6 million was paid in January 2005 as a result of the successful achievement of a performance milestone and a further $0.7 million was accrued at June 30, 2005 as a result of the integration of the Dutch subsidiary of our subsidiary MAP with the newly-acquired Resprecare business. The decision to integrate these operations determined the amount of the final future payment, which was paid in January 2006. The acquisition was accounted for using purchase accounting and accordingly, the results of operations of Resprecare were included within our consolidated financial statements from December 1, 2004. An amount of $4.4 million, representing the excess of the purchase price over the fair value of identifiable net assets acquired of $2.8 million, was recorded as goodwill, which is tax deductible. An independent third party completed a valuation of identifiable intangible assets associated with the Resprecare acquisition. As a result of this valuation, $1.7 million was recorded as a customer relationship intangible asset and is being amortized over its estimated useful life of seven years. Fiscal year ended June 30, 2004 On July 2, 2003 we acquired the assets of Respro Medical Company Limited (“Respro”), our Hong Kong distributor for total consideration of $184,000 in cash. The acquisition has been accounted for using purchase accounting and accordingly, the results of operations of Respro has been included within our consolidated financial statements from July 2, 2003. An amount of $89,000, representing the excess of the purchase price over the fair value of net identifiable assets acquired of $95,000, has been recorded as goodwill. (19) Legal Actions and Contingencies In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not have a material adverse effect on our consolidated financial statements taken as a whole. During September and October 2004, the Company began receiving tax assessment notices for the audit of one of its German subsidiaries by the German tax authorities for the years 1996 through 1998. Certain of these adjustments are being contested and appealed to the German tax authority office. We believe no additional provision is necessary for any tax adjustment that may result from the tax audit. However, the outcome of the audit cannot be predicted with certainty. Should any tax audit issues be resolved in a manner not consistent with management’s expectations, the Company could be required to adjust its provision for income tax in the period of resolution. On December 23, 2002, three former contractors of our subsidiary MAP Medizin-Technologie GmbH initiated proceedings in Munich 1 Regional Court (Proceedings No. 7 O 23286/02), petitioning the Court for a declaration of inventorship with respect to MAP German Patent Applications identified as No. 100 31 079 and 101 92 802.5 and European Patent Application No. EP 01 967 819.7. On March 10, 2005, the Court entered judgement in favor of the plaintiffs, finding that they should be identified as co-inventors in place of certain individual defendants. In April 2005, MAP filed an appeal of that decision. We do not expect that the outcome of this litigation to have an adverse material effect on our consolidated financial statements. - F27 - RESMED INC. AND SUBSIDIARIES Notes to Consolidated Financial Statements (19) Legal Actions and Contingencies, Continued In March 2006 an Australian university made a demand that ResMed pay extra royalties pursuant to a current patent license agreement. ResMed rejected the demand and the University has agreed to discuss its position. ResMed does not consider the claim to have merit. We do not expect that the outcome of this demand to have an adverse material effect on our consolidated financial statements. (20) In-Process Research and Development Charge (“IPR&D”) On acquisition of Saime in May 2005, we recognized as an expense a charge of $5.3 million with respect to IPR&D programs under active development by Saime that, at date of acquisition, had not reached technological feasibility and had no alternative future use. The estimated fair value assigned to IPR&D was based on an independent appraisal and was comprised of the following projects (in thousands): Project Upgrade of the Elisee Series of ventilators Next generation of portable ventilators Total Value of IPR&D 1,379 $ 3,889 5,268 $ The value of IPR&D was calculated by identifying research projects in areas for which technological feasibility had not been established, estimating the costs to develop the purchased in process technology into commercially viable products, estimating the resulting net cash flows from such products, discounting the net cash flows to present value, and applying the reduced percentage completion of the projects thereto. The discount rate used in the analysis was 25%, which was based on the risk profile of the acquired assets. As of the date of acquisition, these projects had estimated costs to complete totaling approximately $1.1 million. The projects were in various stages of development but are expected to reach completion at various dates ranging from 1 to 3 years. We believe that the assumptions used to value the acquired intangible assets were reasonable at the time of acquisition. No assurance can be given, however, that the underlying assumptions used to estimate expected project revenues, development costs or profitability, or events associated with such projects, will transpire as estimated. For these reasons, among others, actual results may vary from the projected results. (21) Subsequent Events None. - F28 - RESMED INC. AND SUBSIDIARIES VALUATION AND QUALIFYING ACCOUNTS AND RESERVES YEARS ENDED JUNE 30, 2006, 2005 AND 2004 (in thousands) Schedule II Year ended June 30, 2006 Applied against asset account Allowance for doubtful accounts Year ended June 30, 2005 Applied against asset account Allowance for doubtful accounts Year ended June 30, 2004 Applied against asset account Allowance for doubtful accounts Balance at Beginning of Period Charged to costs and expenses Other (deductions) Balance at end of period $3,199 1,577 (131) 4,645 $3,197 611 (609) 3,199 $2,474 1,178 (455) 3,197 See accompanying report of independent registered public accounting firm. RESMED INC. AND SUBSIDIARIES SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. DATED September 8, 2006 ResMed Inc. /S/ PETER C. FARRELL ------------------------------------------------------------ Peter C. Farrell President and Chief Executive Officer Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated. SIGNATURE TITLE /S/ PETER C. FARRELL ------------------------------------------------------------- Peter C. Farrell Chief Executive Officer, President, Chairman of the Board (Principal Executive Officer) /S/ BRETT SANDERCOCK ------------------------------------------------------------ Brett A. Sandercock Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) /S/ CHRISTOPHER G. ROBERTS ------------------------------------------------------------ Christopher G. Roberts Director /S/ MICHAEL A. QUINN ------------------------------------------------------------ Michael A. Quinn Director /S/ GARY W. PACE ------------------------------------------------------------ Gary W. Pace Director /S/ DONAGH MCCARTHY ------------------------------------------------------------ Donagh McCarthy Director /S/ RICHARD SULPIZIO ------------------------------------------------------------ Richard Sulpizio Director /S/ RON TAYLOR ------------------------------------------------------------ Ron Taylor Director /S/ JOHN P. WAREHAM ------------------------------------------------------------ John P. Wareham Director S-1 DATE September 8, 2006 September 8, 2006 September 8, 2006 September 8, 2006 September 8, 2006 September 8, 2006 September 8, 2006 September 8, 2006 September 8, 2006 RESMED INC. AND SUBSIDIARIES EXHIBIT INDEX 3.1 3.2 4.1 4.2 4.3 4.4 Certificate of Incorporation of Registrant, as amended(1) By-laws of Registrant(1) Form of certificate evidencing shares of Common Stock(1) Rights agreement dated as of April 23, 1997(2) Indenture dated as of June 20, 2001, between ResMed Inc. and American Stock Transfer & Trust Company(5) Registration Rights Agreement dated as of June 20, 2001, by and between ResMed Inc., Merrill Lynch & Co., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Deutsche Banc Alex Brown Inc., William Blair & Company, L.L.C., Macquarie Bank Limited and UBS Warburg LLC(5) Registration Rights Agreement dated as of May 14, 2002 between ResMed Inc., and Mr Leslie Hoffman(6) 4.5 10.1 1995 Stock Option Plan(1) 10.2 1997 Equity Participation Plan(3) 10.3 Licensing Agreement between the University of Sydney and ResMed Ltd dated May 17, 1991, as amended(1) 10.5 Loan Agreement between the Australian Trade Commission and ResMed Limited dated May 3, 1994(1) 10.6 Lease for 10121 Carroll Canyon Road, San Diego CA 92131-1109, USA(4) 10.7 Sale and Leaseback Agreements for 97 Waterloo Rd, North Ryde, Australia(5) 10.8 Employment Agreement dated as of May 14, 2002, between Servo Magnetics Acquisition Inc., and Mr Leslie Hoffman(6) 10.9 Agreement for the purchase of Lot 6001, Norwest Business Park, Baulkham Hills, Australia(6) 10.10 2003 Employee Stock Purchase Plan(7) 10.11 Loan Agreement between ResMed Limited and HSBC Bank Australia Limited 10.12 Saime Purchase Agreement 10.13 First Amended and Restated Loan Agreement, dated as of November 1, 2005, by and among ResMed Corp., ResMed EAP Holdings Inc. and Union Bank of California, N.A. (8) 10.14 Security Agreement, dated as of November 1, 2005, by and between ResMed EAP Holdings Inc. and Union Bank of California, N.A. (8) 10.15 Continuing Guaranty, dated as of November 1, 2005, by and between ResMed Inc and Union Bank of California, N.A. (8) 10.16 Commercial Promissory Note, dated as of November 1, 2005, made by ResMed Corp. and ResMed EAP Holdings Inc. (8) 10.17 Commercial Promissory Note, dated as of November 1, 2005, made by ResMed Corp. and ResMed EAP Holdings 10.18 Second Amended and Restated Loan Agreement (9) 10.19 Syndicated Facility Agreement, dated as of June 8, 2006, by and between ResMed Limited and HSBC Bank Australia 10.20 Deed of Guaranty and Indemnity, dated as of June 8, 2006, by and among HSBC Bank Australia Limited, ResMed Limited, ResMed SAS, ResMed GmbH & Co. KG, ResMed (UK) Limited and Take Air Medical Handels-GmbH (10) 10.21 Deed of Guaranty and Indemnity, dated as of June 8, 2006, by and among HSBC Bank Australia Limited, ResMed Inc., ResMed Corp. and ResMed Limited (10) 10.22 Working Capital Agreement, dated as of June 8, 2006, by and among ResMed (UK) Limited and HSBC Bank plc (10) 10.23 Working Capital Agreement, dated as of June 8, 2006, by and among ResMed Limited and HSBC Bank Australia Inc. (8) Limited (10) Limited (10) Independent Registered Public Accounting Firm’s Consent and Report on Schedule 21.1 Subsidiaries of the Registrant 23.1 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002 32.1 Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (1) Incorporated by reference to the Registrant’s Registration Statement on Form S-1 (No. 33-91094) declared effective on June 1, 1995. (2) Incorporated by reference to the Registrant’s Registration Statement on Form 8-A12G filed on April 25, 1997. (3) Incorporated by reference to the Registrant’s 1997 Proxy Statement. (4) Incorporated by reference to the Registrant’s Report on Form 10-K dated June 30, 1998. (5) Incorporated by reference to the Registrant’s Report on Form 10-K for the year ended June 30, 2001. (6) Incorporated by reference to the Registrant’s Report on Form 10-K for the year ended June 30, 2002. (7) Incorporated by reference to the Registrant’s 2003 Proxy Statement. (8) Incorporated by reference to the Registrant’s Form 8-K dated November 8, 2005. (9) Incorporated by reference to the Registrant’s Form 8-K dated March 13, 2006. (10) Incorporated by reference to the Registrant’s Form 8-K dated June 8, 2006. EXHIBIT 21.1 RESMED INC. SUBSIDIARIES OF THE REGISTRANT ResMed Corporation (a Minnesota corporation) ResMed US Assembly Inc. (a Delaware corporation) ResMed (Malaysia) Sdn Bhd (a Malaysian Corporation) (2) ResMed (UK) Limited (a United Kingdom corporation) (1) ResMed Asia Pacific Limited (incorporated under the laws of New South Wales, Australia) (1) ResMed Deutschland GmbH (a German corporation, formerly ResMed Beteiligungs GmbH) (3) ResMed EAP Holdings Inc. (a Delaware corporation) ResMed Finland OY (a Finland corporation) (2) ResMed Holdings Limited (incorporated under the laws of New South Wales, Australia) ResMed Hong Kong Limited (a Hong Kong corporation) (2) ResMed Germany Inc. (a Delaware corporation, formerly ResMed International Inc.) ResMed KK (a Japanese corporation) (2) ResMed Limited (incorporated under the laws of New South Wales, Australia) (1) ResMed New Zealand Limited (a New Zealand Corporation) (2) ResMed GmbH Verwaltung (a German corporation) ResMed GmbH and Co KG (a German corporation) (4) ResMed R&D Limited (incorporated under the laws of New South Wales, Australia) (1) ResMed SAS (a French corporation) (2) ResMed Singapore Pte Ltd (a Singaporean corporation) (2) ResMed Spain SL (a Spanish corporation) (2) ResMed Sweden AB (a Swedish corporation) (2) Servo Magnetics Inc. (a Delaware corporation) ResMed Schweiz AG (A Swiss corporation, formerly Labhardt AG) (2) ResMed Austria Medizintechnik GmbH (an Austrian corporation) (2) MAP Medische Techniek voor Arts en Patient BV (a Dutch corporation) (4) MAP Medizin-Technologie GmbH (a German corporation) (4) MAP Beteiligungs GmbH (a German corporation) (5) Take Air Medical Handels GmbH (a German corporation) (6) SCI PDG (a French corporation) (6) OCA Beteiligung AG (a Luxemburg corporation) (6) Hoefner Medizintechnik GmbH (a German corporation) (9) ResMed Brasil Ltda (a Brazilian corporation) (7) PolarMed A/S (a Danish corporation) (2) PolarMed AS (a Norwegian corporation) (2) ResMed Nederland BV (a Netherlands corporation) (2) Saime SAS (a French corporation) (8) ResMed Property Trust (incorporated under the laws of New South Wales, Australia) (1) A subsidiary of ResMed Holdings Limited (2) A subsidiary of ResMed EAP Holdings Inc. (3) A subsidiary of ResMed Germany Inc. (4) A subsidiary of ResMed Deutschland GmbH (5) A subsidiary of MAP Medizin-Technologie GmbH (6) A subsidiary of Saime SAS (7) A subsidiary of ResMed Corporation (8) A subsidiary of ResMed SAS (9) A subsidiary of ResMed GmbH and Co KG INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM’S REPORT ON SCHEDULE AND CONSENT EXHIBIT 23.1 The Board of Directors and Stockholders ResMed Inc.: The audits referred to in our reports dated September 8, 2006, included the related financial statement schedule as of June 30, 2006, and for each of the years in the three-year period ended June 30, 2006. This financial statement schedule is the responsibility of the Company’s management. Our responsibility is to express an opinion on this financial statement schedule based on our audits. In our opinion, such financial statement schedule, when considered in relation to the basic consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein. We consent to the incorporation by reference in the registration statement (Nos. 333-08013, 333-88231 and 333-115048) on Form S-8 and the registration statements (Nos. 333-70500 and 333-100825) on Form S-3 of ResMed Inc. of our reports dated September 8, 2006, with respect to the consolidated balance sheets of ResMed Inc. as of June 30, 2006 and 2005, and the related consolidated statements of income, stockholders’ equity, cash flows, and comprehensive income for each of the years in the three-year period ended June 30, 2006, and the related financial statement schedule, management’s assessment of the effectiveness of internal control over financial reporting as of June 30, 2006, and the effectiveness of internal control over financial reporting as of June 30, 2006, which reports appear in the June 30, 2006, annual report on Form 10-K of ResMed Inc. /s/ KPMG LLP …………………….. San Diego, California September 8, 2006 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31.1 I, Peter C. Farrell, certify that: 1. 2. 3. 4. I have reviewed this annual report on Form 10-K of ResMed Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; The registrant’s other certifying officer and I, are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting practices; and (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. September 8, 2006 /s/ PETER C. FARRELL ………………………………………. Peter C. Farrell Chairman and Chief Executive Officer Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 EXHIBIT 31.2 I, Brett Sandercock, certify that: 1. 2. 3. 4. I have reviewed this annual report on Form 10-K of ResMed Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; The registrant’s other certifying officer and I, are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; (b) Designed such internal controls over financial reporting, or caused such internal controls over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and preparation of financial statements for external purposes in accordance with generally accepted accounting practices; and (c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and (d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and 5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. September 8, 2006 /s/ BRETT SANDERCOCK ………………………………………. Brett Sandercock Chief Financial Officer EXHIBIT 32.1 The following certifications are being furnished solely to accompany the Report pursuant to 18 U.S.C. § 1350 and in accordance with SEC Release No. 33-8238. These certifications shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall they be incorporated by reference in any filing of the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing. Certification of Chief Executive Officer Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ResMed Inc., a Delaware corporation (the “Company”), hereby certifies, to his knowledge, that: (i) the accompanying Annual Report on Form 10-K of the Company for the year ended June 30, 2006 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: September 8, 2006 /s/ PETER C. FARRELL ………………………………………. Peter C. Farrell Chairman and Chief Executive Officer A signed original of this written statement required by Section 906 has been provided to ResMed Inc. and will be retained by ResMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request. Certification of Chief Financial Officer Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of ResMed Inc., a Delaware, corporation (the “Company”), hereby certifies, to his knowledge, that: (i) the accompanying Annual Report on Form 10-K of the Company for the year ended June 30, 2006 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: September 8, 2006 /s/ BRETT SANDERCOCK ………………………………………. Brett Sandercock Chief Financial Officer A signed original of this written statement required by Section 906 has been provided to ResMed Inc. and will be retained by ResMed Inc. and furnished to the Securities and Exchange Commission or its staff upon request. Internet initiatives ResMed sponsors the following websites, providing our customers with quick and easy access to product information, corporate information and patient support: Transfer agent and registrar Inquiries regarding transfer requirements, lost certificates and changes of address should be directed to: American Stock Transfer and Trust Company 59 Maiden Lane New York, NY 10038 USA Tel: +1 718 921-8275 ResMed (www.resmed.com) MyResMed (www.myresmed.com) HealthySleep (www.healthysleep.com) sleepVantage™ (www.sleepvantage.com) The ResMed Foundation (US) also has its own website (www.resmedfoundation.org) to promote research and awareness about sleep-disordered breathing. More information about the ResMed Foundation (Australia) may be found at www.resmedfoundation.org.au. References 1 Sjostrom C, Lindberg E, Elmasy A, Hagg A, Svardsudd K, Janson C. Prevalence of sleep apnoea and snoring in hypertensive men: a population based study. Thorax 2002;57:602-607. 2 Einhorn D, Erman M, Philis-Tsimikas A, Gordon N. Prevalence and associations of sleep apnea in a population of adults with type 2 diabetes mellitus. (Abstract) Am Diabetes Assoc. Conference 2005. 3 Babu AR, Herdegen J, Fogelfeld L, Shott S, Mazzone T. Type 2 diabetes control, and continuous positive airway pressure in obstructive sleep apnea. Arch Intern Med 2005;165:447-452. 4 Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee of Update 2001 Guidelines for the Evaluation and Management of Heart Failure). American College of Cardiology website. Available at: http://www.acc.org/clinical/guidelines/failure//index.pdf. 5 Gross JB, Bachenberg KL, Benumof JL, Caplan RA, Connis RT, Cote CJ, Nickinovich DG, Prachand V, Ward DS, Weaver EM, Ydens L. Practice guidelines for the perioperative management of patients with obstructive sleep apnea. Anesthesiology 2006;104:1081-1093. 6 National High Blood Pressure Education Program. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7). National Institutes of Health. National Heart, Lung, and Blood Institute, 2003. Computershare, Level 3 60 Carrington Street Sydney, NSW 2000 Australia Tel: +61 2 8234 5000 Legal counsel Latham and Watkins 650 Town Center Drive, Suite 2000 Costa Mesa, CA 92626 USA Independent auditors KPMG LLP 750 B Street, Suite 1500 San Diego, CA 92101 USA Shareholder and investor inquiries On December 14, 2005, we filed with the New York Stock Exchange the most recent Annual CEO Certification as required by Section 303A.12(a) of the New York Stock Exchange Listed Company Manual. To directly receive copies of company news and/or copies of the annual report on Form 10-K as filed with the Securities and Exchange Commission without charge, please contact: Matthew Borer Manager, Investor Relations ResMed Inc. 14040 Danielson Street Poway, CA 92064-6857 USA Tel: +1 858 746-2280 Fax: +1 858 746-2830 Email: investorrelations@resmed.com Brett Sandercock Chief Financial Officer ResMed Inc. 1 Elizabeth Macarthur Drive Bella Vista NSW 2153 Australia Tel: +61 (2) 8884 1000 Fax: +61 (2) 8883 3114 Annual meeting of shareholders November 9, 2006 Date 2 PM Time 14040 Danielson Street Location Poway, CA 92064 USA Activa, ActiveCell, Adapt SV, Adaptiv, Aerial, Aero-Click, Aero-Fix, ApneaLink, AutoVPAP, AutoScan, AutoSet, AutoSet CS, AutoSet Spirit, AutoSet T, AutoSet Vantage, AutoSet.com, AutoSet-CS.com, AutoView, Bubble Cushion, Bubble Mask, Elisée, Eole, Escape, Helia, HumidAire, IPAP MAX, IPAP MIN, Kidsta, Magellan, MAP, MEPAL, Meridian, MESAM, minni Max, Mirage, Protégé, Moritz biLEVEL, Papillon, Poly-MESAM, ResCap, ResControl, ResMed, S6, S7, S8, SELFSET, SleepVantage, SmartStart, Spirit, Spiro+, Sullivan, Swift, TiControl, Ultra Mirage, Vential, VPAP, VS Easyfit, are our trademarks. ©2006 ResMed Inc. USA ResMed Inc. 14040 Danielson Street Poway CA 92064-6857 Telephone: +1 (858) 746-2400 or Telephone: 1-800-424-0737 Fax: +1 (858) 746-2900 Email: reception@resmed.com ResMed Chatsworth Products Servo Magnetics, Inc. 9540 DeSoto Ave. Chatsworth, CA 91311 Telephone: +1 (818) 428-6400 Fax: +1 (818) 428-6401 Australia ResMed Campus (Manufacturing) 1 Elizabeth Macarthur Drive Bella Vista NSW 2153 Telephone: +61 (2) 8884 1000 Telephone: 1-800-658-189 Fax: +61 (2) 8883 3114 Email: reception@resmed.com.au Austria ResMed Austria Medizintechnik GmbH Muthgasse 36 1190 Wien Telephone: +43 01 803 4700 Fax: +43 1 803 4800 Email: info@resmed.at Finland ResMed Finland Oy Eteläinen Salmitie 2 02430 Masala Finland Telephone: +358 (0) 9 8676 820 Fax: +358 (0) 9 8676 8222 Email: reception@resmed.fi France ResMed SA Parc Technologique de Lyon, 292 Allée Jacques Monod, 69791 Saint Priest cedex Telephone: +33 (0)4 26 100 200 Fax: +33 (0)4 26 100 300 Email: reception@resmed.fr ResMed Paris ZI - 25 Rue de l’Etain 77176 Savigny le Temple Telephone: +33 (0)1 64 19 11 11 Fax: +33 (0)1 64 41 81 30 Email: reception@resmed.fr Germany ResMed GmbH & Co. KG Fraunhoferstraße 16 82152 Martinsried Telephone: +49 (0) 89 / 99 01 - 00 Telephone: 0800 2 777 000 (Gebührenfreie Servicenummer) Fax: +49 (0) 89 / 99 01 - 10 55 Email: reception@resmed.de Hong Kong ResMed Hong Kong Limited Room 701, Miramar Tower 132-134 Nathan Road Tsim Sha Tsui, Kowloon Telephone: +852 2366 0707 Fax: +852 2366 4546 Email: reception@resmed.com.hk India ResMed Asia Pacific Ltd Indian Representative Office Eros Corporate Towers Level 15, Regus Business Centre Nehru Place New Delhi 110019 Telephone: +91 11 4223 5348 Fax: +91 11 4223 5378 Email: puneets@resmed.com.au Italy ResMed Italy Piazza 185º Rgt. Art. ‘Folgore’ 2 57128 - LIVORNO Telephone: (+39) 0586 503674 Fax: (+39) 0586 503674 Japan ResMed Japan 3F, Hongo UC Building 3-35-3 Hongo Bunko-ku Tokyo 113-0033 Telephone: +81-03-5840-6781 Fax: +81-03-3812-0360 Malaysia ResMed Malaysia Sdn Bhd Suite E-10-20, Plaza Mon’t Kiara No. 2, Jalan 1/70C, Mon’t Kiara 50480 Kuala Lumpur Fax: +60 (3) 6201 2177 Telephone: +60 (3) 6201 7177 Email: reception@resmed.com.my Netherlands ResMed Nederland BV Badhuisweg 77 2587 CD DEN HAAG Telephone: +31 (0)70 - 79904 00 Fax: +31 (0)70 - 79904 04 Email: ReceptionDH@ResMed.nl New Zealand ResMed NZ Ltd PO Box 51-048 Pakuranga Auckland Telephone: +0800 737 633 Fax: +64 (9) 419 4293 Email: reception@resmed.co.nz Norway PolarMed AS Kirkevn 71A 1344 Haslum Telephone: + 47 67 11 88 50 Fax: + 47 67 11 88 55 Email: post@polarmed.no Website: www.polarmed.no Singapore ResMed Singapore Pte Ltd (Shop Front) 55 Newton Road #01-04 Revenue House Singapore 307987 Telephone: +65 6284 7177 Fax: +65 6284 7787 Email: reception@resmed.com.sg Spain ResMed Spain SL Arbea Campus Empresarial Edificio 2. 2º Planta Crta. Fuencarral a Alcobendas km 3,800 28108 Alcobendas, Madrid Telephone: (+34) 916 393 579 Fax: (+34) 916 398 355 Sweden ResMed Sweden AB Industrigatan 2 S-461 37 Trollhättan Fax: +46 (520) 397 15 Telephone: +46 (520) 420 110 Email: reception@resmed.se Switzerland ResMed Schweiz AG Viaduktstrasse 40 4051 Basel Telephone: +41 61 564 70 00 Fax: +41 61 564 70 10 Email: info@resmed.ch UK ResMed (UK) Ltd 65 Milton Park Abingdon Oxfordshire OX14 4RX Telephone: +44 (1235) 862 997 Fax: +44 (1235) 831 336 Email: reception@resmed.co.uk Global leaders in sleep and respiratory medicine www.resmed.com 10928/1 06 09 

Continue reading text version or see original annual report in PDF format above